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Abstract 
 Dynorphin A 1-17 (Dyn A 1-17) is an endogenous neuropeptide that acts preferentially at 
the kappa opioid receptor.  Elevated concentrations of Dyn A 1-17 have demonstrated 
neurotoxicity via a non-opioid mechanism, potentially mediated by NMDA (N-methyl-D-
aspartate) receptors. This neurotoxicity has further been implicated in a variety of conditions 
including neuropathic pain, stress, depression, and neurological disorders including; Alzheimer’s 
and Parkinson’s disease.  Unlike traditional small molecule neurotransmitters, peptides can 
undergo enzymatic degradation once released into the extracellular space and these metabolites 
can then go on to exhibit their own unique properties in vivo, often at sites far distal to their 
releasing cells.  The investigation of dynorphin metabolism is especially crucial at blood brain 
barrier, where a peptide metabolite may exhibit substantially different transport properties. 
Traditional methods for the quantification of neuropeptides are immunoassays such as ELISA 
(enzyme linked immunosorbent assay) and RIA (radioimmunoassay).  While these techniques 
have excellent limits of detection, cross-reactivity between related species is a significant issue.  
Therefore, it is essential to develop analytical methodologies capable of simultaneously 
determining the concentrations of both the parent peptide and its metabolites.      
In this  thesis,  the metabolism of Dyn A 1-17 in both the central nervous system and 
peripheral tissues as well as with an in vitro cell culture model of the blood brain barrier (BBB) 
is investigated.  Methods for the separation and detection of Dyn A 1-17 and four of its key 
metabolites; Dyn A 1-6, Dyn A 1-8, Dyn A 1-13, and Dyn A 2-17 were developed using 
capillary electrophoresis (CE) with copper complexation and UV detection and liquid 
chromatography-tandem mass spectrometry (LC-MS/MS).  Dyn A 1-6 was found to be a major 
metabolite in the above mentioned systems and therefore its permeability at the BBB was 
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investigated using bovine brain microvessel endothelial cells (BBMECs).  The effect of this 
peptide on the permeability of the low molecular weight, low permeability compound fluorescein 
was also explored.   
In addition to CE and LC-MS/MS, microchip electrophoresis is also investigated.  More 
specifically the development of an immunoaffinity microchip electrophoresis system was begun.  
Online immunoaffinity enables sample clean-up and preconcentration on the separation device.  
By combining immunoaffinity with highly efficient electrophoretic separations, an integrated 
device to investigate dynorphin metabolism is fabricated.  Miniaturization decreases analysis 
time, significantly improving temporal resolution.  Additionally preconcentration will improve 
limits of detection, making the detection of endogenous concentrations of dynorphin peptides 
from biological samples feasible.  Towards this goal, antibody screening and some initial 
microchip electrophoresis studies with amperometric and laser-induced fluorescence detection 
were investigated.  Future directions include the incorporation of this device with on-line 
microdialysis sampling and the development of an immunoaffinity microchip electrophoresis 
system for investigating neuropeptides implicated in neuropathic pain.   
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Chapter One: 
Overall Thesis Objective and Chapter Summaries 
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1.1 Research Objectives 
There is a continuing interest in the determination of peptides in biological samples.  With the 
increasing interest in identifying in vivo signaling molecules and disease biomarkers, the development of 
analytical methods for the determination of peptides in plasma, urine, cerebrospinal fluid (CSF), and 
microdialysates is essential.  Most endogenous peptides are present at low nM to pM concentrations 
within these complex matrices.  Exogenously delivered bio-therapeutics are also becoming increasingly 
popular.  The analytical methods by which these protein and peptide-based drugs are determined must be 
sensitive, quantitative, and robust. 
This thesis explores a variety of techniques for peptide analysis including capillary 
electrophoresis (CE), microchip electrophoresis (ME), liquid chromatography with mass spectrometric 
detection (LC-MS/MS), enzyme-linked immunosorbent assay (ELISA), and immunoaffinity microchip 
electrophoresis (IAME).  In particular, the need for analytical methods capable of simultaneously 
detecting the parent peptide as well as its metabolites is addressed.  The work presented here is focused 
on a specific family of opioid peptides, the dynorphins, although much of it has applicability towards the 
determination of other neuropeptides, especially those which possess a high isoelectric point (pI).     
  
1.2 Thesis Outline and Chapter Objectives: 
1.2.1 Chapter Two 
 This chapter is a review of analytical methods for the quantitation of endogenous peptides.  A 
variety of techniques are covered that have been employed for the determination of peptides in plasma, 
urine, tissues, and microdialysis samples.  The review briefly describes matrix-assisted laser desorption 
ionization, radioimmunoassays, and ELISAs.  However, the primary focus is on separation-based 
analyses including LC, CE, and ME.  A variety of detection methods are also covered including UV, laser 
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induced fluorescence (LIF), amperometry, and mass spectrometry.  Examples from the literature are given 
for a variety of biological matrices.   
1.2.2 Chapter Three 
The development of capillary electrophoresis methods for the separation of dynorphin A 1-17 
(Dyn A 1-17) and four of its key metabolites is presented.  Buffer optimization is discussed in detail.  
Phytic acid was used to circumvent adsorption of high pI peptides to the capillary wall.  Additionally, 
resolution of closely related peptide metabolites was overcome using cyclodextrins.  An on-capillary 
copper complexation technique was explored in an effort to improve limits of detection with UV and also 
to render the peptides electroactive for future applications using microchip electrophoresis with 
electrochemical detection.  The in vitro metabolism of Dyn A 1-17 was investigated in human plasma as 
well as rat brain and spinal cord slices.   
1.2.3 Chapter Four 
 This chapter is focused on the development of a quantitative LC-MS/MS technique for Dyn A 1-
17 and its metabolites.  Two mass spectrometry instruments, a Quattro micro (Waters) and an API 2000 
(AB Sciex), were evaluated.  Optimization for dynorphin peptides was performed on each.  The tunable 
parameters and settings of the two were compared.  The remainder of the chapter is focused on the 
optimization of the liquid chromatographic separation of the dynorphins and the challenges associated 
with the analysis of peptides in biological matrices.  In particular ion suppression in the presence of a cell 
compatible solution, phosphate buffered saline with ascorbic acid (PBSA), was observed and 
modifications to this buffer were necessary for adequate ionization.  This chapter lays the groundwork for 
the in vitro investigations of Dyn A 1-17 metabolism presented in Chapter 5.  
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1.2.4 Chapter Five 
 The LC-MS/MS method developed in Chapter 4 was applied to in vitro studies of Dyn A 1-17 
metabolism.  Initially the in vitro studies were performed in central nervous system (CNS) tissues, namely 
in rat brain and spinal cord slices.  The metabolism was then investigated in the presence of an in vitro 
blood brain barrier (BBB) model consisting of a primary culture of bovine brain microvessel endothelial 
cells (BBMECs).  The identification of Dyn A 1-6 as a key metabolite in each of these systems led to 
further investigations of this peptide’s transport across the BBB.  Directional and temperature dependence 
of this transport are addressed as well as the effect of this peptide on the transport of the low molecular 
weight, membrane impermeant molecule fluorescein.   
1.2.5 Chapter Six 
 This chapter is a review of immunoaffinity capillary and microchip electrophoresis techniques as 
well as preliminary work towards the development of an immunoaffinity microchip system for 
investigating dynorphin metabolism.  In moving towards micro total analysis systems (µTAS) for 
continuous monitoring of peptides, considerable improvements must be made in sensitivity and 
selectivity.  In particular, neuropeptides are present in vivo at low nanomolar-picomolar concentrations.  
While immunoassays address the necessary limits of detection for these species, cross-reactivity with 
structurally homologous species can hinder accuracy.  This is of particular importance when trying to 
study neuropeptide metabolism.  As demonstrated in Chapter 2, electrophoresis offers a highly efficient 
separation format for such studies.  Miniaturization can further improve temporal resolution of such 
techniques.  However, sample clean-up and preconcentration are often essential for analysis in biological 
matrices, especially for the determination of low abundant peptides.  Therefore, incorporation of an 
immunoaffinity port into a microchip electrophoresis device can combine the high specificity of 
immunoassay with the high resolving power of electrophoresis.  For future applications involving in vivo 
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microdialysis studies, such devices have the added benefits of small sample volume consumption and fast 
separation times, making near-real time monitoring of neurochemical processes a conceivable reality.  
1.2.6 Chapter Seven 
 This chapter gives an overview of the research presented in this thesis.  The Dyn A 1-17 
metabolites identified by both CE and LC-MS/MS are summarized.  Future work towards the 
development of an integrated immunoaffinity microchip electrophoresis system for in vitro and in vivo 
investigations of dynorphin metabolism and transport at the blood brain barrier is described.  Also, 
additional experiments involving IAME techniques for biologically related analytes such as an 
“immunoaffinity pain microchip” are addressed.                
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Chapter Two: 
Analytical Strategies for the Determination of Peptides in Physiological Samples 
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2.1 Introduction 
Peptides are involved in a plethora of signaling pathways in vivo including pain 
perception, blood pressure regulation, and neurotransmission.  They can act as neurotransmitters, 
hormones, antibiotics, toxins, enzyme inhibitors, and immune modulators.  Endogenous peptides 
have been implicated as potential biomarkers for a variety of diseases including neurological 
disorders such as Alzheimer’s and Parkinson’s diseases, diabetes, arthritis, neuropathic pain and 
some cancers.  Exogenously delivered biotherapeutics are also gaining popularity, and thus their 
stability and pharmacokinetic properties in vivo must be investigated.  Additionally, much of the 
work in the proteomics arena is focused on the analysis of peptide fragments, used to determine 
structural information about key proteins of physiological interest.   
The analysis of peptides is therefore an important analytical pursuit for a variety of 
scientific areas including pharmaceutics, neurochemistry, clinical testing, biomarker discovery, 
proteomics, and peptidomics.  More specifically, this analysis must be applied to in vivo and in 
vitro samples which are complicated matrices, containing other protein and peptide components 
that can interfere with analysis and diminish sensitivity.  This chapter will therefore discuss 
analytical methods for the determination of peptides in biological samples.  In particular, 
methods for analyzing known peptides in blood, urine, and cerebrospinal fluid (CSF) will be 
addressed, as well as the analysis of microdialysates from a variety of tissues and animal models.  
Common methods for sample preparation will be briefly described as they apply to biological 
samples.  Primarily, mass spectrometric- and separation-based techniques will be discussed, 
although a brief discussion of immunoassays is also included.      
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2.2 Sample preparation 
 Several key challenges exist with the analysis of peptides, specifically those in biological 
fluids.  The first, of course, is accurately determining the concentration of analyte(s) of interest in 
complicated matrices such as blood, urine, and cerebral spinal fluid, all of which contain a 
variety of salts, amino acids, peptides, and proteins that can interfere with analysis.  In addition 
to these body fluids, peptides can be sampled from tissues via microdialysis, studied in tissue 
homogenates, and investigated with in vitro samples such as cell culture.  Therefore, clean-up 
and desalting prior to analysis is often necessary.  There are four commonly employed sample 
preparation methods that can aid in decreasing the effects of matrix components on analysis: 
solid phase extraction (SPE), protein precipitation (PP), liquid-liquid extraction (LLE), and 
immunoaffinity purification.   
Protein precipitation is likely one of the simplest and least expensive sample clean-up 
procedures.  PP is easily employed by the addition of at least twice the volume of either an 
organic (usually acetonitrile) or an acidic solution.  Due to the fact that co-precipitation of 
peptides is possible, PP can risk loss of the analyte(s) of interest.  This method is also often 
incorporated with other sample clean-up methods because remaining matrix components can still 
cause interference with subsequent analysis.   
Liquid-liquid extraction relies on the different solubility of a compound in aqueous 
versus organic solvent.  This method is difficult to employ for most peptides due to their inherent 
polarity.  However, certain applications of LLE are beneficial, specifically when the peptide of 
interest is cyclic or contains modified N- and/or C-termini.  Solid phase extraction (SPE) can be 
performed with a variety of materials including non-polar, polar, ion-exchange and mixed 
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materials, making this method selective and versatile.  In addition to selecting the appropriate 
material for the desired application, solvents and elution solutions are also optimized for 
recovery of the peptides of interest.  SPE can also conveniently be incorporated online prior to 
reverse phase LC with column switching techniques.   
Immunoaffinity purification is a sample clean-up method with high specificity for the 
compounds of interest.  For example, antibodies immobilized on magnetic beads can be used 
prior to analysis [1].  While offline immunoaffinity can be utilized, an advantage of such a 
technique is the various ways to incorporate online cleanup directly to the analysis method.  For 
example, antibody modified affinity columns can be used prior to RP HPLC with the use of 
column switching.  Antibodies can also be immobilized into capillaries or reservoirs for clean-up 
prior to analysis by capillary or microchip electrophoresis. 
For many biological matrices, especially blood, large proteins such as albumin are 
responsible for a large portion of the matrix interference.  Simple methods such as molecular 
weight cut-off filters can significantly reduce interference from these proteins.  Care must be 
taken to determine recovery of the peptides of interest and account for loss following filtration.  
In addition to sample preparation to remove interfering matrix components, peptide adsorption to 
vials, pipette tips, as well as instrument components can interfere with accurate analysis, 
especially in low concentration samples.  This issue will be very compound specific and will 
need to be addressed on a case-by-case basis during the method development phase for each 
peptide.  In this thesis, the adsorption of dynorphin peptides to the wall of a fused silica capillary 
during analysis  by CZE and the addition of ion-pairing agents in the sample and run buffer to 
prevent this (Chapter 3) [2] is discussed.  In addition, silanization of glass side-by-side diffusion 
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chambers is employed in Chapter 5 to prevent dynorphin adsorption during cellular transport 
assays.   
Sample stability is another important consideration in peptide analysis, both at room 
temperature, during sample prep and analysis, as well as during storage (typically frozen).  Most 
reports have included various enzyme inhibitors to prevent degradation.  As can be seen in 
Figure 2.1, the stability of bradykinin is significantly improved with the inclusion of both an 
ACE-inhibitor and an N-carboxypeptidase inhibitor (captopril and MEGETPA specifically) [3].         
          
2.3 Analytical Techniques for Peptide Analysis 
2.3.1 Immunoassays 
 Historically immunoassays have been employed for the quantitation of peptides.  These 
methods are highly sensitive, and are typically aimed at the quantitation of one particular 
compound.  Despite their sensitivity, cross-reactivity with peptides of similar structure or 
sequence can generate false results.  This is especially problematic when sampling from a 
biological fluid that will likely contain other peptides.  Assays are also time consuming and 
expensive.  Radioimmunoassays (RIA) in particular are expensive due to the use of radiolabeled 
compounds and carry some risk of handling such reagents.  Enzyme-linked immunosorbent 
assays (ELISAs) circumvent the use of radiolabeled compounds, but are still relatively 
expensive.  Nevertheless, immunoassays have extensively been employed for the determination 
of peptides from a variety of biological fluids.  Immunoassays have been reported for the 
detection of peptides in blood [4], plasma [5], urine [6, 7], and CSF [8-11].  A recent report 
describes a novel radioimmunoassay (RIA) for the quantitation of the iron regulatory peptide  
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Figure 2.1  Bradykinin degradation in bovine plasma is inhibited by the addition of both the 
ACE-inhibitor captopril and the N-carboxypeptidase inhibitor MEGETPA (square data points) as 
compared to the stability of bradykinin in plasma without inhibitors (diamond data points).  Full 
inhibition was not achieved with captopril alone (1 mM – circle data points or 2 mM- triangle 
data points).  Reprinted with permission from [12]. 
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hepcidin in human plasma, verifying the peptide’s relationship to iron levels in patients with 
chronic kidney disease [5].  Patient hepcidin levels increased dramatically 24 hours post I.V. iron 
infusion (Figure 2.2).   
In addition to the expense and time, immunoassays are typically employed for the 
detection of a single analyte.  In most cases of peptide analysis, it is desirable to detect several 
related peptides simultaneously.    For example, the investigation of peptide metabolism is 
essential for understanding the unique role of metabolites in vivo.  Therefore, the remainder of 
this review will focus on methods that are capable of monitoring several related peptides in a 
single assay.  This includes mass spectrometry- and separation-based methods for determining 
peptides in physiological fluids.  In addition to the techniques discussed in the following 
sections, many researchers have found that a combination of separation techniques aids in the 
analysis of such complicated samples.  Two dimensional chromatography [13-16], 
immunoaffinity CE [17, 18] and ME [19-21], and on-line CE-LC separations [22] have all been 
employed to improve limits of detection and decrease interferences from matrix components.  Of 
particular importance to the work in this thesis is the increased combination of immunoaffinity 
purification on-line with electrophoretic separations.  
2.3.2 Matrix assisted laser desorption ionization mass spectrometry (MALDI MS) 
Matrix assisted laser desorption ionization mass spectrometry ionizes samples that have 
been co-crystallized with a compound which is usually a UV-adsorbing weak organic acid.  
Molecules are transferred to the gaseous phase following UV laser excitation.  MALDI mass 
spectrometry is most often paired with time-of-flight (TOF) mass analyzers.  Most MALDI MS  
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 Figure 2.2  Hepcidin (grey bars) and ferritin (black bars) concentrations in patients with chronic 
kidney disease pre- and post-IV treatment with 200 mg iron sucrose.  Reprinted with permission 
from [5]. 
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applications are qualitative in nature and achieve accurate peptide identification in biological 
samples. 
There are some semi-quantitative techniques reported, however; most reports utilize 
MALDI for its sensitivity, ionization interested readers should consult the following review [25].  
MALDI also offers an attractive alternative of intact peptides and proteins, molecular weight 
determination, and wide mass range.  One advantage of MALDI over electrospray ionization 
(ESI) is the increased ability to ionize samples in the presence of salts and buffers that are 
common contaminants in biological samples without signal suppression.  De-salting prior to 
spotting on MALDI plates however, is still a common sample preparation technique.  
Additionally, ionization by MALDI is highly dependent upon the matrix chosen and sensitivity is 
both highly compound and matrix dependent.  A variety of matrix components have been 
investigated to enhance ionization of peptides from biological samples [23, 24].  A detailed 
discussion of these processes is beyond the scope of this review, however; for the analysis of 
cyclic peptides which typically exhibit decreased ionization by ESI when compared to linear 
peptides.  For example, the metabolism of the peptide cyclotide kalata B1 in plasma was 
characterized by both LC-MS and MALDI and the limits of detection were improved by two 
orders of magnitude with MALDI [26].   
MALDI mass spectrometry has been applied extensively to studies investigating peptide 
metabolism in a variety of tissues, such as the degradation of neurotensin in human and rat 
plasma [27].  Chait and Kreek developed MALDI methods for the identification of dynorphin 
metabolites in both human and rhesus monkey blood ex vivo [28-30].  Additionally, the group 
investigated the in vivo metabolism of the peptide Dyn A 1-17 in rat striatum [31].  Reed et al 
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examined the biotransformation of the opioid peptide β-endorphin in the rat striatum via 
microdialysis [32].  The opioid activity of the identified peptide fragments (Figure 2.3) was 
further evaluated.  In addition to the in vivo metabolism, the work also characterized β-endorphin 
degradation in rat cerebrospinal fluid and rat brain striatum slices.  MALDI has also been used 
by others to analyze neuropeptide content in rat brain slices.  Different neuropeptide patterns 
were exhibited between animals previously identified as low and high cocaine responders, 
suggesting a link between neuropeptide expression and addictive behavior [33].  MALDI has 
also been applied to the analysis of peptide biomarkers in urine [34, 35].     
In addition to traditional peptide identification studies, recent work has focused on 
molecular imaging capabilities of MALDI (IMS).  Several recent reviews are published on 
advances in this area [36, 37].  Direct analysis of peptides within tissue sections generates a 
three-dimensional representation of peptide distribution within whole organs, thus rendering not 
only molecular information, but also spatial localization [38].  For definitive peptide 
identification additional techniques, such as LC-MS/MS and MALDI-MS/MS, are often 
employed after MALDI imaging analysis is completed.  Seeley and Caprioli reported the use of 
IMS for determining β-amyloid distribution in a mouse model of Alzheimer’s disease [39].  Like 
traditional staining techniques, IMS enables the localization of these peptides in specific brain 
regions, but the technique also differentiates between various amyloid isoforms that are present 
in the disease model (Figure 2.4).   
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Figure 2.3   MALDI mass spectra of microdialysis samples from the rat brain striatum following 
microinfusion of β-endorphin.  The appearance of new metabolites was observed with increased 
time.  Reprinted with permission from [32]. 
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Figure 2.4  Imaging mass spectrometry (IMS) of β-amyloid plaques in an Alzheimer’s disease 
model.  Not only can plaque localization be determined, but also the molecular composition of 
those plaques. Reprinted with permission from [39]. 
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2.3.3 Liquid chromatography 
 Liquid chromatography (LC) is a commonly employed separation technique for peptide 
analysis.  Most applications utilize reverse phase stationary phases (C8 and C18 are common), 
and retention is based on the interaction of hydrophobic moieties on the peptide with the column 
stationary phase.  LC can be paired with a variety of detectors including UV, fluorescence, and 
though not as common, electrochemical.  UV detection is by far the most commonly employed 
mode of detection; however, the lack of specificity is a significant drawback, especially when 
sample matrices are complicated.  Fluorescence and electrochemical detection both require 
derivatization of samples prior to analysis, as peptides lacking tryptophan residues are not 
inherently fluorescent and those lacking tyrosine residues are not electroactive.  Nevertheless, 
there are still reports of peptide quantitation using these techniques.  LC with UV detection has 
been employed for the quantitation of enkephalin and vasopressin analogs spiked into human 
urine [40].  Thompson et al utilized LC-UV for the determination of leucine enkephalin 
metabolism and transport at the blood brain barrier [41-43].   
Weber’s group has extensively evaluated the ability of peptides to form complexes with 
copper (II) ions, rendering even des-tyrosine peptides electroactive.  They were able to detect a 
pharmaceutically relevant peptide in bovine serum using this method [44].  The peptide 
investigated, TP9201, is both cyclic and N-amidated preventing the applicability of most 
fluorescent labeling schemes for this analysis.  Pre-column complexation with copper was 
utilized by Kennedy’s group for the determination of vasopressin and bradykinin in rat 
microdialysates using capillary LC with electrochemical detection.  The authors report 
concentration detection limits in the low picomolar range [45].   
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LC with fluorescence detection enabled the determination of leucine enkephalin (0.31 
nmol/mL) in spiked human plasma following pre-column derivatization with NDA/CN- [46].  
Quantitative analysis of the opioid peptide drug DADLE and two cyclic prodrugs of the same 
peptide was achieved in rat plasma also employing pre-column NDA/CN- derivatization [47].  
SPE was used prior to peptide labeling, and the reported limit of quantitation was 6 ng/mL.  In 
the work of Schwartz and Matuszewski a peptide-doxorubicin conjugate was evaluated as a 
prodrug approach to deliver the cytotoxic drug doxorubicin using LC with fluorescence detection 
[48].  Following I.V. administration stability was evaluated in chilled human plasma that 
contained the additive EDTA which prevented further ex vivo metabolism of the peptide-drug 
conjugate (Figure 2.5).   
Matrix interference is often a significant issue with UV, electrochemical, and 
fluorescence detection due to the lack of specificity with all three of these detection methods.  
Sample clean-up is essential and often long gradient separations are required to separate peptides 
of interest from interfering species to accurately determine peptide concentrations.  For these 
reasons, mass spectrometry is the most attractive detector for the analysis of peptides in 
biological fluids, and several reviews have been published on the topic [49-51].  The selectivity 
of mass spectrometry and the improved sensitivity and specificity gained from tandem mass 
spectrometry techniques make it an attractive mode of detection following LC separation.  In 
LC-MS applications, special considerations must be taken when selecting a mobile phase system.  
Non-volatile buffers, for example, are not compatible with MS.  Narrow-bore columns as well as 
capillary columns are more often employed in these systems to increase ionization efficiency due 
to decreased volumetric flow rate.  Most applications involve direct coupling of the LC flow to 
electrospray ionization sources (ESI), and many also utilize tandem mass spectrometry  
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Figure 2.5  A- Human plasma 45 min post I.V. dose of compound I; B- Human plasma 2.5 hours 
post I.V. dose of compound I.  Compounds I-IV (I= doxorubicin-conjugate, II-doxorubicin, 
III=leucine-doxorubicin, IV=internal standard).  Reprinted with permission from [48]. 
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functionality for the increased sensitivity and specificity as well as the improvements in 
quantitation.    
Of all the body fluids, blood products are by far the most commonly analyzed.  Its 
removal from patients is relatively non-invasive, and therefore much of the work towards 
identifying disease biomarkers has focused on peptide determination in plasma or serum.  Drug 
plasma levels are also crucial for assessing pharmacokinetic properties of therapeutics, making 
assays that enable accurate and sensitive high throughput quantitation of peptides from this 
matrix essential for drug development.  Researchers investigating melanotan-II, a synthetic 
peptide analog thought to have therapeutic potential for the treatment of obesity, were able to 
determine concentrations in both mouse plasma and brain homogenates following isoperitoneal 
(I.P.) administration of the peptide [52].  The method employed protein precipitation with 
acetonitrile prior to LC-MS/MS analysis and improvements over previously reported limits of 
detection were achieved in both plasma and brain tissue: 0.5 ng/ml and 2.5 ng/mL respectively 
versus 5 ng/mL and 40 ng/mL as previously reported [53].  Work by van den Broek and 
colleagues has utilized LC coupled to tandem MS for a variety of assays to quantitate peptide 
biomarkers in human serum and plasma [3, 12, 54, 55].            
Pharmaceutical applications of exogenously administered peptides typically utilize LC-
MS/MS for determination of drug plasma concentrations.  Due to the high potency and therefore 
low dose of these drugs, analytical methods for the determination of these compounds in plasma 
must achieve excellent limits of detection.   Muraro et al generated a plasma concentration-time 
profile of a synthetic parathyroid hormone analog in rat plasma after I.V. administration (Figure 
2.6) [56].  The method enabled lower limits of detection of 0.2 ng/mL for the synthetic peptide.
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Figure 2.6  Plasma concentration-time profile in rat of [M1]-PTH(1-14)NH2 after I.V. 
administration (100 µg/kg).  Reprinted with permission from [56]. 
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Determination of the HIV inhibitor, sifuvirtide, was accomplished in HIV+ human 
plasma by LC-MS/MS with a simple protein precipitation sample clean-up procedure [57].  A 
lower limit of quantitation of 9.75 ng/mL was reported.  Quantitative determination of a peptide 
drug in clinical trials is described by Lovgren et al with lower limit of quantitation reported as 
5.0 pg/mL in human plasma [13].  The method employed a cyano column-C4 reverse-phase 
column-C18 reverse phase column couple to remove phospholipids known to cause ion 
suppression.  The LC system was further coupled with an ESI-triple quadrupole mass 
spectrometer for tandem MS. 
While blood (plasma and serum specifically) is by far the most extensively investigated 
biological fluid, urine has received considerable attention as a body fluid for screening 
biomarkers of disease.  Very few intact proteins are found in the urine, therefore smaller peptide 
metabolites can more easily be identified [58-60].  The determination of type II collagen 
degradants by LC-MS/MS is described by multiple groups [61-63].  Type II collagen is known to 
degrade in patients afflicted with osteoarthritis, and as such is a potential biomarker for 
osteoarthritis for both diagnosis and progression.  It is thought that metalloproteinases are 
responsible for this degradation, and therefore proteolytic peptide fragments of type II collagen 
are of interest as disease biomarkers.  In these studies, immunoaffinity chromatography was 
performed online with a quantitative LC-MS/MS method to determine collagen peptides in rat 
and human urine [62].  The experimental set-up is shown in Figure 2.7.  The potential with this 
method is a clinical assay for earlier diagnosis of osteoarthritis.  C-reactive protein is another 
peptide investigated extensively as a biomarker in urine by LC-MS/MS [14, 58-60, 64].   
The application of mass spectrometry to the quantitation of peptides in the central 
nervous system has also been employed.  LC-MS/MS has been used for monitoring the release of  
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Figure 2.7  Immunoaffinity column switching diagram. Immunoaffinity (IA) column was 
functionalized with antibodies to the neoepitope of type II collagen (NET2C).  At t = 0 min, 500 
µL urine was injected onto the IA column (diverted to waste), at t = 1.7 min the sample was 
eluted from the IA column and focused on the trap column, and at t = 4.3 min gradient elution 
off the trap column and through the analytical column to the mass spectrometer was performed.  
Reprinted with permission from [62].   
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neuropeptides into the extracellular space following microdialysis sampling [65-67] and for the 
analysis of peptides in cerebral spinal fluid (CSF) [68-71].  In vitro investigations of blood brain 
barrier transport characteristics of endogenous neuropeptides [72] and synthetic peptide analogs 
[73-74] have also been explored using LC with tandem mass spectrometry. 
2.3.4 Electrophoresis 
 Electrophoresis is also a convenient format for the separation of peptides since they are 
charged species.  Separation occurs based on each compound’s mass to charge ratio.  Advantages 
of this mode of separation include small sample volumes, efficient separations with high 
resolution, and the potential for miniaturization which decreases sample volume further and 
improves assay time and often sensitivity.  The simplest format of capillary electrophoresis is 
capillary zone electrophoresis (CZE); however, variations to this technique can be made to 
improve resolution and alter peptide electrophoretic behavior.   
Capillary electrophoresis can be modified in rather simple ways to alter migration order 
and resolution, thereby improving the separation of peptides from interfering substances for each 
specific application.  For example, surfactants can be incorporated to reverse the electroosmotic 
flow for faster detection of anionic species, modifiers such as cyclodextrins can improve 
resolution of closely related species, capillaries can be modified to prevent adsorption issues and 
alter electroosmotic flow, and transient isotachophoresis (tITP) can be used prior to CZE to 
preconcentrate samples thereby improving limits of detection.  Similar modifications can be 
made in the microchip format as well, and the selection of microchip material can also be 
optimized for each desired application.  Additionally a variety of detection schemes can be 
employed.  Below a discussion of both capillary and microchip electrophoresis details other 
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important advantages of the two techniques as well as applications of each to peptide analysis in 
physiological fluid.  
2.3.4.1 Capillary electrophoresis (CE) 
A variety of detection modes can be employed with CE for the analysis of peptides 
including: UV [75], fluorescence [75, 76], electrochemical [77-79] and mass spectrometry [80, 
81].  As with LC, UV detection is the most common; however, since this is a universal detector, 
matrix interference can be problematic.  Nevertheless, CE with UV has still been employed for a 
variety of biological applications, simply because of its ease of operation and inclusion in most 
commercially available instrumentation.  Most studies involve spiking the biological matrices of 
interest with known concentrations of peptide(s).  Stroink et al utilized CZE coupled with online 
size exclusion chromatography (SEC) and a reverse-phase C18 trapping column for the detection 
of spiked enkephalins in human cerebral spinal fluid [22].  Angiotensin II and gonadorelin have 
been determined in plasma following spiking [82, 83].  Even when these peptides were spiked 
into plasma, sample clean-up by SPE was still necessary, and transient isotachophoresis was also 
incorporated prior to CZE for preconcentration.       
One important application for which CE has been explored is for the determination of 
peptides in the central nervous system (CNS).  Not surprisingly, perhaps, one of the most recent 
interests in neurochemistry is the development of sensitive assays for biomarkers linked to 
Alzheimer’s disease.  Aggregated forms of β-amyloid (Aβ) peptides are found in the plaques of 
patients with Alzheimer’s disease as determined post mortem.  Aβ peptides were investigated in 
CSF using CE with UV detection [84].  Sample preparation, storage conditions, and background 
electrolyte selection were optimized to prevent aggregation.  As is demonstrated in Figure 2.8 A, 
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the separation of five amyloid peptide standards was achieved.  The presence of Aβ 1-40 in the 
CSF of an Alzheimer’s patient is confirmed following de-salting and 20-fold concentration of the 
sample (Figure 2.8 B).      
Fluorescence and electrochemical (EC) detection have been utilized with CE; however, 
both typically require sample derivatization prior to analysis.  Most labeling techniques require 
reaction with amine groups such as the peptide N-terminus or lysine residues.  Therefore 
peptides with modified N-termini or those lacking a lysine residue will not be detected.   Copper 
complexation however, is an attractive technique for the detection of peptides electrochemically 
[85-88].  It does not require an amine for the reaction and it is selective over amino acids 
residues and peptides of less than 3 amino acids in sequence.  Complexation can be carried out 
on-capillary so that additional sample dilution is not necessary.  CE-EC with copper 
complexation has been utilized by our group previously for the quantitation of enkephalin and 
angiotensin peptides spiked in human plasma [89, 90].  Non-aqueous CE has also been 
performed with electrochemical detection for the determination of leucine enkephalin and 
methionine enkephalin [91].  Conductivity detection has also been employed for the analysis of 
peptides [92-94].  In one particular example, cytochrome c and apomyoglobin were digested on-
capillary with trypsin [95].     
Determination of peptides in physiological fluids has also been performed using CE with 
fluorescence detection.  The metabolism and transport of substance P at the blood brain barrier 
has been investigated by Freed et al utilizing CE-LIF [96, 97].  Samples were derivatized prior to 
CE analysis by NDA/CN-.  Peptide hormones [98] and carnosine-related peptides [99] have also 
been determined in the CSF by CE with LIF following pre-capillary derivatization with 
fluorescein isothiocyante (FITC) and 3-(4-carboxybenzoyl) quinoline-2-carboxaldehyde  
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Figure 2.8  A. CE separation of 5 amyloid peptides using 1,4-diaminobutane (DAB) as a 
dynamic capillary coating to slow electroosmotic flow (EOF) and improve resolution.  B.  
Electropherograms of CSF from a patient with Alzheimer’s disease (AD).  CSF from an AD 
patient (A), CSF from an AD patient, spiked with 5 amyloid peptides (B), CSF from an AD 
patient, desalted and concentrated, Aβ 1-40 confirmed by spiking (C), and CSF from an AD 
patient, desalted and concentrated (D).  Reprinted with permission from [84].  
A. 
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(CBQCA), respectively.  Sheeley et al exploited the high resolving power of CE to separate D-
amino acid-containing peptides from their L-amino acid counterparts [100].  While mass 
spectrometry would not distinguish between these two compounds because their masses are 
identical, CE-LIF does.  Peptides were derivatized with fluorescamine prior to separation and 
then were resolved under MEKC conditions employing the surfactant sodium dodecyl sulfate 
(SDS) as well as gamma cyclodextrin to further improve resolution.  The D-amino acid-
containing peptide, NdWFa, and its counterpart, NWFa, were then detected in the neurons of the 
abdominal ganglia of Aplysia californica.    
CE has also been employed with mass spectrometric detection.  Online coupling of CE to 
MS uses electrospray ionization (ESI), while offline CE-MS analysis is typically accomplished 
with matrix-assisted laser desorption ionization.  CE-ESI-MS uses either a sheath- or sheathless-
flow to directly couple the CE flow to the ion spray source.  Special care must be taken when 
selecting a background electrolyte (BGE) in these applications due to the need for a highly 
volatile solvent for ESI.  Typical BGEs such as sodium phosphate, for example, are incompatible 
with electrospray ionization.  With CE-MALDI-MS, the CE eluent is spotted directly onto 
MALDI plates for identification of peptide samples.  Several reviews on the coupling of CE to 
mass spectrometry can be consulted for more detailed information [80, 81, 101-103].    
Several CE-MS methods have been applied to the determination of polypeptides in urine 
as potential biomarkers for renal diseases and prostate cancer [104-107].  Kaiser et al were able 
to establish polypeptide patterns using CE with ESI-TOF MS [108].  The method developed was 
applied to the analysis of urine from patients with various renal diseases.  As can be seen in 
Figure 2.9, urine polypeptide distribution patterns differ between healthy patients and those with 
diabetic nephropathy, minimal change disease (MCD), and focal segmental glomerulosclerosis  
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Figure 2.9  Differing polypeptide patterns in urine samples of A- healthy patients, B-diabetic 
nephropathy, C-minimal change disease, and D-focal-segmental glomerulosclerosis.  Reprinted 
with permission from [108]. 
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(FSGS).  To obtain structural information about the polypeptides, offline coupling of CE to a 
MALDI TOF-TOF instrument was subsequently performed. 
CE-MS has also been applied to the analysis of blood and plasma.  Work by Cao and co- 
workers separated α- and β-hemoglobin in human blood using CE-ESI-MS [104].  
Neuropeptides were analyzed by on-line SPE-CE-ESI-MS in human plasma [109].  Plasma 
samples were subjected to protein precipitation with acetonitrile and ultafiltration with a 
molecular weight cut-off filter prior to solid phase extraction on a C18 microcartridge and 
analysis by CE-ESI-MS.  Limits of detection ranged from 0.1 to 10 ng/mL depending on the 
peptide.   
2.3.4.2 Immunoaffinity capillary electrophoresis (ICE or IACE) 
 In addition to offline sample clean-up techniques, online incorporation of immune-based 
sample preconcentration is widely explored in conventional CE [110-113].  Antibody 
immobilization at the capillary inlet or into a small frit attached to the capillary enables 
biological samples to interact with selected antibodies prior to electrophoresis.  This effectively 
cleans the sample of any extraneous matrix components while simultaneously concentrating the 
peptides or proteins of interest at the head of the separation capillary. 
 Kalish and Phillips used immunoaffinity CE for the determination of inflammatory 
secretions from single cells [114].  Eleven different cytokines and chemokines were determined 
in single astrocytes following stimulation with vasoactive intestinal peptide (VIP).  The same 
group also reported the detection of neurotrophins in the serum of head trauma patients when 
previously such determinations have only been possible directly from brain tissue or CSF [115].  
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Guzman and coworkers have pioneered the use of this technique for the analysis peptide 
biomarkers and for proteomics [111, 116].  In one such example, immunoaffinity-CE-MS is used 
to differentiate between endogenous erythropoietin (EPO) and exogenously administered EPO 
analogs [117, 118].   
Immunoassays can also be performed on-capillary in solution.  Work by Kennedy’s 
group examined the insulin content of single islets of Langerhans by a capillary-based 
competitive immunoassay with LIF detection [119, 120].  In these instances, detection of the 
free-labeled compound (in this case insulin) and the insulin-antibody complex are detected 
(Figure 2.10).  The effect of glucose and calcium stimulation on insulin secretion were also 
evaluated in these cells (Figure 2.11)   
2.3.4.3 Microchip electrophoresis (ME) 
 Microchip electrophoresis is a miniaturized form of CE.  Channels are fabricated from a 
variety of materials including glass, plastics, and polymers.  Separations by microchip 
electrophoresis boast numerous advantages over the conventional format: decreased reagent 
consumption and analysis time, for example.  Other features such as their small footprint and 
portability, the ability for mass production and fabrication from disposable materials, and 
integration of multiple processes on a single device have fueled the exploration of such devices 
for clinical diagnostics.  Reviews of the application potential for microchip devices in the 
analysis of biomolecules are already published [121, 122].      
The most commonly employed modes of detection for ME are fluorescence and 
electrochemical; however, there are some reports of mass spectrometric detection as well.   
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Figure 2.10  Electropherogram of bound FITC-insulin and free FITC-insulin following on-
capillary immunoassay.  Injection times: A- 400 ms and B- 80 ms.  Reprinted with permission 
from [119]. 
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Figure 2.11  Insulin release from single islet of Langerhans following both glucose and calcium 
stimulation.  Reprinted with permission from [120]. 
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Electrochemical detection can be miniaturized without a loss in sensitivity.  Amperometry is 
commonly employed due to simplicity of electrode integration within the microchip device, 
especially when polymer substrates such as PSMS (poly (dimethylsiloxane)) are used.  Work in 
our lab employed the previously mentioned copper complexation technique to leucine 
enkephalin peptides offline prior to analysis on PDMS microchips with both carbon paste and 
carbon fiber working electrodes in a dual electrode format [123, 124].  Conductivity detection 
has also been illustrated for the detection of peptides; however, the application of these devices 
for physiological samples has not yet been extensively explored [125-129].    
Both fluorescence and chemiluminescence have been utilized for on-chip analysis of 
peptides.  Huynh et al performed on-chip derivatization of peptides with naphthalene 2,3-
dicarboxaldehyde/2-mercaptoethanol (NDA/2ME) from microdialysate, enabling subsequent ME 
separation with laser induced fluorescence, and demonstrating the utility of these devices for 
integrated sample preparation, separation, and on-line sampling [130].  Microchip analyses have 
also been performed for the determination of carnosine-related peptides in both human CSF and 
canine plasma following derivatization with a chemiluminescent label [131].  The same group 
analyzed the intracellular sulfhydryl protein hemoglobin in single human red blood cells [132].  
Cells were injected and lysed on-chip and their contents separated and determined downstream 
following on-chip labeling.       
While these examples highlight the use of microchips for the determination of peptides in 
“real” biological samples, much of the work in this arena thus far is still in its early stages of 
development.  Techniques for sample concentration prior to analysis as well as improved clean-
up of matrix constituents are currently being explored by numerous groups to advance the 
microchip platform in these research areas.  One such technique, involving antibody 
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immobilization within miniaturized devices, has received considerable attention in the past 
decade and is discussed in further detail in the next section of this chapter.   
2.3.4.4 Immunoaffinity Microchip Electrophoresis 
Much of the work with microchips for the analysis of physiological samples has 
incorporated sample-cleanup and preconcentration on the microchip device itself.  To this end, 
immunoaffinity microchip electrophoresis has been extensively explored.   As mentioned at the 
beginning of this chapter, immunoassays have long been the standard method for quantitation of 
peptides and proteins.  However, the need to analyze more than one peptide simultaneously and 
often peptides of similar structure renders cross-reactivity a significant drawback to these 
techniques.  Analytical researchers have, however, found convenient means for exploiting the 
antibody-antigen reaction in combination with electrophoretic separation.   
Online incorporation of immunoaffinity preconcentration and sample purification to both 
CE and ME is quickly becoming a go-to method for peptide and protein analysis [110-113].  
This work has been pioneered in part by the work of Dr. Terry Phillips.  Work in his lab has 
demonstrated the potential of these methods for the analysis of clinical samples ranging from 
skin biopsies to tears [17-21, 114, 115, 133].  In one report, the use of an immunoaffinity 
microchip electrophoresis system with LIF detection enabled the quantitation of twelve 
neuropeptides simultaneously in just two minutes [19] as can be seen by the electropherogram in 
Figure 2.12.  Additionally, brain-derived neurotrophic factor (BDNF) concentrations were 
determined in human skin biopsies.  These levels are related to atopic inflammatory events and 
can distinguish between patients who experienced no allergic reaction to severe atopic 
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dermatitis.  The relationship between the location of the tissue biopsy (i.e. distance from the skin 
lesion) was also explored (Figure 2.13) [21].      
The inclusion of sample preconcentration on a microchip device is essential for the 
application of such methodologies to the analysis of complex samples.  Progress in this area, in 
combination with work towards miniaturized detectors, on-chip derivatization, and on-line 
sampling, such as the coupling of microdialysis directly to the separation device, will enable the 
development of fully functional micro total analysis systems for fast, portable assays.         
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Figure 2.12  Electropherograms of neuropeptide standards (SP, CGRP, BDNF, IL-1β, VIP, NY, 
NT-4, β-endorphin, ACTH, CRH, IL-6, and TNF-α) following immunoaffinity microchip 
electrophoresis.  Reprinted with permission from [19].  
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Figure 2.13  Effect of distance from skin lesion on BDNF concentration in patients with varying 
degrees of atopic dermatitis.  Reprinted with permission from [21].   
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2.4 Summary 
 This chapter reviews a variety of separation-based techniques for the determination of 
peptides from physiological solutions.  Sample preparation is briefly addressed as well as 
immunoassays which have long been the gold standard for peptide and protein quantitation.  The 
applications of these methods to the analysis of blood, urine, CSF, microdialysate, and cell 
culture studies are also described and examples are presented.  
 Each of the methods discussed in this review has advantages and disadvantages for the 
determination of peptides in physiological fluids.  Both ELISA and RIA boast excellent limits of 
detection, enabling the determination of endogenous concentrations of low abundance peptide 
biomarkers.  However, the expense and problems associated with cross-reactivity limit their 
applicability for simultaneous determination of similar peptides.  This is especially problematic 
for investigating peptide metabolism.  MALDI mass spectrometry can simultaneously monitor a 
plethora of peptides without suffering ion suppression to the same extent as other ionization 
methods, such as electrospray.  Imaging capabilities with this technique make it not only a tool 
for molecular identification, but also spatial localization within organs.  Its quantitative abilities 
are limited, however, making this a method primarily used for peptide identification. 
 Separation-based techniques offer advantages over immunoassays and MALDI MS in 
that they can be paired with various detectors often enabling quantitative analysis while also 
simultaneously determining multiple peptides within a given sample.  Liquid chromatography, 
capillary electrophoresis, and microchip electrophoresis are described in this chapter as they 
apply to peptide analysis.  UV, electrochemical, fluorescence, and mass spectrometric detection 
have been employed to varying degrees with most of these separation techniques.   
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Liquid chromatography is a robust separation technique that has been used extensively 
for peptide analysis.  Specifically LC-MS/MS has seen extensive use for peptide analysis and is 
considered the gold standard of analytical techniques in most industrial applications such as 
pharmaceutics.  Instrumentation and columns can be costly, and long gradients are often 
necessary for peptides.  Electrophoresis offers an attractive separation for peptides which are 
charged species.  The highly efficient separations and low sample volumes are advantageous 
when analysis of volume-limited samples (such as microdialysis) is desired.  The low injection 
volumes can be problematic when very low abundance peptides are the analytes of interest, and 
therefore pairing CE with sensitive detectors is especially advantageous.  Miniaturization of the 
separation device decreases the sample volume requirements even further and offers faster 
analysis times and portability as additional advantages.  Resolution of structurally related 
peptides can be problematic in these microchip devices; however, various substrate and design 
options offer the users flexibility.     
UV detection is the most commonly used detection method with both LC and CE.  Its use 
is simple and most commercially available instrument comes outfitted with such detectors.  For 
peptide analysis, however, it is limited primarily by its selectivity, especially when analyzing 
biological samples containing interfering substances.  Electrochemical detection requires an 
electroactive moiety, such as tyrosine.  Its applications to peptide analysis have been extended by 
derivatizing strategies such as copper complexation.  This detection method has seen extensive 
application in microfluidic devices due to its inherent scalability.  Miniaturization of electrodes 
does not impact its sensitivity in the same way decreased pathlength decrease UV absorbance.  
Similarly, fluorescence detection typically necessitates a derivatization or labeling step unless 
peptides contain tryptophan.  Limits of detection with this method of detection are excellent.  A 
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limiting factor of many labeling chemistries is the requirement of a specific amino acid residue 
(often lysine) or an unmodified N-terminus.   
Mass spectrometry has been paired with LC, CE, and to a lesser extent ME.  This 
detection method offers the advantages of both specificity and sensitivity especially when 
tandem mass spectrometry is employed.  Most reports of LC or CE mass spectrometry employ 
electrospray ionization.  One of the concerns when using ESI is its propensity for ion suppression 
from matrix components.  Samples must therefore be adequately de-salted and rid of additional 
proteins and lipids prior to detection.   
Each of the techniques presented in this chapter has its own set of advantages and 
disadvantages.  Careful selection of the best analytical tool(s) is essential for quantifying 
peptides in complicated biological matrices.  Many of these techniques are best employed in 
tandem, used to supplement, confirm, and validate each report.  The development of hybrid 
techniques such as immunoaffinity CE and two-dimensional separations promises to advance the 
area of peptide determination.      
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3.1 Introduction 
Dynorphin A 1-17 (Dyn A 1-17) is an endogenous opioid peptide with selectivity for the 
kappa opioid receptor.  The structures of dynorphin and its major metabolites are shown in 
Figure 3.1.  The investigation of dynorphin analogs as potential therapeutics for treatment of 
cocaine abuse and peripheral pain management has also revealed a neurotoxic component to this 
peptide’s in vivo activity [1].  Elevated levels of dynorphin have been implicated in a variety of 
neurodegenerative disorders including Alzheimer’s disease [2], Parkinson’s disease [3], and 
neuropathic pain [4], as well as stress and depression [5].  It is hypothesized that the neurotoxic 
effects are non-opioid in nature and may arise from activation of the N-methyl-D-aspartate 
(NMDA) receptor [6, 7].  Once released into the extracellular space, dynorphin is subject to 
enzymatic degradation with each metabolite exhibiting its own unique biological effects.  It is 
possible that one (or more) of these metabolites is responsible for the neurotoxicity of dynorphin.  
Therefore, methods to study the metabolism of dynorphin in vivo are necessary to further 
elucidate the mechanisms of neurotoxicity.   
The most common method for quantitation of dynorphin in vivo is radioimmunoassay 
(RIA).  However, a major drawback to this approach is that cross-reactivity with metabolites can 
lead to falsely elevated results [8].  To circumvent this issue, chromatographic separation can be 
performed prior to the immunoassay.  In one report, HPLC/RIA was employed to investigate the 
metabolism of Dyn A 1-13 in human blood [9].  This process took over 24 hours and involved 
solid phase extraction for sample clean-up and relatively long LC gradients (>20 min), followed 
by fraction collection prior to RIA.  Another disadvantage of RIA is the use of expensive 
radioactive reagents and assay kits, as well as the costs associated with the disposal of 
radioactive waste.  A variety of other methods have been used to quantify opioid peptides such  
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Figure 3.1  Structure of Dynorphin A 1-17 (Y-G-G-F-L-R-R-I-R-P-K-L-K-W-D-N-Q) with 
metabolites of interest (1-6, 1-8, 1-13, 2-17) indicated by dotted lines.  
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as the enkephalins, endomorphins, and smaller dynorphin peptides including HPLC with UV 
detection [10], LC-MS [3, 11], CE-UV [12, 13], CE-LIF [13, 14], and CE-MS [15-19].  A review 
of these methods is provided in Chapter 2 of this thesis.  Qualitative and semi-quantitative 
MALDI methods have also demonstrated potential for monitoring dynorphin peptides [20-23].  
Mass spectrometry provides conclusive metabolite identification; however, the instrument 
requirements are expensive.   
   Capillary electrophoresis provides several advantages for monitoring peptides of 
biological and pharmacological interest [24, 25].  Highly efficient and fast separations are 
possible without the use of organic modifiers, separations can be performed at high pH, and 
various complexation strategies can be employed on-capillary.  The small volume requirements 
of CE enable the analysis of volume-limited samples and allow the use of expensive separation 
additives.  In this work, on-capillary copper complexation was investigated for the detection of 
dynorphin peptides.  Performing this complexation on-capillary is advantageous over pre- or 
postcolumn derivatization methods because sample dilution is avoided.  This is especially 
important for the analysis of expensive compounds and volume-limited biological samples such 
as microdialysis samples. 
In the late 1970s and early 1980s, Margerum and co-workers extensively characterized 
the coordination of Cu (II) with nitrogens in the peptide backbone [26-29].  This method is based 
on the biuret reaction, and can be used to improve UV detection of peptides as well as for the 
electrochemical detection of non-tyrosine containing peptides.  Weber’s group exploited this 
method for postcolumn derivatization of peptides to enable electrochemical detection following 
LC separation [30-33].  In a separate report, Kennedy’s group achieved picomolar detection 
limits of neuropeptides from microdialysis samples following precolumn derivatization with 
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copper and both UV and electrochemical detection [34].  Previous work in our group has applied 
on-capillary copper complexation for the amperometric detection of enkephalin and angiotensin 
peptides [35-37].  A major advantage of this approach is that it is selective for peptides in the 
presence of amino acids because at minimum a tripeptide is required for complexation.  
Additionally, in contrast to many fluorescence derivatization techniques based on reactions with 
primary amines, N-terminally modified and cyclic peptides are also capable of forming 
complexes with copper.   
In this chapter, a capillary electrophoresis based separation of Dyn A 1-17 and four 
previously identified metabolites is described.  Phytic acid and various forms of cyclodextrins 
are investigated as run buffer additives to prevent peptide adsorption and improve resolution 
between metabolites.  The copper complexation method is applied to in vitro metabolism in 
human plasma as well as rat brain and spinal cord.  To the best of our knowledge, this is the first 
report of studying dynorphin metabolism with capillary electrophoresis. 
 
3.2 Materials and Methods 
3.2.1 Reagents 
All dynorphin peptides (Dyn A 1-17, 2-17, 1-13, 1-8 and 1-6) were obtained from 
Bachem Biosciences, Inc. (King of Prussia, PA, USA).  Capillaries were obtained from 
Polymicro Technologies (Phoenix, AZ, USA).  Sodium tetraborate, phytic acid, D, L tartaric 
acid, copper (II) sulfate, β-cyclodextrin, and (2-hydroxypropyl)-β-cyclodextrin were all 
purchased from Sigma-Aldrich (St. Louis, MO USA).  Sulfobutyl ether-beta-cyclodextrin was 
obtained from Dr. Stella’s laboratory at the University of Kansas.  Mesityl oxide which was used 
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as a neutral marker for electroosmotic flow (EOF) determination was also purchased from 
Sigma-Aldrich (St. Louis, MO USA).  Human plasma was obtained at Watkins Health Center 
(University of Kansas, Lawrence, KS, USA).  Brain and spinal cord samples were obtained from 
male Wistar rats (Charles River, Wilmington, MA, USA).     
3.2.2 Human plasma samples 
Human plasma was obtained from a healthy volunteer at Watkins Health Center and used 
1-2 hours after withdrawal.  Plasma was diluted 1:10 in 100 mM sodium tetraborate with 25 mM 
phytic acid, pH 9.0, to slow enzyme activity and prevent the capillary from clogging.  Dyn A 1-
17 was added at a concentration of 200 µM and kept at room temperature to further retard 
enzyme activity.  An initial aliquot was taken at t = 0 and subsequent aliquots were taken 
approximately every 40 minutes, corresponding to a 25-minute separation and flushes with 
NaOH and run buffer between runs.  The run buffer for plasma analysis consisted of 100 mM 
sodium tetraborate, 25 mM phytic acid, 3 mM tartaric acid, 2 mM cupric sulfate, and 20 mM 
sulfobutyl ether-beta-cyclodextrin (SBE4-β-CD), pH 9.0.   
3.2.3 Rat brain and spinal cord slices 
The brains and spinal cords of male Wistar rats were removed on the day of analysis and 
kept in ice cold artificial cerebrospinal fluid (aCSF) prior to experiments.  Animals that could no 
longer be used for studies due to their weight were graciously donated by Dr. Craig Lunte’s 
laboratory at the University of Kansas. Tissue slices were prepared with a clean razor blade in a 
petri dish on a bed of ice.  The tissue slices were exposed to dynorphin at room temperature to 
slow enzyme activity.  For brain samples, a 5 mm by 5 mm section was bathed in 100 mM 
sodium tetraborate with 25 mM phytic acid, pH 9.0 that was spiked with 200 µM Dyn A 1-17.  
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Immediately, an aliquot was removed and analyzed by the optimized copper-complexation 
method.  Subsequent aliquots were removed at approximately 40-minute intervals to permit a 25-
min CE separation followed by flushes with NaOH and run buffer.  Similarly, a 5 mm length of 
spinal cord was prepared and bathed in buffer spiked with Dyn A 1-17.  Aliquots were removed 
every 40 minutes.  The run buffer for rat tissue slice analysis consisted of 100 mM sodium 
tetraborate, 25 mM phytic acid, 3 mM tartaric acid, 2 mM cupric sulfate, and 20 mM SBE4-β-
CD, pH 9.0.     
3.2.4 Capillary electrophoresis analysis 
Separations were performed on a Beckman Coulter PACE/MDQ (Brea, CA, USA) with 
UV detection at 200 nm and 280 nm.  The system was controlled using 32 Karat software, and 
all subsequent data analysis was performed with this software as well.  Fused-silica capillaries 
(50 µm id x 360 µm od) were obtained from Polymicro Technologies (Phoenix, AZ, USA).  A 50 
cm capillary (40 cm to detector) was used for native dynorphin and a 60 cm capillary (50 cm to 
detector) was used for the dynorphin-copper complexes.  A small window was burned through 
the polyimide coating 10 cm from the capillary end for UV detection.  Pressure injections were 
performed at 6.9 kPa for 5.0 seconds, and a separation voltage of 25 kV was applied with the 
anode at the injection end.   
Buffers were prepared in 18 MΩ deionized (D.I.) H2O and adjusted to pH 9.0 with the 
addition of NaOH.  Dynorphin stock solutions were prepared at a concentration of 1mg/mL in 18 
MΩ D.I. H2O and kept frozen until use when they were diluted to desired concentrations in 
sodium tetraborate (50 or 100 mM) with 25 mM phytic acid (pH 9.0).  Native dynorphin 
separations were accomplished using an optimized background electrolyte consisting of 50 mM 
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sodium tetraborate, 25 mM phytic acid, and 5 mM (2-hydroxypropyl) beta-cyclodextrin (HP-β-
CD), pH 9.0.  Separation of the copper complexes was achieved using 100 mM sodium 
tetraborate, 25 mM phytic acid, 3 mM D,L tartaric acid, 2 mM cupric sulfate, and 20 mM SBE4-
β-CD, also pH 9.0.      
 
3.3 Results and Discussion 
3.3.1 Separation optimization of native dynorphin peptides 
To study the metabolism of dynorphin in vitro, this work focused on the development of 
an electrophoretic separation of Dyn A 1-17 from four previously identified metabolites-two of 
which, in particular, have been implicated in neurotoxicity and neuropathic pain (1-13 and 2-17).  
Initially 50 mM sodium phosphate, pH 7.0, and 50 mM tetraborate, pH 9.0, were investigated as 
possible background electrolytes.  Under these conditions dynorphin peptides were not detected.  
Upon repeated injections very broad peaks with inconsistent migration times were observed; 
however, virtually no separation was seen between metabolites of interest.  To reduce adsorption 
of the basic peptides onto the capillary wall, phytic acid was added to the background electrolyte.  
Phytic acid is a polyanion and acts as an ion-pairing agent to shield positively charged amino 
acid side chains from interaction with the silanol groups on the capillary wall [38-41].  This has 
been used previously by our group to prevent adsorption of substance P metabolites [42].  In 
addition to preventing peptide adsorption at the capillary wall, phytic acid has also been shown 
to improve resolution [39-41].   
Ion-pairing with highly basic peptides was also shown to result in longer migration times 
due to an overall change in their net charge [38-39].  Phytic acid concentrations of 15, 20, and 25 
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mM were evaluated in the run buffer and sample buffer, and 25 mM was determined to be 
sufficient to prevent analyte adsorption while keeping currents low enough to avoid excessive 
Joule heating.  The structure of phytic acid and representative electropherograms of the 
concentration comparison can be seen in Figure 3.2.  Although incomplete resolution of Dyn A 
1-17 and 2-17 was still observed, higher phytic acid concentrations were not investigated due to 
high background currents resulting in increased noise and occurrence of bubble formation.  
There are several aromatic residues present in dynorphin that are capable of forming 
inclusion complexes with cyclodextrin, specifically Tyr1, Phe4, and Trp14.  To further improve 
the resolution of Dyn A 1-17 and the des-Tyr metabolite, 5 mM HP-β-CD was included in the 
optimized run buffer.  The final optimized separation is shown in Figure 3.3 along with the 
structure of HP-β-CD.  The UV response at 200 nm was linear over the concentration range of 
2.5-50 µM (R2= 0.991-1.000, 5 concentrations, n=3 for each).   
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Figure 3.2  Representative electropherograms demonstrating the effect of phytic acid (structure 
shown from food-info.net) concentration on peak shape, migration time and resolution.  Buffer: 
50 mM sodium tetraborate, 15, 20, or 25 mM phytic acid, pH 9.0.  Peptides are 100 µM in 50 
mM sodium tetraborate, various phytic acid concentrations, pH 9.0.  
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Figure 3.3  Optimized separation of native dynorphin peptides upon inclusion of HP-β-CD 
(structure shown from http://astrobiology.berkeley.edu).  Buffer: 50 mM sodium tetraborate, 25 
mM phytic acid, 5 mM HP-β-CD, pH 9.0.  Peptides are 100 µM in 50 mM sodium tetraborate, 
25 mM phytic acid, pH 9.0.  
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3.3.2 Separation optimization of copper-complexed dynorphin peptides 
It has been shown that, at basic pH, peptides can form complexes with copper (II) via 
nitrogens in the peptide backbone.  The complexation typically begins at the N-terminus, and the 
reaction of Cu(II) with a model peptide is demonstrated in Figure 3.4.  Copper complexation has 
been shown to effectively improve UV sensitivity while also rendering peptides electroactive 
[26-37].  As shown in Figure 3.5, complexation could be confirmed based on the shift in 
migration time seen with Dyn A 1-17 in copper-containing buffer (4.56 +/- 0.14 min versus 3.98 
+/- 0.08 min, n=3 for each).  This later migration time is due to the increase in overall negative 
charge on the peptide following complexation due to resonance delocalization at the dynorphin-
copper coordinate sites [26-29].  Inclusion of copper in the run buffer causes minimal if any  
The previously optimized 25 mM phytic acid was included in both run buffer and sample 
buffer during the optimization of the dynorphin-copper complex separation.  On-capillary 
complexation was performed using conditions previously optimized in our group employed for 
both enkephalin and angiotensin peptides [35-37].  The run buffer therefore included 50 mM 
sodium tetraborate, 25 mM phytic acid, 3 mM tartaric acid, and 2 mM cupric sulfate.  However, 
under these conditions, the resolution between all five peptides was decreased compared to 
native dynorphin peptides.  Copper complexation increases the overall negative charge on each 
peptide, reducing the differences in their mass-to-charge ratio, and thus, their electrophoretic 
mobilities.  All of the Cu (II)-peptides migrated later, with Dyn A 1-6 and 1-8 co-migrating, 
followed by 1-13, 1-17 and 2-17 co-migrating.  This resolution was improved somewhat when 
the EOF was decreased by increasing the concentration of sodium tetraborate to 100 mM.   
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Figure 3.4  Schematic of model 4-amino acid peptide with copper (II).  
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Figure 3.5  Comparison of migration time of Dyn A 1-17 with (blue) and without (purple) copper 
run buffer.  Native run buffer: 50 mM sodium tetraborate, 25 mM phytic acid, pH 9.0, Copper 
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run buffer: 50 mM sodium tetraborate, 25 mM phytic acid, 2 mM CuSO4, 3 mM tartaric acid, pH 
9.0.  Peptides were 100 µM.  Average migration times are reported, n = 3. 
To further improve the separation of the Cu (II) complexed peptides, several different 
types of beta-cyclodextrins were investigated.  Beta-cyclodextrins consist of seven 
oligosaccharides in a cyclic arrangement.  Inclusion complexes between hydrophobic amino acid 
residues and the cyclodextrin core form on capillary [43-44].  In particular, three aromatic amino 
acid residues in the dynorphin sequence- Tyr1, Phe4, and Trp14 -could complex with cyclodextrin.  
Changes in the substitution on the hydrophilic exterior of cyclodextrins alter their mobility on 
capillary.  HP-β-CD was evaluated at both 5 and 10 mM, unsubstituted beta-cyclodextrin (β-CD) 
was investigated at 5 and 10 mM, and SBE4-β-CD was evaluated at 2, 10, 15, and 20 mM.  The 
structures of these cyclodextrins as well as comparisons of the resulting electropherograms can 
be seen in Figure 3.6.   
Not surprisingly, sulfobutyl-ether-beta- cyclodextrin exhibited the most significant 
improvements in resolution due to its negative charge.  Interaction with the hydrophobic core 
resulted in a higher negative electrophoretic mobility for the peptide complex.  The effect of 
SBE4-β-CD concentration on the separation of dynorphin metabolites is shown in Figure 3.7 and 
3.8.  The optimal concentration of SBE4-β-CD was determined to be 20 mM and was included in 
all subsequent studies.  Under these conditions, UV response at 200 nm was linear over a range 
of 20-75 µM (R2=0.9808-0.9915, 5 concentrations, n=3 for each).  The optimized separation is 
shown in Figure 3.9.  
In general, copper complexation increased the peak heights and areas of dynorphin 
peptides when detected at both 200 and 280 nm.  Detection was most sensitive at 200 nm; 
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however, 280 nm offered more selectivity for copper-complexed peptides.  The calculated peak 
efficiencies for native dynorphin and dynorphin-copper complexes are reported in Table 3.1.  As 
can be seen in this table, the overall the separation efficiency improved upon complexation.    
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Figure 3.6  Representative electropherograms demonstrating the effect of various cyclodextrins 
(structure shown from http://astrobiology.berkeley.edu) on resolution of dynorphin-copper 
complexes.  Buffer:  50 mM sodium tetraborate, 25 mM phytic acid, 2 mM CuSO4, 3 mM 
tartaric acid, pH 9.0.  Peptides are 100 µM in 50 mM sodium tetraborate, 25 mM phytic acid, pH 
9.0.  
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Figure 3.7  Effect of SBE-β-CD on relative migration time. Run buffer contained 100 mM 
sodium tetraborate, 25 mM phytic acid, 3 mM tartaric acid, 2 mM cupric sulfate, and specified 
amount of SBE-β-CD. Peptides are 100 µM in 100 mM sodium tetraborate, 25 mM phytic acid.  
Migration times are based on averages of triplicate runs, relative to mesityl oxide a neutral 
marker. 
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Figure 3.8  Electropherogram overlays demonstrating the effect of SBE-β-CD on relative 
migration time. Run buffer contained 100 mM sodium tetraborate, 25 mM phytic acid, 3 mM 
tartaric acid, 2 mM cupric sulfate, and specified amount of SBE-β-CD. Peptides are 100 µM in 
100 mM sodium tetraborate, 25 mM phytic acid.   
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Figure 3.9  Optimized separation of dynorphin-copper complexes.  Buffer: 100 mM sodium 
tetraborate, 25 mM phytic acid, 20 mM SBE-β-CD, 3 mM tartaric acid, 2 mM CuSO4, pH 9.0.  
Peptides are 100 µM in 100 mM sodium tetraborate, 25 mM phytic acid, pH 9.0.   
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Peptide 
 
Native Dynorphin (N) 
 
Dynorphin-Copper Complexes (N) 
Dyn A 1-6 1200 19000 
Dyn A 1-8 18000 17000 
Dyn A 1-13 4100 4700 
Dyn A 1-17 5000 10000 
Dyn A 2-17 2300 9000 
 
 
 
Table 3.1.  Effect of copper complexation on separation efficiency.  
 
Each peptide was 100 µM (n=3) in sodium tetraborate buffer with 25 mM phytic acid.   Run 
buffer conditions: Native (50 mM sodium tetraborate, 25 mM phytic acid, 5 mM HP-β-CD, pH 
9.0, Complexes (100 mM sodium tetraborate, 25 mM phytic acid, 2 mM CuSO4, 2 mM tartaric 
acid, 20 mM SBE4-β-CD, pH 9.0). 
Efficiency (N) was calculated using the following equation: N=16(tR/wb)2. 
 
 
 
3.3.3 Analysis of in vitro dynorphin metabolism in biological tissues of interest 
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The analytical methods described above were then used to monitor the metabolism of 
dynorphin A 1-17 in vitro in biological tissues of interest.  Metabolic enzymes can vary greatly 
from tissue to tissue and species to species.  The neurotoxic effects of dynorphin peptides have 
generated an interest in the downstream effects of its metabolic processing since it may be a 
metabolite that is producing these effects.  More specifically, the role of dynorphin and its 
metabolites on the generation of neuropathic pain is of importance.  In particular, the transport 
and metabolism of this peptide at the blood brain barrier is of interest and could provide insight 
into the mechanism of dynorphin neurotoxicity.   
In these studies, the metabolism of Dyn A 1-17 was investigated in several tissues, 
including human plasma, rat brain, and rat spinal cord, using the optimized copper complexation 
method.  A 1:10 dilution of human plasma was spiked with Dyn A 1-17 (200 µM).  The 
metabolism was then monitored at 40-minute intervals.  As can be seen in Figure 3.10, at time t 
= 0, only one peak is present in the electropherogram.  The migration time of this peak 
corresponds with that of Dyn A 1-17. This peak was present only after spiking with dynorphin 
and was not observed in the plasma blank.  Therefore, it has been identified as the parent peptide.  
At time t = 160, two new peaks appear in the electropherogram.  The early migrating metabolite 
is identified as Dyn A 1-13 and the later migrating peak as Dyn A 1-6.  Again these peaks were 
identified based on injections of single metabolite standards and migration time comparisons.  
A similar experiment was performed to examine the metabolism of dynorphin in brain 
and spinal cord tissue slices.  A 5 mm x 5 mm section of each tissue was removed and bathed in 
a buffer solution spiked with Dyn A 1-17 (200 µM).  The metabolism of Dyn A 1-17 was 
monitored over time, and these electropherograms can be seen in Figure 3.11 (rat brain slice) and 
3.12 (rat spinal cord slice).  In the rat brain slice, at time t = 0, one dominant peak is observed for 
75 
 
the parent peptide.  The peptide is rapidly degraded in the presence of the brain tissue sample as 
can be seen by the complete absence of the 1-17 peak after 40 minutes.  At this same time, a later 
migrating peak also appears, and based on migration time, it is identified as Dyn A 1-6.  An early 
migrating peak also appears at this time point.  The migration time of this new peak does not 
correspond to that of any of the metabolites that were investigated in this study.  Interestingly, 
this early migrating unidentified metabolite also appears over time in the rat spinal cord sample.  
However, in the spinal cord slice, the metabolism of Dyn A 1-17 is considerably slower and only 
a small decrease in peak height of the parent compound is observed after 160 minutes.  
One of the limitations of CE for the analysis of basic peptides is the potential for analyte 
adsorption to the negatively charged silanol groups at the capillary wall [45].  Dynorphin is a 
highly basic peptide (pI= 11.4) [46] that has been shown to adsorb rapidly to glass and plastic 
surfaces [47].  While the use of polymer modified capillaries has been explored for separations 
of basic drugs and proteins, these are expensive and time-consuming to produce in house [48-
49].  A less expensive alternative employs an ion-pairing buffer additive.  Phytic acid is a 
polyanion that acts to shield the positive charges on basic amino acid residues from the capillary 
wall.  Kostel et al were able to prevent substance P adsorption to capillaries by including phytic 
acid in the run buffer [42].   
Resolution of closely related species can also be problematic in these applications.  
Micellar electrokinetic chromatography (MEKC) has been used to improve the resolution of 
opioid peptide analogs, providing an additional mode of separation within a bare fused silica 
capillary [12].  In addition, cyclodextrins have been exploited as run buffer additives and have  
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Figure 3.10  Metabolism of Dyn A 1-17 in a 1:10 dilution of human plasma.   
Metabolites (1-6 and 1-13) were identified based on migration times of standard injections of 
each peptide.  Separation conditions same as those in Figure 3.9    
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Figure 3.11  Metabolism of Dyn A 1-17 in rat brain slice.  Metabolites were identified based on 
standard single injections of each peptide.  X = unidentified metabolite.  Separation conditions 
same as in Figure 3.9. 
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Figure 3.12  Metabolism of Dyn A 1-17 in rat spinal cord slice.  Metabolites were identified 
based on standard single injections of each peptide.  X = unidentified metabolite.  Separation 
conditions same as in Figure 3.9. 
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been shown to improve resolution for peptide metabolites and enantiomers of relevant 
pharmaceuticals [43, 44].  In this work, various forms of beta-cyclodextrin were investigated to 
improve resolution of closely related metabolites, and sulfobutyl-ether-β cyclodextrin was found 
to be optimal.  The optimized separation has been used to examine in vitro metabolism of Dyn A 
1-17 in human plasma as well as in rat brain and spinal cord.   
Previous reports of dynorphin metabolism have identified a variety of metabolites present 
in blood.  Kreek’s group investigated the in vitro metabolism of Dyn A 1-17 in both human and 
rhesus monkey blood using MALDI [20-21, 23].  Human or monkey blood was spiked with Dyn 
A 1-17, and three major metabolites were identified, one opioid (Dyn A 1-6) and two non-opioid 
(Dyn A 2-17 and 7-17) peptides.  These major metabolites were further degraded to 2-6, 8-17, 9-
17, 11-17, 3-17, and 4-17.  The Dyn A 1-6 and 7-17 fragments arise from cleavage at paired 
basic amino acid residues Arg(6)-Arg(7).  The endopeptidase responsible for this metabolite has 
been termed dynorphin A converting enzyme (DCE) [50, 51].  Cleavage of the N-terminal 
tyrosine to produce Dyn A 2-17 is likely the result of nonspecific aminopeptidase activity [52, 
53].  While the metabolism products were similar in human and monkey blood, their time course 
differed considerably, with metabolism occurring much faster in rhesus monkeys.   
The studies presented here detected the generation of two major metabolites over a 160 
time period.  The metabolites Dyn A 1-6 and Dyn A 1-13 were identified based on single 
injections of metabolite standards and correlating migration times.  The presence of Dyn A 1-6 
agrees well with the aforementioned studies performed in the Kreek lab [20, 21, 23], 
demonstrating the utility of CE in monitoring dynorphin metabolism.  It is thought that the 
peptidase responsible for the cleavage of the N-terminal tyrosine is membrane-bound [52].  The 
studies presented in this paper were done in plasma as opposed to whole blood.  This is a 
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possible explanation for why Dyn A 2-17 was not observed in this work, but was reported 
previously [20, 21, 23].      
Due to the neurotoxicity of Dyn A 1-17, its metabolism has also been studied in the brain.  
Several enzymes have been implicated in the metabolism of opioid peptides in the brain.  In the 
early 1980’s an aminopeptidase from Sprague Dawley rat brains was purified by Berg and Marks 
and shown to cleave the N-terminal tyrosine from enkephalin and dynorphin peptides [52, 53].  
However, the reactivity of this enzyme decreased with increasing size of the peptide, suggesting 
a conformational component to the availability of the tyrosine residue for enzymatic cleavage.  
As mentioned previously, the endopeptidase responsible for cleavage at the paired basic amino 
acids- Arg6 and Arg7- is termed dynorphin A converting enzyme and has been isolated and 
purified from human cerebrospinal fluid and human spinal cord tissue [50, 51].  
Kreek’s group investigated the metabolism of dynorphin A 1-17 in the striatum of 
Fischer rats using microdialysis [22].  MALDI was employed for identification following direct 
infusion of Dyn A 1-17.  Dyn A 1-7, 8-17, 1-6, and 9-17 were observed.  Interestingly, the 
counterpart metabolites (7-17 and 1-8) were not detected.  Andren’s group has also investigated 
the metabolism of dynorphin using microdialysis and nanoLC/ESI-TOF MS [3].  Their study 
compared dynorphin metabolism in the brains of healthy Sprague Dawley rats and those with 
unilateral 6-OHDA lesions to mimic Parkinson’s disease.  Several metabolites were found in the 
brains of the lesioned rats that were not present in healthy rats, exemplifying the importance of 
these metabolic events and their potential role in various neurological disorders.  
To examine the metabolism of Dyn A in the central nervous system, in vitro studies with 
both rat brain and rat spinal cord slices were performed in this work.  In the rat brain slice the 
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appearance of two metabolites was observed, however only one could be identified by standard 
injections and migration time correlation.  This metabolite is Dyn A 1-6, suggesting the presence 
of dynorphin converting enzyme in the rat brain.  The earlier migrating metabolite does not 
correspond to any of the metabolites investigated in this study.  Interestingly, Dyn A 1-6 does not 
appear in studies with the rat spinal cord but, again, an unidentified early migrating metabolite is 
present.  The time course of the metabolism in all three tissues also varies.  Parent peptide is still 
present after 160 minutes in both the plasma and the spinal cord.  In the rat brain, however, the 
peak for Dyn A 1-17 is completely absent by the 40-minute time point.  Differences in the 
metabolic kinetics between species and tissues have been previously reported.  For example, 
Kreek’s group found the metabolism of Dyn A 1-17 to be much faster in monkey blood than in 
human blood [20, 23].   
 
3.4 Summary  
A method for on-capillary copper complexation of dynorphin peptides has been 
developed.  The method described here demonstrates the usefulness of capillary electrophoresis 
for examining peptide degradation in a single assay where the parent peptide and metabolites are 
detected simultaneously following electrophoretic separation.  It is clear that the metabolism of 
dynorphin is a complex process that varies between tissues and species.  Capillary 
electrophoresis provides a convenient format for the separation and detection of the parent 
peptide and its metabolites.   
The use of on-capillary complexation improves the efficiency of these separations and 
has the potential to render even the des-tyrosine metabolites electroactive, making amperometric 
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detection feasible.  Future work will focus on electrochemical detection of the peptides to 
improve limits of detection.  Additionally, transferring this separation to a microchip device for 
even faster analysis is being explored.  In these studies, metabolism was slowed by diluting the 
plasma and performing the analysis at room temperature.  In a microchip format, these steps 
could potentially be avoided, enabling a more physiologically relevant investigation of 
dynorphin metabolism.  The length of time for the CE runs is the limiting factor with respect to 
temporal resolution, and microchip electrophoresis would improve this from 40 minutes to less 
than 5 minutes.  This miniaturized format would enable direct coupling to microdialysis 
sampling, making near real-time monitoring of dynorphin metabolism in vivo possible.  
Microchip analysis of dynorphin peptides will be further discussed in Chapter 6 of this thesis.  
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Chapter Four: 
Development of an LC-MS/MS method for the quantitation of dynorphin peptides 
in biological matrices  
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4.1 Introduction 
Liquid chromatography in conjunction with tandem mass spectrometry is a popular 
means for separation and quantitation of peptides and proteins.  Several  reviews have recently 
been published on this topic [1, 2].  LC-MS/MS has been employed for the analysis of naturally 
occurring peptides in both in vitro [3] and in vivo metabolism studies as well as for the 
investigation of peptide transport across biological barriers such as the blood brain barrier [4-6].  
The use of LC-MS/MS has also been employed for the determination of the stability, 
pharmacokinetics, and pharmacodynamics of peptide-based pharmaceuticals [7-9].  While 
MALDI has advanced as a qualitative means for identifying peptides in biological matrices [10-
13], more quantitative techniques are often desirable for the aforementioned applications.  In 
particular, electrospray ionization (ESI) enables direct coupling of LC flow to the ionization 
source of mass spectrometers, creating a means for sample de-salting prior to detection, 
increased through-put, and automation [1, 2]. 
Under ESI conditions, compounds that carry a charge in solution are transferred into the 
gas phase as evaporation of the volatile solvents used in liquid chromatography occurs.  Charge 
repulsion, within the aerosol droplet, results in the release of single ions into the gaseous phase.  
ESI is a gentle ionization process and can be performed in either positive or negative mode 
depending on the application and compounds of interest.  A schematic of the ionization process 
can be seen in Figure 4.1.    Peptides and proteins will produce multiply charged ions under ESI 
conditions enabling their detection on instruments with somewhat limited mass to charge (m/z) 
range.  For example, a peptide with a molecular weight of 3000 is above the 1800 limit of the 
instrument employed for the majority of these studies; however, a doubly charged ion of this 
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peptide has a mass to charge ratio of 1501 [(MW + 2)/number of charges = 3002/2) and will 
therefore be detected.   
A variety of experiments can be performed using a triple quadrupole mass spectrometer 
including precursor ion scans, product ion scans, neutral loss or gain, and multiple reaction 
monitoring.  In this work, precursor and product ion scans were used in the optimization of 
instrument parameters for the analytes of interest.  Precursor ion(s) are identified in the first 
quadrupole.  For small compounds this would be the molecular mass (plus 1 for the addition of a 
proton), but for peptides there are typically multiple ions representing multiple charge states 
(Figure 4.2). These precursor ions are then fragmented in the collision cell and the product ions 
are identified (Figure 4.3). The information gained from these scans is in the form of a mass 
spectrum, and the identified precursor ions are then used in additional experiments such as 
multiple reaction monitoring or MRM.   
MRM is most often employed for quantitation, improving sensitivity and enabling high 
specificity for the analytes of interest.  In the first quadrupole, the precursor ion is selected.   This 
ion is then collisionally dissociated (by an inert gas) in the second quadrupole, and the third 
quadrupole scans for these specific product ions (Figure 4.4).  The conversion of one precursor 
ion to one product ion is called a transition.  By focusing on only a handful of specific transitions 
(typically one to two per analyte), dwell time on the ions of interest is increased, improving 
sensitivity in comparison to the data collected in scan mode.  Data is presented in this case not as 
a spectra, but instead as a chromatogram, where ion intensity is plotted on the y-axis versus time 
on the x-axis.  A total ion chromatogram (TIC) can be viewed, which is a sum of all ions 
detected from all the specified transitions, or each transition can be observed separately in an 
extracted ion chromatogram (XIC).  Multiple reaction monitoring not only improves selectivity, 
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but with the inclusion of an appropriate internal standard (IS), more accurate quantitation can be 
achieved correcting for ion suppression [1].  Ideally an internal standard is an isotopically-
labeled version of the analyte of interest; however, these compounds are expensive and their use 
is not always practical or feasible.  
This chapter will discuss important analytical considerations for peptide analysis via LC-
MS/MS including method development, internal standard selection, and specific challenges 
when sampling from biologically compatible matrices.  In particular, this chapter will lay the 
groundwork for Chapter 4 in which the metabolism of Dyn A 1-17 is investigated in the presence 
of rat brain and spinal cord as well as bovine brain microvessel endothelial cells, a blood brain 
barrier mimic.   
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Figure 4.1  Cartoon depiction of electrospray ionization, modified from Waters website 
(www.waters.com).  
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Figure 4.2  Cartoon depiction of a precursor ion scan.  Experiments are performed to identify 
precursor ions (multiple charge states in the case of peptides).  Precursor ion scans are typically 
performed to optimize voltages prior to precursor mass selection for use in MRM experiments.  
Example values are given for Dyn A 1-17: 537.6 (4+ charge state) and 716.5 (3+ charge state) 
and bradykinin: 530.0 (2+ charge state) precursor ions.   
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Figure 4.3  Cartoon depiction of a product ion scan.  These are typically preformed to tune CID 
parameters for optimization prior to MRM.  Example transitions shown are for Dyn A 1-17 (the 
parent 4+ ion 537.6 is fragmented to 136.0 and 120.2). 
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Figure 4.4  Cartoon depiction of multiple reaction monitoring.  These experiments are typically 
performed when quantitation of known analytes of interest is desired.  Two chromatograms are 
shown on the right, one for the XIC for Dyn A 1-17 and for the TIC for Dyn A and the IS.  
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4.2 Materials and Methods 
4.2.1 Reagents 
All dynorphin peptides (Dyn A 1-17, 2-17, 1-13, 1-8, and 1-6) were obtained from 
Bachem Biosciences, Inc. (King of Prussia, PA, USA).  Bradykinin was purchased from Sigma-
Aldrich (St. Louis, MO USA).  Fisher Optima acetonitrile (LC-MS grade) was used for all 
mobile phases containing organic (Fisher Scientific, Fair Lawn, NJ, USA).  Formic acid was 
purchased from Acros Organics (Morris Plains, NJ, USA) at 99.9% purity.  All aqueous mobile 
phases were made from 18 MΩ deionized (D.I.) water from a benchtop Milli-Q Synthesis A10 
Water Purification System (Millipore, Billerica, MS, USA), filtered with 0.2 µm Magna nylon 
filters from Osmonics (Minnetonka, MN, USA).  Minimum Essential Media and Ham’s F12 
were purchased from Life Technologies, Invitrogen Corporation (Carlsbad, CA, USA).  All other 
reagents were purchased from Sigma Aldrich (St. Louis, MO, USA).     
4.2.2 Liquid Chromatography-Tandem Mass Spectrometry Instrumentation 
Two LC-MS/MS systems were used for the studies in this dissertation.  The first was a 
Waters Micromass Quattro micro triple quadrupole mass spectrometer with a Waters 2690 
HPLC system (Waters, Milford, MA, USA) on the front end.  The LC system included a 
refrigerated autosampler and a column oven as well as an external diverter valve.  The system 
was operated using MassLynx 3.5 software.  The second system consisted of an API 2000 triple 
quadrupole mass spectrometer (AB Sciex, Foster City, CA, USA) with a Shimadzu Prominence 
LC (Shimadzu, Japan) complete with two LC20-AD pumps with a solvent mixer, a CMB-
20ALite controller, degasser (DGU-20A3), autosampler (Sil20A-HT), and column heater (CTO-
20A).  The system was operated using Analyst 1.5 software.  Analyst was also used for data 
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analysis of quantitative experiments.  A 1.0 x 50 mm C18 analytical column with 5 µm particles 
and the corresponding guard column (Vydac Microbore, C-18 MS columns, Grace Davidson 
Discovery Sciences, Deerfield, IL, USA) were utilized for all experiments. 
 With both instruments a variety of parameters are considered tunable for each compound 
of interest investigated.  In general these parameters are voltages– responsible for guiding the 
ions through the pathway of the instrument, gas flows– which aid in the transport of ions through 
the mass spectrometer and prevent contaminants from entering the instrument, and temperature 
settings– which aid in the desolvation of charged droplets and the entrance of ions into the 
gaseous phase.  A detailed discussion about the different instrumental parameters and 
configurations follows. 
4.2.2.1 Waters Micromass Quattro micro  
 There are two categories of parameters for which a user can optimize the ionization and 
fragmentation of their compounds of interest: the source parameters and the analyzer parameters.  
Two source parameters, the cone voltage and capillary voltage are extremely compound specific, 
and therefore can be set for each analyte of interest.  The capillary voltage (kV) is applied to the 
ESI probe and contributes to the formation of charge aerosol droplets as the LC eluent exits the 
end of the stainless steel capillary.  The cone voltage (V) is applied to the sample cone, the first 
orifice of entrance into the portion of the mass spectrometer that is under vacuum.  The cone 
voltage must be carefully optimized so as to prevent in source decay of the analytes of interest.  
For example, if the cone voltage is tuned to a value higher than necessary, fragmentation of 
peptides can occur at the ion source, decreasing the amount of intact molecule available for 
entrance to the spectrometer thus reducing sensitivity.   
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The remaining source parameters are tunable for a series of compounds, in this case, for 
an entire family of dynorphin peptides.  The extractor parameter (V) is a voltage applied to the 
extraction cone which rests behind the sample cone.  It is responsible for directing and focusing 
the ions into the first quadrupole.  The RF lens value (V) is the voltage applied to the hexapole 
(collision cell).  It guides ions into the collision cell.  The locations of these applied voltages 
along the mass spec quadrupoles can be seen in Figures 4.5 and 4.6.  In addition to these 
voltages, the source and desolvation temperatures (°C) and the cone and desolvation gas flows 
(L/h) must be optimized.  The source temperature settings aid in the evaporation of the LC eluent 
from the charged droplet.  The temperature must be sufficiently high to improve sensitivity while 
preventing this evaporation from occurring too rapidly which hinders ionization.  Both the cone 
gas and desolvation gas are nitrogen gas (from a liquid nitrogen source) which surround the cone 
and probe respectively and aid in eluent evaporation.   
In addition to the source parameters, a variety of settings on the analyser are also tunable.  
These values will have different values depending on the experiment being performed.  The 
resolution values (LM and HM 1 and 2) are most often set to 15; however, when performing 
MRMs the resolution can be sacrificed to some degree in order to improve sensitivity.  For 
example, decreasing these values to the range of 10.0-13.0 can bring the peak width at half 
height from 0.5 to around 1.0 increasing sensitivity.  In MS1 scan mode, the entrance and exit 
values are set to 50 and no collision energy is applied.  This allows ions to pass through the 
quadrupoles, reaching the detector more quickly.  When MS/MS experiments are performed the 
entrance and exit values are lowered to extend the dwell time of the ions within the collision cell, 
resulting in more complete fragmentation.  Also during these experiments, collision energy is 
applied and optimized for each compound of interest.  Similarly, ion energy 1 and 2 are  
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Figure 4.5  Diagram of the Z-spray ionization source on the Waters Quattro micro.  Figure 
modified from www.waters.com.  
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Figure 4.6  Diagram of the quadrupole “rail” on the Waters Quattro micro featuring a hexapole 
collision cell.  Figure modified from Waters user manual.  
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Source Parameters Units Range
Recommended 
Values
Capillary Voltage kV 2.5-4 3
Cone Voltage V 10-150 60
Extractor V 0-4 3
RF Lens N/A 0-5 0.2
Source Temperature °C 70-120 120
Desolvation 
Temperature °C 150-450 350
highly dependent 
on flow rate
Cone gas L/h 50-200 1-100
Desolvation gas L/h 0-1200 700
highly dependent 
on flow rate
Analyser Parameters Units Range
Recommended 
Value MS1
Recommended 
Value MS2
LM1 and HM1  
Resolution N/A 15
15 (13 to increase 
ionization)
Ion Energy 1 N/A 0.5 0-3
Entrance N/A 50 -5 to 5
Collision N/A 1 1-200
Exit N/A 50 1 to 5
LM2 and HM2 
Resolution N/A 15
15 (13 to increase 
ionization)
Ion Energy 2 N/A 3 0-3
Cell Pirani Pressure mbar 1 e-4 (argon) 3.6 e-3 (argon)
Multiplier Voltage V 650 650
 
Table 4.1  Tunable Mass Spec Parameters for the Waters Quattro micro instrument. 
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optimized differently for MS1 versus MS/MS experiments.  These values are applied to exit of 
quad 1 and quad 3, respectively.  A summary of these tunable values can be seen in Table 4.1.   
4.2.2.2 Applied Biosystems API 2000 
With the API 2000, the following parameters are tunable during method development for 
specific compounds.  Their location along the quadrupole can be seen in Figures 4.7 and 4.8.  
The declustering potential (DP) controls the difference in potential between the skimmer (held at 
ground) and the orifice plate.  This potential difference decreases the occurrence of solvent 
cluster ions, resulting in more efficient ionization.  The entrance potential (EP) parameter 
controls the difference between voltage on quadrupole zero (Q0) and ground, guiding the ions 
into the Q0 region which is under high pressure.  The EP parameter also aids in focusing the ions 
as they enter Q0.  All other ion path voltages are dependent on the EP value, and therefore this is 
one of the first parameters optimized.  The collision cell entrance potential is a mass-dependent 
parameter that controls the potential difference between Q0 and the entrance of quadrupole 2 
(Q2).  It focuses ions into the collision cell.  During MS/MS scans this parameter is optimized 
for the precursor ion.  The collision cell exit potential similarly is used to focus and accelerate 
ions as they leave Q2.  This parameter is optimized for the product ion in MS/MS scans.  Two 
parameters control how the precursor ions fragment in the collision cell: the collision energy 
(CE) and the collisionally activated dissociation (CAD) gas.  The CE parameter controls the 
energy that the precursor ions receive as they enter the second quadrupole.  The CAD parameter 
control the pressure of the collision gas in the collision cell during MS/MS scans.  Both the CE 
and CAD parameters control the product ions produced and are very compound specific.  They 
are optimized to the lowest setting that will generate a reproducible fragment ion with the highest 
sensitivity.     
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Figure 4.7  Diagram of the ionization source on the API 2000.  Figure modified from training 
materials at the API training course.  
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Figure 4.8  Diagram of the quadrupole “rail” on the API 2000.  Figure modified from training 
materials at the API training course.  
 
 
 
 
 
105 
 
Three gases are optimized by flow injection analysis because they are dependent upon the 
mobile phase and flow rate employed: curtain gas (CUR), gas 1 and gas 2 (GS1 and GS2).  The 
curtain gas flow prevents contaminants from entering the ion path by flowing in an outward 
direction from behind the curtain plate and in front of the orifice.  The highest setting that does 
not compromise sensitivity should be utilized.  Two additional gas parameters are optimized 
using FIA: gas 1 and gas 2.  The GS1 parameter controls the nebulizer gas on the TurboIonSpray 
probe.  It aids in the generation of small droplets and is crucial for maintaining stable flow at the 
probe.  This parameter plays a significant role in sensitivity and is greatly influenced by the 
position of the probe in the source.  The GS2 parameter controls the auxiliary gas and aids in the 
evaporation of spray droplets.  This parameter works in conjunction with the temperature setting 
(TEM) to vaporize the LC solvent.  Lastly the ion spray voltage controls the potential applied to 
the needle in the source.  It is responsible for the ionization of the sample and also contributes to 
the stability of the spray and the sensitivity.  The acceptable values for these parameters are 
summarized in Table 4.2.   
   
4.3 Results and Discussion 
4.3.1 Optimization of mass spectrometric parameters for Dyn A 1-17 (API 2000 system) 
Prior to infusing compound, the ion spray must be adjusted so as to prevent spraying 
directly down the orifice of the instrument.  This is crucial for protecting the instrument from 
contaminants that will ultimately diminish sensitivity.  The spot size will depend on the flow rate 
and volatility of the mobile phase composition and should be aimed directly below the curtain  
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Compound-
Dependent 
Parameters Units Range
Typical 
Optimized 
Ranges Typical Value Step Size
Declustering Potential 
(DP) V 0 to 400 20 to 200 50 5 or 10 V
Entrance Potential (EP) V 2 to 15 10
Collision Cell Entrance 
Potential (CEP) V 0 to 188 10 to 70 mass dependent 1 V
CAD Gas (CAD) N/A 0 to 12 5
Collision Energy (CE) V 5 to 130 No typical value 5V
Collision Cell Exit 
Potential (CXP) V 0 to 55 0 to 20 mass dependent 0.5 V
Source-Dependent 
Parameters Units Range
Typical 
Optimized 
Ranges Typical Value Step Size
Nebulizer Gas (GS1) N/A 0 to 90 40 to 60
Auxillary or Turbo Gas 
(GS2) N/A 0 to 90 45 to 65
Temperature of the 
Turbo Gas (TEM) °C 0 to 750 600 25°C
Curtain Gas (CUR) N/A 10 to 50 10
IonSpray Voltage V 4500 to 5500 5000
 
 
Table 4.2  Tunable mass spec parameters for the API 2000. 
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Figure 4.9  A. Diagram of the ion source housing on the API 2000 indicating the vertical and 
horizontal probe adjustments used to optimize the electrospray location on the curtain plate 
(from appliedbiosystems.com).  B. Depiction of the electrospray location on the curtain plate.  
Figure modified from training materials at the API training course.  
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plate orifice as shown in Figure 4.9.  Once this is achieved, compound tuning can commence.  In 
these studies, one micromolar peptide standards were prepared from stock solutions in H2O with 
0.1% v/v formic acid and infused via the integrated syringe pump at a flow rate of 20 µL/min.  A 
scan of the first quadrupole was performed over a user defined m/z range.  In order to determine 
if the peptide concentration was sufficiently high for compound-dependent parameter 
optimization a stable total ion chromatogram (TIC) was obtained with an intensity of at least 1.0 
e6 and no higher than 1.0 e8.  Figure 4.10A shows the TIC for an infusion of Dyn A 1-17 and an 
internal standard (bradykinin).  The corresponding spectrum (Figure 4.10 B) depicts the multiply 
charged ions present for each peptide.  Dyn A 1-17 has a molecular weight of 2147.52 and both 
the 3+ and 4+ ions (716.5 and 537.6 respectively) were detected.  For bradykinin (MW=1060.21) 
only the 2+ ion (530.8) was detected.  In these studies, bradykinin was chosen as an internal 
standard because it has a high pI (12) similar to Dyn A 1-17 (pI 11.5) and was found to behave 
similarly during chromatographic separation.  It was advantageous to use bradykinin over 
another dynorphin peptide due to their structural differences so that there was no possible 
appearance of bradykinin as a metabolite of Dyn A 1-17.      
Next all compound-dependent parameters were optimized using the automated tune 
function within the Analyst software.  In the case of Dyn A 1-17 where two precursor ions were 
observed, the 537.6 m/z was utilized because it was the most intense.  Again 1 µM solutions of 
Dyn A 1-17 and bradykinin were infused together at a flow rate of 20 µL/min.  During the 
infusion, each tunable parameter is ramped through a range of values and the setting that yields 
the highest ion intensity is saved in a tune method.  These parameters include: declustering 
potential (DP), entrance potential (EP), collision cell entrance potential (CEP), collision cell exit 
potential (CXP), collision energy (CE), and collisionally activated dissociation gas (CAD).    
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Figure 4.10  A. Total Ion Chromatogram (TIC) of a 1 ìM Dyn A 1-17 and bradykinin mixture in 
H2O and 0.1% formic. MS Scan, infusion at 20 ìL/min.  B.  Mass spectrum of a 1 ìM Dyn A 1-17 
and bradykinin mixture in H2O + 0.1% formic. MS Scan, infusion at 20 ìL/min.  
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Each of these parameters was described in detail in Section 4.2.2.2, and Table 4.2 
summarizes the acceptable values for these parameters.  DP, EP, and CEP are optimized to 
generate the most intense precursor ions, whereas optimal CXP and CE values are determined 
for the four most intense product ions of each compound.  Dyn A 1-17 produced several 
fragments including: m/z 91.2, 120.1, 130.1, and 136.0 with the 537.6 to 136.0 transition being 
the most intense (Figure 4.11).  Bradykinin produced 98.1, 112.1, 120.1, and 157.1 with the 
530.8 to 120.1 transition being the most intense transition (Figure 4.12).   
Once the voltage optimization was complete and the most intense transition for each 
peptide is determined, further optimization is performed.  The optimized voltage parameters are 
applied during all source parameter optimization.  There are several source parameters optimized 
for each of these transitions and they include: curtain gas (CUR), gas 1 (GS1), gas 2 (GS2), 
temperature (TEM), and ion spray voltage (IS).  These are all dependent on the LC conditions 
(mobile phase composition and flow rate) and for this reason optimization is carried out using 
flow injection analysis (FIA).   A discrete amount (10 µL) of a 1 µM peptide solution is injected 
via the LC autosampler into the mobile phase stream, which consists of 50:50 v/v acetonitrile: 
water (ACN: H2O) and is set at a flow rate of 200 µL/min.  Source parameters are then optimized 
with one value applied during each injection.  Typically three values for each parameter are 
investigated, and each FIA takes a total of 1 minute.  With these parameters optimized, a new 
method is saved that combines all of the voltage and source parameters.  The optimized voltage 
and source parameters for Dyn A 1-17 and bradykinin are summarized in Table 4.3.  Next, the 
LC conditions are optimized and these conditions are added to the acquisition method within the 
Analyst program to create a fully functional MRM method.  
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Figure 4.11  MS/MS of 1 ìM Dyn A in H2O + 0.1% formic.  Collision energy optimization 
during an infusion at 20 ìL/min.  Inset structure is the N-terminus of Dyn A 1-17 and the boxed 
portion corresponds to the 136.0 product ion.  
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Figure 4.12  MS/MS of 1 ìM bradykinin in H2O + 0.1% formic. Collision energy optimization 
during an infusion at 20 ìL/min.  
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Peptide DP FP EP CEP CE CXP CUR IS GS1 GS2 CAD
BK 86 320 9.5 20 91 4 30 3000 40 50 4
Dyn A 1-17 71 270 9 28 43 6 30 5500 40 50 6
 
 
Table 4.3.  Optimized mass spec parameters (API 2000) for Dyn A 1-17 and the internal standard 
bradykinin (BK). 
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4.3.2 Optimization of liquid chromatography conditions for Dyn A 1-17 
Previous work in our group with substance P and dynorphin analogs [3, 4, 14] utilized a 
step gradient that ramped from 100% aqueous to 100% acetonitrile over the course of one 
minute.  This method was therefore used as a starting point for developing a chromatographic 
system for Dyn A 1-17 and bradykinin (I.S.).  A 1.0 x 50 mm C18 analytical column with 5 µm 
particles and the corresponding guard column were employed.  The mobile phase conditions 
utilized were as follows:  100% mobile phase A from 0 to 5 minutes, a linear ramp to 100% 
mobile phase B from 5 to 6 minutes, hold at 100% B from 6 to 15 minutes, a linear return to 
100% A from 15 to 16 minutes, and a column re-equilibration step, holding at 100% A from 16 
to 22 minutes (curve shown in Figure 4.13 inset).  Mobile phase A consisted of 95% H2O, 5% 
ACN with 0.1% formic acid and mobile phase B consisted of 90% ACN, 10% H2O  with 0.1% 
formic acid.   
Under these conditions, a late eluting peak (18.21 min) was observed (Figure 4.13).  This 
peak shifted with respect to the mobile phase return to 95% aqueous conditions, always eluting 
approximately 2 minutes after this return was programmed (data not shown).  Thus it was 
determined that Dyn A 1-17 is not soluble at this high organic content and precipitation of Dyn 
A 1-17 was occurring at the head of the column.  When aqueous mobile phase conditions were 
restored the peptide was resolubilized resulting in a second peak.  The method was adjusted so 
that the final composition of mobile phase B was only 30% ACN, 70% H2O, 0.1% formic acid 
(gradient curve in Figure 4.14 insert).  The second peak disappeared and Dyn A 1-17 eluted at 
7.81 min in a similar fashion to the internal standard which eluted at 7.73 min (Figure 4.14).  
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Figure 4.13  Extracted Ion Chromatograms (XIC) of 1 ìM bradykinin (blue trace) and 0.25 ìM 
Dyn A (red trace) in H2O + 0.1% formic. Second peak observed only in Dyn A 1-17 trace.  LC 
gradient curve shown: mobile phase A is 95% H2O, 5% ACN with 0.1% formic acid.  Mobile 
phase B is 90% ACN, 10% H2O with 0.1% formic acid. 
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Figure 4.14   Extracted Ion Chromatograms (XIC) of 1 ìM bradykinin (blue trace) and 0.25 ìM 
Dyn A (red trace) in H2O + 0.1% formic.  LC gradient curve shown: Mobile phase A is 95% 
H2O, 5% ACN with 0.1% formic acid.  Mobile phase B is 90% ACN, 10% H2O with 0.1% 
formic acid.   
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 Using this LC method, a calibration plot for Dyn A 1-17 standards in H2O with 0.1% 
formic acid was generated.  A linear response was obtained between 0.025 and 1 µM with an R2 
value of 0.9984 as can be seen in Figure 4.15.  The ultimate goal of this project, however is to 
develop an LC-MS/MS method for quantitation of Dyn A 1-17 transport and metabolism with an 
in vitro BBB mimic.  Such studies require the use of high salt solutions to maintain cell viability 
and tight junction integrity for the duration of the studies (typically 2-4 hours).  Therefore, it was 
necessary to characterize the LC-MS/MS when sampling Dyn A 1-17 from these types of 
matrices.   
4.3.3 Characterization of Dyn A 1-17 ionization in cell compatible matrices 
In order to maintain healthy cells during transport and metabolism studies, experiments 
must be carried out under appropriate conditions.  Transport media must maintain isotonicity, 
tight junction integrity, and physiological pH (7.4), as well as provide an energy source 
(typically glucose) for studies lasting longer than one hour [15, 16].   Sampling from high salt 
content matrices present several analytical challenges for LC-MS.  First, high salt solutions are 
incompatible with electrospray ionization as significant damage to the ESI probe can occur.  
Additionally, high salt samples tend to contaminate the front end and eventually the quadrupoles 
of mass spectrometers, if precautions in sample preparation and method development are not 
taken.   
The first line of defense against such damage to expensive mass spectrometry equipment 
is the use of a diverter valve.  This allows the LC flow to be directed to waste at the beginning of 
a run in order to de-salt such samples, since salts will elute with the void volume of the column.  
Prior to the retention time of the analytes, the LC flow is directed back to the mass spectrometer  
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Figure 4.15  Calibration plot of Dyn A 1-17 standards in H2O with 0.1% formic (n=3 at each 
concentration).  Linear response from 0.025 – 1 ìM.     
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for analysis.  The flow is then diverted back to waste following the elution of all compounds of 
interest so as to prevent any lipid-based cellular components from entering the mass spec and 
contaminating the source.  The retention time of Dyn A 1-17 and the internal standard was such 
that diversion for the first five minutes of the LC run was feasible.  At 5 minutes, the LC flow 
was routed to the mass spectrometer and then flow was diverted back to waste again at 12 
minutes.  
 A second line of defense is to dilute samples in mobile phase to decrease the salt 
concentration.  In these experiments, standards of Dyn A 1-17 were prepared in phosphate 
buffered saline with ascorbic acid (PBSA) and cell experimental media.  Aliquots (60 µL) were 
removed and diluted with 48 µL H2O with 0.1% formic and 12 µL of internal standard (10 µM 
stock).  Therefore the resulting concentration of Dyn A 1-17 was always half that of the original 
standard, and this value could be used for the creation of a calibration plot.   
Previous work concerning the transport and metabolism of Substance P and Dyn A 1-11 
amide analogs by BBMEC used media composed of a 50:50 mixture of Minimum Essential 
Media (MEM) and Ham’s F12 with 10 mM HEPES [3-4, 14].  However, for Dyn A 1-17, 
significant ion suppression was observed in the presence of this cell compatible solution, and 
considerable run to run variation was observed, as demonstrated by the overlay of 
chromatograms in Figure 4.16.  Samples of lower concentration (25-100 nM) were analyzed and 
only peaks for the internal standard were observed (data not shown).   
In order to identify the component responsible for this ion suppression and obviate the 
problem, PBSA alone was investigated.  This is also commonly employed for cell transport 
studies and consists of phosphate buffered saline supplemented with MgSO4, CaCl2, ascorbic  
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Figure 4.16  XIC for 500 nM Dyn A 1-17 (n=3) in experimental cell media.  Chromatograms are 
shifted so that peaks can be more easily viewed.  Actual retention times are listed above.    
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acid, and glucose.  Although the peak intensity did not vary as drastically from run to run in the 
presence of PBSA as compared to the experimental cell media, the peak area was still diminished 
in comparison to standards in H2O with formic acid and Dyn concentrations of less than 500 nM 
were not detected.   
Overlays of the triplicate injections of Dyn A 1-17 in PBSA are shown in Figure 4.17.  
As can be seen in Figure 4.18, the peak area of the internal standard was not significantly 
affected by the presence of these solutions, suggesting that a structural component of dynorphin 
was responsible for this observed signal suppression.  The formation of strong phosphate and 
sulfate adducts with positively charged side chains of peptides has been reported previously [17].  
Chait and co-workers observed the formation of strong ionic complexes in the presence of 
phosphate and sulfate at low concentrations (approximately 0.050 mM) relative to the quantities 
included in PBSA and cell experimental media used in these studies (~10 mM).    
In an attempt to improve the ionization efficiency of Dyn A 1-17, the phosphate 
concentration was decreased by a factor of 10.  To maintain isotonicity the concentrations of 
NaCl and KCl were increased, and to aid in buffering of the system, 10 mM HEPES was 
included.  To prevent sulfate adduct formation, magnesium chloride was substituted for the 
magnesium sulfate typically included in PBSA.  Magnesium and calcium are essential 
components included in the cell media to maintain tight junction integrity.  Glucose, ascorbic 
acid, and calcium chloride concentrations were not altered.  This new cell culture media will be 
referred to as modified phosphate buffered saline (mPBSA) in this dissertation.  Upon 
modification of the PBSA media, improvements were seen in peak area as well as run to run 
reproducibility.  Overlays of triplicate injections of Dyn A 1-17 in mPBSA are shown in Figure 
4.19.  Also important to note, Dyn A 1-17 was stable in modified PBSA over the course of 5  
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Figure 4.17  XIC for 500 nM Dyn A 1-17 in PBSA (n=3).  Chromatograms are shifted so that 
peaks can be more easily viewed.  Actual retention times are listed above.    
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Figure 4.18  XIC for the internal standard bradykinin (1 ìM) in cell experimental media and 
PBSA.  Chromatograms are shifted so that peaks can be more easily viewed.  Actual retention 
times are listed above.    
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Figure 4.19.  XIC for 500 nM Dyn A 1-17 in modified PBSA.  Chromatograms are shifted so 
that peaks can be more easily viewed.  Actual retention times are listed above.    
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hours at both room temperature and at 37°C.  A comparison of matrix effects on peak area for 
Dyn A 1-17 and bradykinin in various cell compatible medias can be seen in Figure 4.20. 
4.3.4 Optimization of LC-MS/MS parameters for dynorphin metabolites 
Once an appropriate media was identified for cell transport and metabolism studies, the 
tuning procedure outlined in Section 4.2.2.2 was repeated for a mixture of dynorphin metabolites 
utilizing bradykinin as an internal standard.  Briefly the compounds were infused and all source 
parameters were optimized using the automated tune function within the Analyst software.  Next 
flow injection analysis was performed to optimize the LC flow-dependent parameters.  Three of 
the metabolites of interest retain the N-terminal sequence of Dyn A 1-17 and therefore had 
similar fragmentation patterns, with the 136 product ion again being the most intense.  The des-
tyrosine metabolite Dyn A 2-17 produced a unique fragmentation spectrum however, and the 120 
product ion was found to be the most predominant.  The optimized mass spectrometry 
parameters for each of the dynorphin metabolites are summarized in Table 4.4, and the precursor 
and product ions for all analytes of interest are in Table 4.5.   
In addition to tuning each compound to determine optimal ionization and CID 
parameters, LC gradient optimization was also performed.  It was found that in order to 
chromatographically separate Dyn A 1-17 from its metabolites, increasingly shallow gradients 
(decreased %B/min) must be utilized.  This however had a negative impact on peak shape 
(Figure 4.21).  In particular the peak for Dyn A 1-6 was found to be extremely broad under all 
gradient conditions.  It also exhibited a very irreproducible retention time.  By decreasing the 
organic content at the beginning of the gradient, retention of Dyn A 1-6 was achieved and the 
peak shape and retention time for this peptide were improved as can be seen in Figure 4.22.   
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Figure 4.20.  Peak area comparison for 500 nM Dyn A 1-17 (top) and 1 ìM bradykinin (bottom) 
in H2O with formic acid, experimental cell media, PBSA, and mPBSA.  Average peak areas are 
reported for each, n=3.   
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Peptide DP FP EP CEP CE CXP CUR IS GS1 GS2 CAD
Dyn A 2-17 71 180 8.5 20 77 6 30 5500 40 50 6
Dyn A 1-13 51 370 12 10 27 4 40 3000 40 50 6
Dyn A 1-8 71 60 10.5 18 45 6 30 3000 40 50 6
Dyn A 1-6 41 330 8.5 36 23 6 30 5500 50 50 6  
                         
Table 4.4.  Optimized mass spec parameters (API 2000) for the dynorphin metabolites.   
 
 
 
 
 
 
 
 
 
 
 
 
 
128 
 
 
 
 
 
 
          
Peptide
Molecular 
Weight
Precursor Ion 
(m/z)
Charge 
State
Product Ion 
(m/z)
BK 1060.22 530.8 2+ 120.1
Dyn A 2-17 1984.34 496.96 4+ 120.1
Dyn A 1-17 2147.52 537.63 4+ 136.2
Dyn A 1-13 1603.98 401.85 4+ 136.1
Dyn A 1-8 981.2 491.34 2+ 136.1
Dyn A 1-6 711.82 356.72 2+ 136.1
 
 
 
Table 4.5.  Summary of dynorphin ionization (precursor ions, charge state and product ions) 
following optimization of API 2000 parameters. 
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Figure 4.21.  A. Effect of gradient steepness on peptide retention time (values indicate %B/min).  
B. Overlay of extracted ion chromatograms for dynorphin peptides under shallow gradient 
conditions of 1.2 %B/min.   
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Figure 4.22.  Effect of starting mobile phase composition on Dyn A 1-6 peak shape and retention 
time.  Starting conditions of 5% acetonitrile (red trace) and 3% acetonitrile (blue trace). 
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Superior peak shapes were observed for all the peptides at the steeper step “gradient”.  
Ion suppression due to the co-elution of dynorphin peptides was not observed utilizing the short 
step gradient.  This method increased through-put by maintaining shorter run times and relied 
primarily on the mass spectrometer to separate each compound based on its specific transitions 
as can be seen in the extracted ion chromatograms in Figure 4.23.  Additionally, there was no 
cross-talk observed from one run to the next indicating that the ions were adequately cleared 
from the quadrupole from run to run.   
Final optimized LC conditions  consisted of the following:  initial conditions of 97% A, 
3% B from 0 to 5 minutes, a linear ramp from 3 to 30% B from 5 to 6 minutes, holding at 30% B 
from 6 to 15 minutes, a linear return to initial conditions from 15 to 16 minutes, and column 
equilibration from 15 to 22 minutes holding at 3% B,  where mobile phase A consisted of 100% 
H2O with 0.1% formic acid and mobile phase B consisted of 100% ACN with 0.1% formic acid 
(Figure 2.24).  Calibration plots for each metabolite were constructed using this optimized 
method, and the results are summarized in Table 4.6.  The smaller metabolites exhibited better 
sensitivity and lower limits of detection, supporting the hypothesis that more basic residues in 
the peptide chain contribute to ion suppression due to phosphate adduct formation.  
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Peptide Trace Color Retention Time (tR)
Dyn A 1-6 Pink 7.79
Dyn A 1-8 Blue 7.84
Dyn A 1-13 Orange 7.71
Dyn A 1-17 Red 7.84
Dyn A 2-17 Green 7.79
Bradykinin Black 7.75
 
 
Figure 4.23  Extracted ion chromatograms for each dynorphin metabolite and the internal 
standard bradykinin with optimized mass spec and LC parameters.  Chromatograms are shifted 
so that peaks may be more easily viewed.  Actual retention times are listed above. 
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Figure 4.24  Final optimized gradient conditions.  Initial conditions of 97% A, 3% B from 0 to 5 
minutes, a linear ramp from 3 to 30% B from 5 to 6 minutes, holding at 30% B from 6 to 15 
minutes, a linear return to initial conditions from 15 to 16 minutes, and column equilibration 
from 15 to 22 minutes holding at 3% B.  
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Peptide
Linear Range in 
mPBSA (μM) R^2 LOD LLOQ
Dyn A 1-6 0.001- 5 0.9994 0.2 nM 0.6 nM
Dyn A 1-8 0.001- 5 0.9968 0.1 nM 0.3 nM
Dyn A 1-13 0.1-5 0.9963 32 nM 108 nM
Dyn A 2-17 0.5-5 0.9831 30 nM 102 nM
Dyn A 1-17 0.1-5 0.9844 45 nM 116 nM
in H2O + 0.1% formic
Dyn A 1-17 0.025-1 0.9984 1 nM 4 nM
 
 
 
Table 4.6. Linearity, limit of detection (LOD, S/N =3), and lower limit of quantitation (LLOQ, 
S/N = 10) for Dyn A 1-17 and metabolites (n=3 at each concentration, 6 point calibration plots).  
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4.4 Summary 
 This chapter described the method development necessary for LC-MS/MS determination 
of Dyn A 1-17 and several of its key metabolites.  Ionization and LC conditions were optimized 
for each of the peptides in a cell compatible media to enable investigations of dynorphin 
metabolism and transport at the blood brain barrier and further investigations of metabolism in 
the CNS.  Modifications of the typically employed PBSA were necessary to improve ionization 
conditions for the highly basic dynorphin peptides.  Specifically dilution of the phosphate and 
sulfate concentrations was necessary to prevent adduct formation.  Chapter 4 will discuss in 
detail the application of this method to in vitro studies of metabolism and transport. 
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Chapter Five: 
Investigation of the metabolism of Dyn A 1-17 and the blood brain barrier transport of its 
key metabolite, Dyn A 1-6 
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5.1 Introduction 
5.1.1 The blood brain barrier 
 The blood brain barrier (BBB) consists of a network of endothelial cells connected by 
intracellular tight junctions that are responsible for maintaining brain homeostasis (Figure 5.1) 
[1-3].  It serves not only as a physical barrier, but also as a metabolic one, due to its expression 
of various metabolic enzymes [4-9].  The barrier possesses a number of features including efflux 
transporters [10-12], decreased pinocytosis, minimal fenestration, and high electrical resistance 
effectively protecting the brain from external substances [13, 14].  In addition to protecting the 
central nervous system from xenobiotics, the barrier is integrated with nutrient transporters to 
maintain proper levels of essential compounds such as amino acids [15].  The characterization of 
the behavior of endogenous substances at the blood brain barrier is important when investigating 
their potential role as biomarkers for neurodegenerative diseases.  In particular the metabolism 
and transport of neuropeptides at the blood brain barrier will provide insight into their role in 
central nervous system (CNS) disorders.     
5.1.2 Dynorphin and the blood brain barrier 
Upregulation of dynorphin has been implicated in a variety of neurological disorders 
including Alzheimer’s [16], Parkinson’s disease [17], neuropathic pain [18], stress and 
depression [19].  This opioid peptide has been show to exhibit preferential binding to the kappa-
opioid receptor and at elevated concentrations has been shown to be neurotoxic.  Most reports 
investigating the pharmacology of dynorphin employ immuno-based techniques for quantitation.  
These methods have notoriously low limits of detection, essential for studying endogenous levels 
of neuropeptides; however, cross-reactivity with related peptides and metabolites can  
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Figure 5.1  Schematic of the BBB with depictions of possible transport mechanism indicated by 
a-e.  Used with permission from [3].  
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significantly compromise their accuracy [20].  Reported elevated levels of dynorphin may in fact 
be due to detection of a metabolite.  Therefore it is essential to gain a clear understanding of the 
differing roles of the parent peptide and metabolites, since it is possible a metabolite may in fact 
be responsible for the reported neurotoxic effects.  Of particular interest in this work is the 
potential for dynorphin metabolites to display unique transport properties and therefore 
physiological effects at the blood brain barrier.  This chapter will therefore describe the 
investigation of the metabolism of Dyn A 1-17 in tissues of the central nervous system and by 
cells that create an in vitro model of the blood brain barrier.  The transport of the major 
metabolite (Dyn A 1-6) at the blood brain barrier is also investigated.   
5.1.3 Methods for studying the blood brain barrier 
A variety of in vivo and in vitro methods exist for studying a peptide’s behavior at the 
blood brain barrier.  In vivo methods include microdialysis sampling and brain perfusion studies.  
Continuous monitoring is possible utilizing microdialysis sampling, and experiments can be 
performed on anesthetized or awake, freely-moving animals.   
Microdialysis is also useful for examining site specific metabolism of peptides [17, 21-
23].  Peptides of interest can be included in the perfusate and delivered directly to the brain in 
order to study in vivo metabolism.  Additionally, if the peptides of interest are delivered 
peripherally, the transport across the blood brain barrier can be characterized by sampling via the 
microdialysis probe [24].  The effect of peripherally administered compounds on the 
permeability or metabolism of the peptide of interest as well as on the release of 
neurotransmitters can also be investigated.  For example, peripheral administration of various 
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metabolic inhibitors can be used to further characterize a peptide’s metabolism at the BBB.  A 
major concern that must be addressed when using microdialysis  to measure peptide transport 
into the brain is the generally low recovery of these compounds  across the probe membrane 
[25].  In addition, quantitation from such samples is difficult due to low sample volumes.   
In situ rat brain perfusion directly delivers compounds of interest to the brain via the 
carotid artery [26].  Compounds (often radiolabelled) are delivered directly to the brain at 
constant concentration, and the rate of infusion can be manipulated.  The perfusions are stopped 
at various times and brain uptake is typically determined by scintillation counting when 
radiolabeled compounds are used.  If metabolism is a concern or interest, chromatographic 
separations are usually employed.  From these data points, uptake kinetics can then be 
determined.  This method avoids metabolism by liver enzymes as well as peripherally circulating 
enzymes.    
In vitro cell culture models of the BBB simplify the biological aspects of the blood brain 
barrier considerably by enabling the investigation of a compound’s behavior at the brain 
endothelium as opposed to whole brain [14].  An in vitro cell culture model of the BBB was 
developed by Audus and Borchardt using primary cultures isolated from the grey matter of 
bovine brains (Figure 5.2) [13].  A variety of enzymes have been identified at the BBMEC 
monolayer, including angiotensin converting enzyme, and various peptidases and hydrolases, 
which have been shown previously to cause peptide metabolism [4, 5, 27].  These cells exhibit 
many of the physical characteristics typical of the BBB including tight junctions, decreased 
pinocytosis, and minimal fenestration.  Efflux transporters, as well as specific uptake transport 
systems, are also expressed by this cell line.  These cells have been extensively characterized, 
making this a useful model for investigating BBB transport.   
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Isolation of Bovine Brain Microvessel Endothelial Cells 
(BBMEC)
Obtain bovine brains from slaughter house 
on day of isolation 
in ice-cold MEM pH 7.4
Remove meningesand white matter
Enzymatic digestion of cortical grey matter 
with collagenase and dispase
Separation of red blood cells and lipids 
by dextran and percoll gradients
Store isolated cells at -80°C in complete culture medium 
supplemented with 12% horse serum and 10% DMSO
 
 
 
Figure 5.2  Summary of the BBMEC isolation procedure. 
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The isolated endothelial cells are grown on polycarbonate membranes and mounted in 
Side-by-SideTM diffusion chambers to perform permeability screening (Figure 5.3).  An 
advantage of this in vitro method for investigating BBB permeability is the ability of the 
experimentalist to manipulate a variety of variables including temperature and compound 
concentration.  Experiments performed at 4°C exhibit the effect of reduced ATP activity on 
transport, indicating when active processes are involved in compound permeation.  Bi-directional 
permeability can also be investigated by spiking either the apical (blood side) or basolateral 
(brain side) chambers and monitoring transport in either direction.  Additionally, peptide 
metabolism can be characterized by growing BBMECs in 12-well culture plates and incubating 
the cells with the peptide in cell media (Figure 5.4).   
Recent work with in vitro models of the BBB has focused on the development of 
immortalized brain endothelial cell lines [28].  This decreases the time necessary to reach 
confluency (7 versus 14 days) as well the workload on the laboratory scientist.  The isolation 
procedures for primary cells are very time and labor intensive as is evident by the method 
described in this chapter.  Additionally, the role of other cell types on the behavior of the brain 
endothelium, specifically on the formation of tight junctions, is of interest.  This has driven the 
development of co-culture systems.  Specifically the role of astrocytes on tight junction 
formation has been investigated using co-cultures with Transwell systems and endothelial cells 
grown in astrocyte-stimulated media [14, 29-31].   
This chapter utilized the BBMEC primary cell culture model to investigate the 
metabolism of Dyn A 1-17.  The experimental set-up is shown in Figure 5.3.  The BBB transport 
of the major metabolite, Dyn A 1-6, was then examined using Side-By-SideTM diffusion 
chambers.  The in vitro model simplifies the BBB investigations (in comparison to in vivo  
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Figure 5.3  Experimental set-up for BBMEC permeability study with Side-By-SideTM diffusion 
chambers.  Donor and receiver indicate the typical apical to basolateral experiment at 37°C.  
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Figure 5.4.  Experimental set-up for BBMEC metabolism studies.   
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techniques such as microdialysis) by focusing exclusively on the role of the brain endothelium 
on peptide metabolism.     
5.1.4 Analytical methods for quantifying peptides of interest 
 A detailed discussion of analytical methods for the quantitation of peptides is included in 
Chapter 2 of this thesis; therefore, a brief discussion of the methods utilized for investigating 
metabolism and transport at the blood brain barrier follows.  One of the simplest methods for 
determining the transport of compounds across the BBB is the use radiolabeled compounds and 
scintillation counting [15, 32].  This is most often employed in competitive studies that are done 
to determine if saturable, carrier-mediated processes are responsible for a peptide’s permeation.  
In these studies a radiolabeled peptide is added to the diffusion chamber and its permeability is 
determined.  Then the effect of un-labeled peptide on the permeation of the radiolabeled 
compound is evaluated.  Alterations in the permeation of the labeled compound indicate the two 
species are competing for the same transport system.  This method, however, can be costly due 
to the expense of producing labeled compounds.  Radiolabeled peptides are also not always 
commercially available and safety considerations must be addressed before handling such 
compounds.   
Other popular methods include a separation method (LC or CE) coupled with UV [5, 33-
34], fluorescence [21], or mass spectrometric [35] detection.  In general, the sensitivity of an 
analysis method using UV detection is low due to wavelengths employed (typically 210 nm for 
peptides).  Fluorescence detection, although highly sensitive, requires labeling as peptides 
lacking a tryptophan residue are not natively fluorescent.  Labeling must also be accomplished 
following assay completion because structural modifications to the peptide will alter its behavior 
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(its metabolic stability and permeability) in vitro.  Fluorescent tagging of peptides is usually 
accomplished at a particular amino acid residue (such as lysine) and therefore only peptides and 
metabolites containing these residues are tagged, thus limiting the applicability of this approach.   
Improved specificity can be achieved by employing mass spectrometric detection. 
Peptides can be detected without any labeling.  Typically, LC-MS/MS is performed with the 
direct coupling of the LC eluent to the electrospray ionization (ESI) source, providing a means 
for online sample de-salting prior to analysis [35].  Multiple reaction monitoring significantly 
improves the detector selectivity for the peptides of interest and provides more accurate 
quantitation results.  Important considerations for developing LC-MS/MS methods for dynorphin 
peptides are covered in detail in Chapter 4 of this thesis. 
This chapter employs liquid chromatography with tandem mass spectrometry for the 
investigation of Dyn A 1-17 metabolism in the central nervous system and in the presence of 
BBMECs.  The method does not require any labeling of the dynorphin peptides and minimal 
sample preparation is necessary.  Improved limits of detection were achieved using LC-MS/MS 
in comparison to the CE-UV method described in Chapter 3.  This method was then utilized to 
examine the BBB transport of Dyn A 1-6, the predominant metabolite identified from the 
metabolism studies, using the BBMEC culture system and Side-By-SideTM diffusion chambers.   
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5.2 Materials and Methods 
5.2.1 Reagents 
All dynorphin peptides (Dyn A 1-17, 2-17, 1-13, 1-8, and 1-6) were obtained from 
Bachem Biosciences, Inc. (King of Prussia, PA, USA).  Bradykinin was purchased from Sigma-
Aldrich (St. Louis, MO USA).  Fisher Optima acetonitrile (LC-MS grade) was used for all 
mobile phases containing organic (Fisher Scientific, Fair Lawn, NJ, USA).  Formic acid was 
purchased from Acros Organics (Morris Plains, NJ, USA) at 99.9% purity.  All aqueous mobile 
phases were made from 18 MΩ deionized (D.I.) water from a benchtop Milli-Q Synthesis A10 
Water Purification System (Millipore, Billerica, MS, USA), filtered with 0.2 µm Magna nylon 
filters from Osmonics (Minnetonka, MN, USA).  Minimum Essential Media and Ham’s F12 
were purchased from Life Technologies, Invitrogen Corporation (Carlsbad, CA, USA).  All other 
reagents were purchased from Sigma Aldrich (St. Louis, MO, USA).   
5.2.2 Metabolism studies in at central nervous system tissues  
 The brains and spinal cords of male Wistar rats (350-400 grams) were removed on the 
day of the study and kept in ice cold mPBSA prior to experiments.  Animals that could no longer 
be used for microdialysis studies were graciously donated by Dr. Craig Lunte’s laboratory at the 
University of Kansas. Tissue slices were prepared with a sterile razor blade in a petri dish on a 
bed of ice.  For the metabolism studies, the tissue slices were exposed to dynorphin at room 
temperature (instead of 37 °C) to slow enzyme activity.  For brain tissue slices, a 5 mm by 5 mm 
section was bathed in mPBSA spiked with 25 ìM Dyn A 1-17.  Aliquots (50 µL) were collected 
at various time points over a 4 hour period, mixed with 50 µL of ice-cold aqueous 0.1% formic 
acid solution, and centrifuged on a table-top centrifuge for 2.5 min.  Following centrifugation a 
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60 µL aliquot was removed and further diluted with 48 µL H2O with 0.1% formic acid.  Prior to 
analysis by LC-MS/MS, 12 µL of a 10 µM bradykinin solution was added to serve as an internal 
standard for quantitation.  Similarly, a 5 mm length of spinal cord (width approximately 2 mm) 
was prepared and bathed in mPBSA spiked with 25 ìM Dyn A 1-17.  Following the metabolism 
study, the brain and spinal cord slices were homogenized in PBSA and analyzed for total protein 
content by the Pierce BCA assay (Pierce, Rockford, IL, USA).  Metabolism results are expressed 
as ìM dynorphin peptides per mg of protein.   
5.2.3 Isolation and maintenance of bovine brain microvessel endothelial primary cultures 
 Microvessel endothelial cells were isolated from the cortical grey matter of bovine brains 
by enzymatic digestion and centrifugation as described by Audus and Borchardt in 1986 [13].  
Briefly, bovine brains were obtained from a slaughter house in DeSoto, KS and transported to 
the laboratory in ice cold minimum essential medium (MEM), pH 7.4.  Collagenase and dispase 
digestions in conjunction with centrifugation steps and both dextran and percoll gradients were 
used to isolate the endothelial cells from red blood cells and lipids.  Following isolation the 
bovine brain microvessel endothelial cells were stored at -80 °C for up to 6 weeks in complete 
culture medium supplemented with 12% horse serum and 10% DMSO.  
 BBMECs were thawed and then seeded, at a density of approximately 50,000 cells/cm2, 
on polycarbonate culture plates or 0.4 µm polycarbonate membranes (Nuclepore Track-etch, 13 
mm, Whatman, United Kingdom) that were pre-coated with rat tail collagen and fibronectin.  
The plating medium consisted of 50% Minimum Essential Medium (MEM) and 50% Ham’s F12 
supplemented with 100 µg/mL streptomycin, 100 µg/mL penicillin G, 13 mM sodium 
bicarbonate, 10 mM HEPES,  10% platelet poor horse serum, 150 µg/mL heparin, and 50 µg/mL 
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polymixin B.  Seventy two hours after plating, the media was changed.  The changing medium 
consisted of 50% Minimum Essential Medium (MEM) and 50% Ham’s F12 supplemented with 
100 µg/mL streptomycin, 100 µg/mL penicillin G, 13 mM sodium bicarbonate, 10 mM HEPES,  
10% platelet poor horse serum, 100 µg/mL heparin, and 0.5% endothelial cell growth 
supplement (ECGs).  The changing medium was then replaced every 48 hours.  The cells were 
grown to confluency (12-14 days after seeding) at 37 °C in an atmosphere of 5% CO2 and 95% 
relative humidity.   
5.2.4 Metabolism studies in the presence of BBMECs 
 BBMECs were seeded onto 12-well polycarbonate cell culture plates at a density of 
approximately 50,000 cells/cm2.  Cells were grown until a confluent monolayer formed 
(typically 12 to 14 days after seeding) as determined by light microscopy.  Metabolism studies 
were performed in modified phosphate-buffered saline supplemented with CaCl2, MgCl2, 
glucose and ascorbic acid, pH 7.4 (mPBSA) which was previously described in Chapter 4.  
Before beginning each metabolism study, the growth medium was aspirated off and the cells 
were rinsed three times with pre-warmed (37 °C) mPBSA.  The 12-well plate was kept in a 
benchtop incubator (Boekel, Feasterville, PA, USA), maintained at 37 °C and stirred 
continuously by a shaker (Stovall Belly Dancer, Cole Palmer, Vernon Hills, IL, USA ).  Cells 
were incubated with Dyn A 1-17 at varying concentrations and 60 µL aliquots were removed at 
various timepoints over the span of four hours.  Aliquots were placed directly into autosampler 
vials containing 48 µL H2O with 0.1% formic acid and were frozen (-20 °C) until analyzed.  
Prior to analysis, the samples were thawed, vortexed, and 12 µL internal standard (10 µM 
bradykinin) was added and analysis was performed via LC-MS/MS.  
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5.2.5 BBMEC permeability studies 
 BBMECs were grown on 0.4 µm polycarbonate membranes in a petri dish at a density of 
approximately 50,000 cells/cm2.  Cells were grown until a confluent monolayer formed 
(typically 12 to 14 days after seeding) as determined by light microscopy.  Transport studies 
were performed in modified phosphate-buffered saline supplemented with CaCl2, MgCl2, 
glucose and ascorbic acid, pH 7.4 (mPBSA).  Before beginning each study, the growth medium 
was aspirated off and the cells were then rinsed three times with pre-warmed (37 °C) mPBSA.  
The membranes were then removed and mounted in Side-by-SideTM diffusion chambers (Crown 
Glass Inc., Somerville, NJ, USA).  Prior to studies, the diffusion chambers were silanized with 
Sigmacote (Sigma Aldrich, St. Louis, MO, USA) to prevent peptide adsorption to the chamber 
walls during the study.   
Chambers were then pre-warmed (37°C) and rinsed three times with mPBSA.  Following 
membrane placement, one side of the diffusion chamber was filled with 3 mL of mPBSA and 
examined for leaks.  If the membrane was mounted correctly and no leaks were present, the other 
side of the chamber was filled with 3 mL of mPBSA as well.  The chamber temperature was 
maintained for the duration of the study by external circulating water baths (at either 37 °C or 4 
°C depending on the experiment) and each chamber was stirred constantly at 600 rpm by Teflon 
coated magnetic stir bars driven by an external console. The donor side was then spiked with the 
peptide of interest and 60 µL aliquots were removed from the receiver side at various time points 
and then replaced with an equal volume of mPBSA to prevent changes in volume that could 
affect flux.  Studies typically lasted 2-4 hours.  Samples were collected directly into autosampler 
vials pre-filled with 48 µL H2O with 0.1% formic acid and then stored at -20 °C until use.  Upon 
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thawing, samples were vortexed and 12 µL internal standard (10 µM bradykinin) was added and 
analysis was performed using an LC-MS/MS.   
Upon completion of the transport study, fluorescein or [14C]-sucrose were added to the 
apical side of the monolayer and utilized to test the monolayer integrity.  These low permeability 
markers do not readily cross the blood brain barrier and are an indicator of monlayer integrity.  
Fluorescein samples were placed directly into a 96-well plate and analyzed by a fluorescence 
microplate spectrophotometer (Molecular Devices, Sunnydale, CA, USA) at excitation and 
emission wavelengths of 490 and 520 nm respectively.  Sucrose samples were mixed with 10 mL 
of scintillation fluid and analyzed by liquid scintillation counting (Beckman, Fullerton, CA, 
USA).      
  For studies determining the permeability of fluorescein without Dyn A 1-6 pre 
treatment, chambers were filled with the modified media (mPBSA), and the cells were allowed 
to equilibrate for 5 minutes.  After the equilibration period, fluorescein was added to the apical 
side of the cell membranes such that the final concentration was 10 ìM.  Immediately a 100 ìL 
aliquot was removed from the donor chamber and collected into a 96 well plate.  Additional 100 
ìL aliquots were taken from the receiver chamber (t=10, 20, 30, and 60), and a final sample was 
taken from the donor chamber after 60 minutes as well.  These fluorescence values were 
determined on a microplate spectrophotometer.  The permeability of fluorescein was then 
determined using the following equation: 
Papp = (ÄQ/Ät)/ A x C0 
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Where, ÄQ/Ät is the linear appearance of fluorescein in the receiver chamber, A is the 
cross sectional area of the cell monolayer (0.636 cm2), and C0 is the initial concentration in the 
donor chamber at t=0 (in this case, 10 ìM).     
 In the Dyn A 1-6 transport studies, 20 ìL of mPBSA was removed from the donor 
chamber and replaced with 20 ìL of a Dyn A 1-6 stock solution, resulting in 18.6 ìM peptide in 
the chamber.  Bi-directional studies were performed by adding Dyn A 1-6 to either the apical 
(blood) or basolateral (brain) side of the mounted monolayers at 37°C.  Aliquots (60 ìL) were 
taken from the receiver chamber at various time points over a 4 hour period.  Studies done at 4°C 
were carried out in the apical to basolateral direction over a 2 hour period at the same 
concentration.  All samples were collected into autosampler vials containing H2O with formic 
acid.  Mass balance samples were collected from the receiver chamber at the start and finish of 
each experiment.  Quantitation was performed via LC-MS/MS.  Peptide permeability was 
calculated with the same equation described above for fluorescein.    
5.2.6 Liquid chromatography-tandem mass spectrometry instrumentation 
An API 2000 triple quadrupole mass spectrometer (AB Sciex, Foster City, CA, USA) 
equipped with a Shimadzu Prominence LC (Shimadzu, Japan) consisting of two LC20-AD 
pumps with a solvent mixer, a CMB-20ALite controller, degasser (DGU-20A3), autosampler 
(Sil20A-HT), and column heater (CTO-20A) was employed for these studies.  The system used 
Analyst 1.5 software for control and data analysis.  A 1.0 x 50 mm C18 analytical column with 5 
µm particles and the corresponding guard column, 1.0 x 10 mm (Vydac Microbore, C-18 MS 
columns, Grace Davidson Discovery Sciences, Deerfield, IL, USA) were utilized for all 
experiments. 
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5.2.7 Analysis of metabolism and permeability studies by LC-MS/MS 
Transport samples were analyzed by the LC-MS/MS protocol described extensively in 
Chapter 4.  Briefly, 60 µL aliquots were diluted with 48 µL H2O with 0.1% formic, and prior to 
analysis 12 µL of a 10 µM bradykinin solution was added to serve as an internal standard for 
quantitation.  Sample de-salting and separation were achieved using a 1.0 x 50 mm C18 
analytical column with 5 µm particles and the corresponding guard column, 1.0 x 10 mm (Grace 
Davidson Discovery Sciences, Deerfield, IL, USA).  The mobile phase was diverted to waste for 
the first 5 minutes of the LC run, then to the mass spectrometer from 5 to 12 minutes and again 
back to waste for the remainder of the run.  The LC gradient program was as follows:  initial 
conditions of 97% A, 3% B from 0 to 5 minutes, a linear ramp from 3 to 30% B from 5 to 6 
minutes, holding at 30% B from 6 to 15 minutes, a linear return to initial conditions from 15 to 
16 minutes, and column equilibration from 15 to 22 minutes holding at 3% B.  Mobile phase A 
consisted of 100% H2O with 0.1% formic acid.  Mobile phase B consisted of 100% ACN with 
0.1% formic acid.  Multiple reaction monitoring was performed by the API 2000 and all 
ionization conditions and transitions were optimized previously (Chapter 4).   
 
5.3 Results and Discussion 
5.3.1 In vitro metabolism of Dyn A 1-17 in central nervous system tissues 
 Elevated concentrations of dynorphin have been implicated in a variety of neurological 
disorders. Due to cross-reactivity exhibited by immunoassays, these reportedly elevated 
concentrations may, in fact, be indicative of an increase in a dynorphin metabolite instead.  It is 
therefore possible that it is a metabolite and not the parent peptide that is actually responsible for 
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these neurotoxic effects.  Consequently, elucidating the metabolic profile of Dyn A 1-17 in the 
central nervous system is essential to understanding the role it plays in vivo.  Toward this end, in 
vitro metabolism studies were performed with both rat brain and spinal cord slices.   
To ascertain that accurate results were attainable in modified PBSA (mPBSA), the 
stability of Dyn A 1-17 in mPBSA was determined at room temperature and at 37°C over ten 
hours.  The dynorphin concentration remained constant throughout (data not shown).  There was 
no appearance of metabolites over time, however, the Dyn A 1-17 standards did contain peaks 
for the Dyn A 1-8, 1-13, and 2-17 metabolites even at the initial (t = 0) timepoint.  The 
concentrations of these compounds were constant and did not increase during the stability study 
(Figure 5.5 and 5.6).  The presence of dynorphin metabolites in Dyn A 1-17 standards could be 
contaminants from the synthetic process.  The metabolite peaks were seen even when fresh Dyn 
A 1-17 standards were made and analyzed immediately.  The concentrations also did not change 
over time which would have been expected if the Dyn A 1-17 was undergoing degradation in 
mPBSA.   
If the peaks were due to contaminants from the synthetic process, one would expect an 
increase in the fragment concentrations when higher Dyn A 1-17 concentrations were used.  
However, the same concentrations were observed when both 1 ìM and 25 ìM Dyn A 1-17 stocks 
were analyzed.  Another explanation is that in-source fragmentation is occurring, producing 
smaller peptidic ions at the electrospray source.  This is a commonly reported phenomena when 
analyzing peptides by electrospray and is especially common for peptides with multiple charge 
sites [36-38].  Data for these fragments (1-8, 1-13, and 2-17) is therefore presented as percent 
increase in concentration during the study duration (4 hours) to account for the initial metabolite 
concentrations present due to contamination or in-source fragmentation.   
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Dynorphin Metabolite Average Conc (µM) Standard Deviation
Dyn A 1-6 0.008 0.00018
Dyn A 1-8 0.039 0.00038
Dyn A 1-13 0.202 0.00758
Dyn A 2-17 0.454 0.05171
 
 
Figure 5.5  Dynorphin metabolite concentrations in Dyn A 1-17 standards (1 ìM) in mPBSA at 
25 °C.  Values were constant over time as represented by the standard deviations (n=10).  
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Dyn A 1-6 0.002 0.00053
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Figure 5.6  Dynorphin metabolite concentrations in Dyn A 1-17 standards (1 ìM) in mPBSA at 
37 °C.  Values were constant over time as represented by the standard deviations (n=10).  
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For Dyn A 1-6 which is not present as a contaminant, the change in concentration from t =0 to t 
= 240 minutes is plotted.    
Once the stability of the parent peptide was established, in vitro metabolism could be 
investigated in rat brain and rat spinal cord samples.  The tissue slice was placed in mPBSA and 
prior to the addition of Dyn A 1-17, a basal sample was collected and analyzed via LC-MS/MS.  
No dynorphin peaks were observed in this sample with either tissue (Figure 5.7 A & B).  Dyn A 
1-6 was the most abundant metabolite of Dyn A 1-17 in the presence of three separate rat brain 
slices, although the overall concentrations and time course of metabolism varied as can been 
seen in Figure 5.8.  Dyn A 1-13 and Dyn A 2-17 were produced to a much lesser extent than Dyn 
A 1-6, exhibiting 23.0% and 27.8% increases, respectively, from the initial levels observed due 
to in-source fragmentation.  Dyn A 1-8 did not significantly increase over time.  The average 
percent increase for Dyn A 1-8, 1-13, and 2-17 following 4 hour incubation with rat brain slices 
is summarized in Table 5.1.   
Dyn A 1-6 is produced by the cleavage of the Arg6-Arg7 bond by dynorphin converting 
enzyme (DCE) [39, 40].  DCE was first isolated from human cerebral spinal fluid (CSF) and 
human spinal cord.  The presence of Dyn A 1-6 as a metabolite in rat brain was previously 
confirmed in Chapter 3 of this thesis via analysis by copper complexation with capillary 
electrophoretic separation and UV detection [41].  Dyn A 1-6 has also been identified as a 
metabolite in the rat striatum via microdialysis sampling by Reed et al [23].  Dyn A 2-17 is 
thought to arise following cleavage of the N-terminal tyrosine by a non-specific aminopeptidase 
[42-43].  Dyn A 1-13 was previously identified in human plasma [41], however it has not 
previously been detected in rat brain.  The cleavage of the Lys13-Trp14 bond to produce this 
metabolite may be due an endopeptidase present in the brain tissue [17, 23].   
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Figure 5.7  Basal rat brain  (A) and rat spinal cord  (B) slices spiked with 1 ìM internal standard 
(bradykinin).  Overlays of extracted ion chromatograms for Dyn A 1-6, 1-8, 1-13, 1-17, 2-17, 
and bradykinin.  Only one peak is observed for bradykinin.   
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Figure 5.8  Appearance of Dyn A 1-6 in rat brain slices following incubation with 25 ìM Dyn A 
1-17.  Each graph represents data from 1 rat (A).   Concentrations (ìM) are normalized to total 
protein content.  Bar graph plots the average values (ìM peptide/mg of protein) at t = 0 and t = 
240 min, standard deviation as error bars n=3.  Experiments performed in mPBSA at 25°C.  
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Dynorphin Metabolite Average Percent Increase
Dyn A 1-8 2.01% 
(+/- 1.40)
Dyn A 1-13 23.0% 
(+/- 4.65)
Dyn A 2-17 27.8% 
(+/- 11.2)
 
Table 5.1  Average percent increase of dynorphin metabolites 4 hour following incubation of 
Dyn A 1-17 with rat brain slices.  Standard deviations in parentheses, n = 3. 
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In addition to investigating the metabolism of Dyn A 1-17 in rat brain slices, the 
metabolism in rat spinal cord slices was also investigated.  Again Dyn A 1-6 was observed as the 
most abundant metabolite.  The time course of Dyn A 1-6 appearance was even more varied than 
in the rat brain samples (Figure 5.9).  In the first rat (Figure 5.9, blue diamonds), the Dyn A 1-6 
appears to undergo additional metabolism itself after two hours in the presence of rat spinal cord, 
shown by the decrease in concentration after the two hour sample.  In the third rat (Figure 5.9, 
green triangles), Dyn A 1-6 is only produced to a small degree (less than 0.1 ìM/mg of protein) 
until just after 2 hours when a rise in the metabolite concentration occurs. Dyn A 1-13 and 2-17 
were also produced, only to a much lesser degree.  Again, an increase in Dyn A 1-8 
concentration was not observed.  The average percent increase for Dyn A 1-8, 1-13, and 2-17 
following 4 hour incubation with rat spinal cord slices is summarized in Table 5.2. 
Some of the differences observed here can be attributed to inter-animal variability.  
Factors such as the age and weight of the animal can alter their metabolism.  The isolation of the 
spinal cord was also a more tedious surgery.  Unlike the brain (which is easily removed as a 
whole organ and then sliced in a reproducible way), often the spinal cord was removed in small 
segments.  Therefore, there was more variability with regard to the section of the spinal cord that 
was used in each experiment.  Additionally, the viability of the tissues over the course of the 
study also plays a significant role in these studies.  Rat central nervous system tissues are known 
to degrade more rapidly than the CNS tissues of other mammalian species (bovine and human 
for example).   This would explain the increase in variability observed at the later timpoints of 
the metabolism studies.  Interestingly, Dyn A 1-6 was not observed in rat spinal cord using the 
CE method [41].  The detection of this peptide in these experiments is most likely due to the 
improvements in sensitivity when using mass spectrometry versus UV detection.  The limits of 
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Figure 5.9  Appearance of Dyn A 1-6 in rat spinal cord slices following incubation with 25 ìM 
Dyn A 1-17.  Each graph represents data from 1 rat (A).   Concentrations (ìM) are normalized to 
total protein content.  Bar graph plots the average values (ìM peptide/mg of protein) at t = 0 and t 
= 240 min, standard deviation as error bars n=3 Experiments performed in mPBSA at 25°C.  
165 
 
 
 
 
 
 
 
 
Dynorphin Metabolite Average Percent Increase
Dyn A 1-8 1.04% 
(+/- 0.14)
Dyn A 1-13 35.6% 
(+/- 20.8)
Dyn A 2-17 17.4% 
(+/- 0.88)
 
Table 5.2  Average percent increase of dynorphin metabolites 4 hour following incubation of 
Dyn A 1-17 with rat spinal cord slices.  Standard deviations in parentheses, n = 3. 
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detection are 0.2 nM using LC-MS/MS versus 2.5 ìM with the CE UV method.  Sensitivity as 
well as selectivity are further increased by using MRM.   
5.3.2 In vitro metabolism of Dyn A 1-17 in the presence of BBMECs 
 In addition to investigating the metabolism of Dyn A 1-17 in the presence of rat brain and 
spinal cord, the metabolism in the presence of BBMECs was also explored.  Wells without added 
Dyn A 1-17 were used as a control, and no dynorphin peaks were observed in the control wells 
throughout the duration of the experiment (data not shown).  Percent increase in each of the 
metabolites was again calculated to account for the initial levels of fragmentation produced at the 
electrospray source.    
 The time course of Dyn A 1-17 metabolism is seen in Figure 5.10.  A clear decrease in 
Dyn A 1-17 concentration over time is apparent.  In order to identify the appearance of 
metabolites over time, LC-MS/MS data is presented as percent increase over the duration of each 
four hour study.  No appreciable increase in Dyn A 1-8, 1-13, or 2-17 concentrations were 
observed as summarized in Table 5.3.  Low amounts of the peptides were present for the 
duration of the study due to in-source fragmentation; however, in each of the wells, the 
concentration did not change over time.  The concentration of Dyn A 1-6 however did increase 
over time as can be seen in Figure 5.11.  The presence of Dyn A 1-6 as a major metabolite of 1-
17 agrees well with the previously reported metabolism in the rat brain and rat spinal cord.  
Therefore characterizing the transport of this metabolite at the blood brain barrier could 
contribute to a better understanding of the role dynorphin may play in neuropathic pain and other 
neurological disorders.           
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Figure 5.10   Metabolism of Dyn A 1-17 in the presence of BBMECs following a 1 ìM spike (n = 
3).  Experiment performed in mPBSA at 37 °C.  
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Dynorphin Metabolite Average Percent Change
Dyn A 1-8 2.19% 
(+/- 0.503)
Dyn A 1-13 -0.869% 
(+/- 1.31)
Dyn A 2-17 -1.15% 
(+/- 0.903)
 
Table 5.3  Average percent increase of dynorphin metabolites 4 hour following incubation of 
Dyn A 1-17 with BBMECs.  Standard deviations in parentheses, n = 3.  
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Figure 5.11. Appearance of Dyn A 1-6 in the presence of BBMECs following incubation with 1 
ìM  Dyn A 1-17.  Each trace is the data from 1 well of a 12 well cell culture plate (A).  Average 
concentration (n = 3) in the initial sample (t = 0 min timepoint, blue) and the concentration 
following a 4 hour incubation (t = 240 min, red) (B).  Experiment performed in mPBSA at 37 °C.  
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5.3.3 Blood brain barrier permeability of Dyn A 1-6, a major metabolite of Dyn A 1-17 
 Dyn A 1-6 has been identified as a major metabolite of the parent peptide Dyn A 1-17 in 
both the central nervous system [17, 41, 44] (brain and spinal cord) as well as in peripheral 
tissues (blood and plasma) [41, 45-47].  For this reason, the BBB permeability of Dyn A 1-6 was 
investigated, using BBMECs grown on polycarbonate membranes and mounted in Side-by-
SideTM diffusion chambers.  Fluorescein was utilized as a low permeability control following all 
experiments to examine monolayer integrity.   
Most permeability experiments performed with Side-by-SideTM diffusion chambers use 
PBSA; however, as described in Chapter 4, the more basic dynorphin peptides exhibited ion 
suppression likely due to sulfate and/or phosphate adduct formation in PBSA.  Therefore, 
modifications were made to the cell media to decrease this effect and improve ionization.  The 
concentration of phosphate was decreased and magnesium chloride was substituted for 
magnesium sulfate.  Table 5.4 lists the components of PBS and PBSA as well as the components 
of the modified media (mPBSA).  To ensure that mPBSA did not alter the integrity of the cell 
monolayer, the permeability value for fluorescein was determined before commencing with the 
Dyn A 1-6 transport experiments.  Fluorescein permeability was calculated to be 3.42 x 10-5 cm/s 
(+/- 2.90 x 10-5 n = 4).  This value agrees well with previously reported literature [33, 34] 
indicating that the modifications did not have a negative impact on tight junction integrity.   
 Next, Dyn A 1-6 permeability was screened by the above method.  Both the directional 
and temperature dependence of Dyn A 1-6 permeability were determined.  The apparent 
permeability coefficient of Dyn A 1-6 was calculated to be Papp = 6.59 x 10-5 cm/s (+/- 1.74 x 10-5 
n = 4), in the apical to basolateral direction, and Papp = 6.43 x 10-5 cm/s (+/- 1.61 x 10-5 n = 4), in  
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PBS PBSA mPBSA
129 mM NaCl 129 mM NaCl 144 mM NaCl
2.5 mM KCl 2.5 mM KCl 4.0 mM KCl
7.4 mM Na2HPO4 7.4 mM Na2HPO4 0.74 mM Na2HPO4
1.3 mM KH2PO4 1.3 mM KH2PO4 0.13 mM KH2PO4
0.63 mM CaCl2 0.63 mM CaCl2
0.74 mM MgSO4 0.74 mM MgCl2
5.3 mM Glucose 5.3 mM Glucose
0.1 mM Ascorbic Acid 0.1 mM Ascorbic Acid
10 mM HEPES
 
Table 5.4. A comparison of phosphate buffered saline (PBS), phosphate buffered saline with 
additives (PBSA, typically used for transport studies), and the modification of PBSA employed 
in these studies to improve  electrospray ionization of highly basic dynorphin peptides.  
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the basolateral to apical direction.  There was no difference in the permeability based on 
direction (Figure 5.12).  A decrease in permeability was observed at 4°C, Papp = 1.11 x 10-5 cm/s 
(+/- 2.90 x 10-6, n = 4, p < 0.005) indicative of a carrier-mediated transport system (Figure 5.13).  
Fluorescein was utilized as a control following the end of each experiment.  Values for 
fluorescein permeability are presented in Figure 5.14.   
An interesting observation was made when the fluorescein permeability controls were 
analyzed following studies with Dyn A 1-6.  It was found that the permeability values for 
fluorescein were increased following the Dyn A 1-6 exposure at 37°C.  However, at 4°C the 
permeability coefficient of fluorescein was not affected by the peptide.  This effect was further 
investigated by incubating mounted monolayers for 2 hours in mPBSA at 37 °C.  Following the 
2 hour incubation, 0, 20, and 100 ìL of mPBSA were removed and replaced with Dyn A 1-6 
resulting in final concentrations in the chamber of 0, 18.6, and 46.6 ìM.  The fluorescein 
permeability increased in a linear fashion with increasing exposure to Dyn A 1-6, R2 = 0.9995 
(Figure 5.15).  The permeability values for Dyn A 1-6 in the apical to basolateral and basolateral 
to apical directions fall along this line, as shown by the purple and orange data points in Figure 
5.16, suggesting that this peptide is responsible for increasing BBB permeability.   A similar 
phenomenon was observed by Thompson and Audus with the opioid peptide leucine enkephalin 
[33, 34], and the reported values for fluorescein permeability both with and without leucine 
enkephalin pretreatment are also plotted in Figure 5.16.   
It has been reported previously that leucine enkephalin can increase the permeability of 
low molecular weight, membrane impermeant molecules such as sucrose and fluorescein in a 
concentration-, energy-, and temperature-dependent manner [33, 34, 48].  Metabolites of Leu-
enkephalin did not exhibit this effect nor did metabolically stable analogs.  It is also well known 
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that there exists a saturable peptide transport system for small, N-tyrosinated peptides at the 
blood brain barrier [49-51], and that this system is responsible for the brain to blood efflux of the 
small opioid peptide leucine enkephalin.  Thompson and Audus found that non-opioid peptides 
capable of utilizing this transport system did not alter BBB permeability to fluorescein or sucrose 
suggesting that binding this efflux system is not responsible for BBB opening.  However, the use 
of naloxone, a mu- and delta-opioid antagonist, was shown to attenuate the increased transport 
caused by the Leu-enkephalin [33-34].  This indicates that opioid receptor activity (delta or mu) 
may play a role in the ability of these peptides to open the BBB.  Dyn A 1-17 preferentially acts 
at the kappa-opioid receptor, while Dyn A 1-6 shares affinity for the kappa, mu, and delta 
receptors.  Dyn A 1-6 has not been implicated in the neurotoxicity of Dyn 1-17; however, it may 
be responsible for opening the blood brain barrier, allowing for increased transport of the parent 
peptide.  Further studies would be necessary to determine the mechanism responsible for the Dyn 
A 1-6-induced increase in BBB permeability.   
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Figure 5.12  Bi-directional apparent permeability coefficients of Dyn A 1-6 (n =4 in each 
direction). 
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Figure 5.13  Temperature dependence of the apical to basolateral transport of Dyn A 1-6 (n =4 at 
each temperature) p < 0.005.  
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Figure 5.14  Effect of pre-treatment with 18.6 ìM Dyn A 1-6 on the BBB permeability of the low 
molecular weight, low permeability marker, fluorescein (10ìM), n=4.  
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Figure 5.15  Effect of pre-treatment with varying Dyn A 1-6 concentrations on the BBB 
permeability of the low molecular weight, low permeability marker, fluorescein (10 ìM), n  = 1 
for each data point.  
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Figure 5.16  Effect of pre-treatment with varying Dyn A 1-6 concentrations (    ) on the BBB 
permeability of the low molecular weight, low permeability marker, fluorescein (10 ìM).  
Fluorescein permeability without Dyn A 1-6 incubation (    ), fluorescein permeability following 
240 min Dyn A 1-6 pretreatment A to B (   ) and B to A (   ), and fluorescein permeability 
following 120 min Dyn A 1-6 pretreatment at 4 °C (   ).  Also shown are literature values for the 
permeability of fluorescein alone (x) and following pre-treatment with leucine enkephalin (+).   
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5.4 Summary 
 The metabolism of Dyn A 1-17 has been characterized in the presence of rat brain and 
spinal cord slices as well as in the presence of BBMECs, an in vitro model of the BBB.  Dyn A 
1-6 was found to be the predominant metabolite in each of these systems.  The transport of this 
metabolite across the BBB was then characterized and was found to be bi-directional.  Dyn 1-6 
transport was decreased at 4°C indicating energy (ATP) driven transport mechanism.  The 
metabolite was also found to increase the permeability of the blood brain barrier to a low 
molecular weight, low permeability control substance, fluorescein.  Such effects suggest a role of 
this dynorphin metabolite in the opening of the blood brain barrier, and potentially a role of the 
metabolite in the neurotoxic effects of Dyn A 1-17.  Further studies would be necessary to 
determine the mechanism by which this opening occurs.       
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Chapter Six: 
Work towards the development of an immunoaffinity microchip electrophoresis device for 
the investigation of the neuropharmacology of Dyn A 1-17  
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6.1 Introduction 
The past decade has led to an increasing interest in combining the fields of 
immunochemistry and separation science, in particular capillary and microchip electrophoresis 
(CE and ME respectively), and there are several comprehensive reviews published on the 
advances in this area [1-4].  One of the touted advantages of capillary- and microchip-based 
electrophoretic separation techniques is the small sample volume requirements, especially in the 
case of volume-limited biological samples.  In the case of the detection of low abundance 
biomarkers, however, this is also its significant drawback.  Nanoliter injection volumes 
characteristic of CE and ME can result in only a few molecules of low concentration compounds 
being injected.  This necessitates sufficiently concentration-sensitive detection options and/or 
concentration prior to analysis.  Thus, improvements in limits of detection are essential for the 
use of CE and ME for the analysis of low concentration compounds of interest.  Immunoaffinity 
techniques have been employed in combination with electrophoresis in a variety of formats.  
Offline immunoextraction prior to separation is a common method; however, this chapter will 
focus on the coupling of immunoextraction directly to the separation technique.  This can be 
accomplished in both the capillary and microchip format and several approaches will be detailed.  
Many depictions of antibody immobilization on the surfaces of such devices use a similar 
cartoon, characteristically a Y-shaped molecule, to illustrate the entire antibody chemically 
attached to the capillary or microchip substrate.  Figure 6.1 depicts a cartoon antibody structure 
indicating important structural elements including the Fc or constant fragment, the two FAb 
fragments responsible for antigen binding, and the flexible hinge region joined by disulfide 
bonds.  While intact antibodies can be immobilized directly, the orientation of the antibody on  
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Figure 6.1  Typical antibody schematic illustrating several important regions of the molecule.  
Figure adapted from [27]. 
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the support surface can be problematic.  If attachment chemistries are not specific, antibodies can 
in effect “lay down” on the support, hindering the availability of the binding site and decreasing 
the available surface area on which other antibodies can bind [1].  In order to reproducibly 
immobilize intact antibodies, modifications must be made to both the immobilization surface and 
the Fc portion of the antibody.  One method of immobilizing whole antibodies is to use proteins 
expressed in the coat of bacteria, namely protein A and G.  These proteins are expressed in 
bacteria to protect the organisms from immune responses in their host organism.  Both proteins 
recognize the Fc portion of the antibody.  When these proteins are immobilized onto solid 
supports they can ensure the proper orientation of antibodies; however, reactivity between 
protein A and protein G and antibodies is not ubiquitous.  The IgG antibodies of some species, 
for example, do not react with protein A. 
Another popular method for immobilizing intact antibodies exploits the high binding 
affinity of biotin and avidin (or streptavidin).  As depicted in Figure 6.2, glass surfaces of 
capillaries or microchip substrates can be silanized and then activated with a N,N,’-carbonyl-
diimidazole (CDI).  Avidin protein is then immobilized via a free amine.  Antibodies are 
biotinylated and will then bind the avidin modified surface.  Biotinylation, however, can be 
carried out at any free amine group and often times this chemistry is not specific enough.  
Therefore hydrazine chemistries are typically exploited to better control the site of biotinylation.  
Biotin hydrazine is commercially available.  Following oxidation of the carbohydrate moiety on 
the Fc region of the antibody, preferential biotinylation of the Fc region can be achieved, thus 
controlling the antibody-surface chemistry.  Hage’s group utilized this immobilization method to 
create immunoaffinity restricted access medias (IA-RAM) [5].  Antibodies are first immobilized  
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Figure 6.2  Reaction of  biotin hydrazine with the carbohydrate moiety on the Fc fragment of an 
intact antibody.  Following this reaction, antibodies are immobilized on a silanized substrate 
functionalized with avidin.  Figure adapted from [27]. 
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on spherical silica particles containing small pores.  The spheres are then treated with papain for 
digestion.  Due to steric hindrance, only the antibodies on the outer portion of the supports are 
digested, thus “disabling” their antigen binding capabilities.  The antibodies within the restricted 
access area remain intact, selectively enabling the devices to capture small analytes of interest 
and not proteins or other macromolecules (Figure 6.3).            
Therefore, antibody fragments are commonly employed in immunosorbent methods.  
Digestion of antibodies is achieved using either pepsin or papain.  The resulting fragments from 
these two enzymatic reactions are illustrated in Figure 6.4.  Pepsin produces one F(Ab’) fragment 
that must be further reduced.  FAb fragments retain their antigen binding sites and are more 
easily immobilized via the free thiol group.  Linker molecules are often used to bind the free 
thiol.  This decreases steric hindrance that could interfere with antigen binding.  One popular 
method for the immobilization of FAb fragments onto glass substrates utilizes the bifunctional 
cross-linker 4-(N-maleimidomethyl) cyclohexane-1-carboxylic-3-sulfo-N-hydroxysuccinimide 
ester (SSMCC).  This is often used when glass capillaries or substrates have been silanized, for 
example with aminopropyl triethoxy silane.  The maleimide functionality of SSMCC reacts with 
the free thiol groups on the digested antibody fragments, and the succinimide ester is then free to 
react with amine groups on the substrate surface (Figure 6.5).  These chemistries can be 
performed on the walls of treated capillaries at the sample inlet [6-10] (Figure 6.6) or microchip 
ports (Figure 6.7).  
In addition to direct coupling of the antibodies to the separation device, immobilization 
on other solid supports such as glass beads [11] and filter papers is feasible.  Other examples 
have utilized sepharose  beads [12] functionalized with cyanogens bromide.  The beads are  
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Figure 6.3  Antibodies immobilized via the Fc fragment using hydrazine chemistry.  Papain 
digests the antibodies on the outer sphere (a) while the antibodies within the pores remain intact.  
This allows the preferential binding of small analytes over large proteins due to steric hindrance.  
Figure used with permission from [5]. 
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Figure 6.4  Digestion of antibodies with papain and pepsin to produce smaller antigen binding 
fragments for immobilization via free thiol groups.  Figure adapted from [27]. 
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Figure 6.5  Immobilization of FAb fragments via free thiols to a silanized glass surface.  SSMCC 
is used as s linker molecule between the substrate and the antibody. Figure adapted from [27]. 
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 Figure 6.6  Schematic of on-capillary immunoaffinity extraction including antibody digestion 
(1), antibody immobilization (2), affinity capture of analyte (3), and elution of bound antigen and 
capillary electrophoresis of bound analytes (4).  Figured used with permission from [6].  
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Figure 6.7  Schematic of online microchip immunoaffinity extraction.  The process involves 
several steps including: 1. antibody immobilization, 2. sample incubation, 3. affinity capture of 
analyte, 4. elution of bound antibody, 5. electrophoretic separation on-chip, and 6. downstream 
detection.  
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reacted with the primary amine groups on whole antibodies and then packed into small 
microreactors or segments of fused silica capillary that are attached to the separation capillary by 
frits and low volume connectors.  Similarly in the microchip systems antibody fragments can be 
immobilized directly into glass micro-fabricated immunoaffinity ports or onto glass fiber filter 
papers than can subsequently be placed on chip [13-15].  Monolithic supports have also been 
functionalized via epoxy groups reacted with the amine groups of whole antibodies in 
poly(methyl methacrylate) (PMMA) microchips for the detection of  human serum albumin 
(HSA), IgG, green fluorescent protein (GFP), and amino acids [16, 17]. 
The application of these techniques to pharmaceutical and biological samples of interest 
has been pioneered largely by the work of Dr. Terry Phillips, Dr. Norberto Guzman, and Dr. 
David Hage.  Research in the Phillip’s laboratory has utilized immunoaffinity CE and ME for a 
variety of applications including the analysis of cellular release following stimulation [6, 8, 9, 
18], analysis of proteins and peptides from microdialysates [10], and for clinical applications 
including analysis from tissue biopsies [15], cytokine clearance profiles in plasma and cerebral 
spinal fluid (CSF) [19], hormone analysis in blood, saliva, and urine [20], and cyclosporine 
determination in tears [21].  Kalish and Phillips also reported an immunoaffinity based method 
for the detection of neurotrophins in the serum of head trauma patients when previously such 
determinations have only been possible directly from brain tissue or CSF [7].  Guzman and co-
workers have utilized immunoaffinity techniques for the determination of endogenous versus 
exogenously administered erythropoietin (EPO) and EPO analogs [11, 12].  Other groups have 
utilized immunoaffinity techniques for the quantitation of enatiomeric compounds when 
immunoassays would not be able to distinguish between such species [22].  Hage’s group has 
developed HPLC immunoaffinity sandwich assays [23, 24].  Using these methods, they were 
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able to determine free versus bound drugs, such as warfarin, in samples with varying 
concentrations of serum albumin [23].    
While most applications involve antibody immobilization and the detection of labeled 
antigens, it is also possible to modify supports with the antigen of interest and detect the 
presence of antibodies.  For example, work by Stege et al modified magnetic nanobeads with the 
antigens of Helicobacter pylori (H. pylori), a gram negative bacterium responsible for chronic 
active type B gastritis and peptic ulcer diseases [25].  Magnetic beads were held in place at the 
inlet of the capillary by an external magnet.  Antigen immobilization, incubation with serum 
samples, and secondary labeled antibody attachment were all performed on-capillary prior to 
separation.  This method enabled the detection of anti-H pylori IgGs in human serum.  Similarly, 
a microchip method has also been developed for the determination of naproxen in serum of 
patients taking the anti-inflammatory drug.  In this system, anti-naproxen antibodies were 
fluorescently labeled off-chip.  Serum samples were reacted with these antibodies on-chip and 
the antigen-antibody complex as well as free antibody was detected by laser-induced 
fluorescence detection (LIF) [26]. 
Previous chapters in this thesis have described both CE and LC-MS/MS methods for the 
detection of Dyn A 1-17 and four of its metabolites.  These methods, however, still lack the 
sensitivity necessary to quantitate endogenous concentrations (low picomolar) of the peptides of 
interest.  As stated in previous sections of this thesis, immunoassays are commonly employed for 
the detection of neuropeptides, and detection limits in the low ng/mL range are typically 
achieved.  While these assays boast low limits of detection, cross-reactivity significantly hinders 
their applicability to metabolism studies.  Therefore, combining the sensitivity of immunoassay 
with the efficiency of electrophoretic separation has the potential to revolutionize investigations 
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of peptide metabolism and transport at the blood brain barrier.  In particular, the incorporation of 
immunoaffinity ports onto miniaturized platforms (microchips) enables integrated sample clean-
up and preconcentration prior to electrophoretic separation on a single device (Figure 6.7).  
Further, the inclusion of on-chip labeling and integrated sampling from microdialysis probes will 
result in a micro total analysis system (µTAS) that has the potential for on-animal applications.  
Continuous, real-time monitoring of neurochemical processes in awake, freely moving animals 
can be correlated to animal behavior using telemetry and time-stamped video. 
For application of this approach in an on-animal separation based sensor system, the 
processes described above must be extensively characterized and optimized.  To that end, 
Chapter 2 of this thesis focused on the development of a CE separation of Dyn A 1-17 from 
several of its metabolites.  The current chapter will review immunoaffinity techniques employed 
for both capillary and microchip electrophoresis (CE and ME respectively), as well as describe 
the characterization of the immunoaffinity portion of an integrated microchip device for the 
detection of dynorphin peptides.  Some shortcomings of current microchip platforms will be 
addressed, particularly as they relate to detection options, microchip substrates, and the 
practicalities of separating closely related species such as peptide metabolites.   
 
 
 
 
 
198 
 
6.2 Materials and Methods 
6.2.1 Reagents 
All dynorphin peptides and antibodies were purchased from Bachem (King of Prussia, 
PA, USA).  Goat anti-rabbit IgG was purchased from Sigma (St. Louis, MO, USA).  Alexa 
Fluor 633 was obtained from Molecular Probes, Invitrogen (Carlsbad, California, USA).  All 
other reagents were obtained from Sigma (St. Louis, MO, USA). 
6.2.2 Antibody screening with traditional microplate ELISAs 
A standard enzyme linked immunosorbent assay (ELISA) was performed to screen 
antibodies to various dynorphin peptides.  Several solutions were made including: PBS, PBS 
with 0.05% Tween 20, carbonate coating buffer and caesin blocking solution (instructions to 
follow).  The carbonate coating buffer consisted of sodium carbonate (40.5 mM), sodium 
bicarbonate (35.7 mM), and sodium azide (3.0 mM), pH 9.8.  Caesin blocking solution was made 
by combining 5.2 g NaOH, 80.0 g casein (Difco Skim Milk Powder), 4.6 g Tris HCl, 8.0 g 
sodium azide, and 27.8 g NaCl in 4 L H2O, pH 7.5.  Note: caesin should be added slowly as it 
will take time to dissolve.  Also, when adjusting the pH with HCl, caesin may precipitate.  
Therefore, add a small amount of HCl, stir to resuspend caesin, and then test the pH. 
All reagents plated were 100 µL unless otherwise noted.  The procedures used in these 
studies were adapted for these studies with assistance from Dr. Terry Phillips (NIH) and Dr. 
Brooke Barrett (Middaugh group, University of Kansas) [27].  All peptides were first diluted in 
carbonate coating buffer to a final concentration of 10 µg/mL, and incubated in each well of a 
96-well plate overnight at 4°C.  Samples were removed, and wells were filled with 250 µL caesin 
blocking solution for 30 minutes at room temperature to prevent non-specific adsorption in the 
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following steps.  Wells were then emptied and the primary antibody diluted in blocking buffer 
was added at a range of concentrations (0.625, 1.25, 2.5, 5, 10, 20, and 40 µg/mL) and allowed to 
react for 1 hour at room temperature.   
Following incubation with the primary antibody, wells were washed three times with 
PBS containing 0.05% Tween 20 and once with PBS buffer alone.  Then the secondary antibody 
(goat anti-rabbit IgG) diluted in PBS was added and allowed to react for 30 minutes at room 
temperature.  Next, wells were washed three times with PBS + 0.05% Tween 20 and once with 
PBS buffer alone.  The substrate, 3,3’,5’-tetramethylbenzidine (TMB), was added and incubated 
for 30 min at room temperature.  Two molar HCl was then added to quench the reaction.  Plates 
were read with a UV SpectraMax M5 microplate spectrophotometer (Molecular Devices, 
Sunnyvale, CA) at 450 nm within 10 minutes of HCl addition. 
In this work, anti-dynorphin A 1-17 was purchased from Bachem and screened by ELISA 
in a traditional 96-well plate format.  The following dynorphin peptides were screened: Dyn A 1-
17, 2-17, 1-13, 1-8, and 1-6 as well as leucine enkephalin.  Bradykinin was used as a negative 
control since this peptide differs structurally from the opioid peptides of interest.  Reactivity with 
bradykinin would be unexpected, and since it is also a neuropeptide, screening for its reactivity 
with anti-Dyn A 1-17 is of interest.  Blank wells (PBS only, no peptide added) are also reported. 
6.2.3 Antibody screening with magnetic beads 
Dynorphin antibodies were prepared for attachment to magnetic nanobeads via 
procedures described previously [27].  Commercially available antibodies were reconstituted in 
18 MΩ deionized (D.I.) water from a benchtop Milli-Q Synthesis A10 Water Purification 
System (Millipore, Billerica, MS, USA) as per product instructions.  EZ-LinkTM Sulfo-NHS-LC-
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LC-Biotin (Pierce Biotechnology, Rockford, IL, USA) was dissolved in calcium chloride and 
heated to 45°C.  Equal volumes of antibody and biotin were then combined and allowed to mix 
for 1 hour.  The biotinylated antibody solution was dialyzed overnight at 4 °C against PBS.  
Streptavidin-coated magnetic beads (Polysciences Inc., Warrington, PA, USA) were washed with 
PBS and mixed with biotinylated antibody solution in a 1:1 ratio (by volume).  After 30 minutes, 
the beads were washed three times with PBS.  When not in use, the modified beads were stored 
in PBS at 4 °C. 
Antibody screening was performed for each dynorphin peptide of interest.  Equal volume 
of antibody-coated beads and peptide were combined in a polypropylene microcentrifuge vial 
and heated (37 °C) on a benchtop shaker for 2 hours.  Following the incubation period, the 
microcentrifuge vial was placed in a magnetic base collecting the beads and any bound antigen 
to the side wall of the tube.  The unbound fraction was then collected into an empty 
microcentrifuge vial and the beads were washed three times with PBS.  Following the last wash, 
HCl (0.1 N) was added to the vial to elute the captured antigen.  This elution buffer was 
incubated with the beads and again heated (37 °C) on a benchtop shaker for 15 minutes.  The vial 
was then placed back in the magnetic base and the bound fraction collected for labeling. 
Labeling with Alexa Fluor 633 was then accomplished under basic conditions (10 mM 
sodium borate, pH 9.5) for efficient labeling.  A 200 µL aliquot of the bound fraction was diluted 
in separation buffer (10 mM sodium borate, pH 9.5) to raise the pH, and then 50 µL of a 1 
mg/mL Alexa Fluor solution (in N,N-dimethyl formamide, DMF) was added and allowed to 
mix at 4 °C overnight.  The labeled fractions were then analyzed on a Micralyne µTK 
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microfluidic electrophoresis system (Micralyne, Edmonton, Canada) that is described in more 
detail in the next section. 
6.2.4 Determination of dynorphin and metabolites by microchip electrophoresis  
6.2.4.1 ME with LIF Detection 
Microchip analysis was performed on a Micralyne µTK microfluidic electrophoresis 
system (Micralyne, Edmonton, Canada).  The system is equipped with eight platinum electrodes 
and a 635-nm, 8-mW red diode laser.  Detection was achieved using an epiluminescence 
confocal microscope coupled with a Hamamatsu H5773-03 photomultiplier tube and 16-bit data 
acquisition.  The system was also equipped with a chip stage form-fitted to accept Micralyne 
standard 16 mm x 95 mm x 2.2 mm deep microchips (described below).  The entire system was 
run on a personal computer running Microsoft Windows 2000 with a compiled LabView 
interface. 
Low fluorescence “Borofloat” glass chips were purchased from Micralyne.  The standard 
chip format was made of two 20 µm deep x 50 µm wide semi-circular channels arranged in an 
offset T.  Each channel has a port (2.0 mm diameter x 0.1 mm deep) at its end into which buffers 
and samples can be loaded.  The separation channel was 8 cm in total length (7.5 cm to the 
detector).  A variety of separation voltages were investigated for the separation of the dynorphin 
peptides.  On-chip injections were performed by applying 1.0 kV between the sample (S) and 
sample waste (SW) reservoir for 5.0 seconds while maintaining the buffer (B) and detection 
reservoirs at ground to prevent leakage of the sample into the separation channel.  Separation and 
injection of a discrete plug of analytes was achieved by applying a separation voltage (1.0 and 
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3.5 V) between the buffer and detection reservoirs while maintaining ground at the sample and 
sample waste reservoirs. 
Dynorphin peptides were derivatized with Alexa Fluor 633 prior to detection.  Stock 
solutions of Alexa Fluor were made in DMF (1 mg/mL).  Dynorphin stock solutions, also 1 
mg/mL, were made in PBS.  Equal parts (v/v) of peptide and dye were combined and allowed to 
react overnight at 4 °C.  Labeled peptide solutions were stored in 20 µL aliquots at -20 °C and 
thawed immediately prior to use.  Fresh labeled peptides were replaced at the beginning of each 
week. 
6.2.4.2 ME with amperometric detection 
The fabrication of glass-PDMS microchips with pyrolyzed photoresist carbon electrodes 
has been described previously [28, 29].  The following chemicals were used as received for 
fabrication procedures: AZ 1518 positive photoresist and AZ 300 MIF developer (Clariant, 
Somerville, NJ, USA); S1818 positive photoresist and Microposit 351 developer (Microchem, 
Newton, MA, USA); SU-8 10, SU-8 2 negative photoresist and SU-8 developer (MicroChem); 
100 and 127mm silicon (Si) wafers (Silicon, Boise, ID, USA); and Sylgard 184 (Ellsworth 
Adhesives, Germantown, WI, USA).  In addition, the following were utilized for microchip 
construction: Pt wire (22 gauge) (Fisher Scientific, Fairlawn, NJ, USA), high-temperature fused 
silica glass plates (4 in x 2.5 in x 0.085 in; Glass Fab, Rochester, NY, USA), conductive epoxy 
(ITW Chemtronics, Kennesaw, GA, USA), and colloidal silver liquid (Ted Pella, Redding, CA, 
USA). 
PDMS electrophoresis channels were fabricated using SU-8 10 negative photoresist that 
was spin coated on a 100 mm Si wafer and subjected to a soft bake procedure. A negative tone 
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transparency film was placed over the coated wafer, brought into hard contact, and exposed to a 
near-UV flood source. Following exposure, both wafers were post-baked, developed in SU-8 
developer, rinsed with isopropanol, and dried under nitrogen. A 10:1 ratio of PDMS was used for 
all analyses.  A simple ‘‘T’’ device containing a 3.5 cm separation channel (from the T 
intersection to the end of the separation channel) and 0.75 cm side arms was employed. The 
width and depth of the electrophoresis microchannels were 50 and 14 mm, respectively. 
Fabrication of pyrolyzed photoresist electrodes has been described previously by our 
group [29].  Briefly, either AZ 1518 or S1818 positive photoresist was dynamically coated on a 
fused silica glass plate. The coated plate was prebaked, then covered with a positive transparency 
film, and exposed to a near-UV flood source. After exposure the plate was developed, rinsed 
with 18.2 MΩ water, dried under N2, and subjected to a post-bake procedure.  A Lindberg/Blue 
M Three-Zone Tube Furnace (Cole-Parmer, Vernon Hills, IL, USA) was utilized for pyrolysis.  
The furnace was continuously flushed with nitrogen at 5 psi to provide an inert atmosphere. The 
temperature of the furnace started under ambient conditions and was increased at the rate of 5.5 
°C/min to 925 °C, held for 1 h, and then allowed to cool to room temperature. The resultant 
width of the PPF electrodes was 40 mm and the height was determined with a surface profiler to 
be 0.6 mm. 
Electrophoresis was carried out in unmodified PDMS microchannels using a 
programmable Jenway Microfluidic Power Supply (Dunlow, Essex, UK).  The buffer was 
degassed (Fisher Ultrasonic Cleaner, Fisher Scientific) and filtered with a 0.22 mm teflon filter 
before use. The PDMS channels were first flushed with 0.1 N NaOH for 3–5 min, then rinsed 
with 18.2 MΩ H2O, and finally filled with buffer by applying a vacuum.  Electrophoresis was 
performed by applying a high voltage (+ 1400 V) at the buffer reservoir (B) and a fraction of this 
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high voltage (+ 1200 V) at the sample reservoir (S), whereas the sample waste and detection 
reservoirs were grounded. A gated injection method was used for introduction of the sample plug 
and was achieved by floating the high voltage at the buffer reservoir for the duration of the 
injection before returning it to + 1400 V.   
Amperometric detection was accomplished using a CHI 802B EC analyzer (CH 
Instruments, Austin, TX, USA) and the current response was recorded using the built-in software 
package.  A three electrode system (working, Ag/AgCl reference, and Pt wire auxiliary) was 
used. For all data reported, the working electrode was set at a potential of + 900 mV (versus 
Ag/AgCl) and end channel alignment was used. 
6.2.5 Conventional capillary electrophoresis for the separation of pain-related neuropeptides 
Separations were performed on a Beckman Coulter PACE/MDQ (Brea, CA, USA) with 
LIF detection at 488 nm.  The system was controlled using 32 Karat software, and all subsequent 
data analysis was performed with this software as well.  Fused-silica capillaries (50 ìm id x 360 
ìm od) were obtained from Polymicro Technologies (Phoenix, AZ, USA) and cut to a 50 cm 
length (40 cm to detector).  A small window was burned through the polyimide coating 10 cm 
from the capillary end for LIF detection.  Pressure injections were performed at 6.9 kPa for 5.0 
seconds, and a separation voltage of 20 kV was applied with the anode at the injection end.  
Buffer was composed of 150 mM boric acid, and 7.5 mM sodium dodecyl sulfate (SDS), pH 9.5. 
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6.3 Results and Discussion 
6.3.1 Antibody Screening 
Commercial antibodies are available to a variety of dynorphin peptides.  Prior to 
immobilization in a capillary or microchip format, the cross-reactivity of the antibodies were 
screened to determine the reactivity with Dyn A 1-17 and related compounds (i.e. metabolites).  
In this work, the reactivity of anti-Dyn A 1-17 towards the dynorphin peptides was determined 
using the ELISA protocol described in section 6.2.2 of this thesis.  The response from incubation 
with 20 µg/mL antibody is presented in Figure 6.8.  As can be seen, significant cross-reactivity 
with the des-tyrosine metabolite (Dyn A 2-17) occurs.  No reactivity was observed with smaller 
dynorphin peptides, suggesting that the epitope for binding is somewhere at the C-terminal end 
of the peptide or is contingent upon a structural element that is absent in shorter peptide 
fragments.  Thus if an immunoaffinity microchip analysis system is to be made for the 
investigation of dynorphin metabolism, additional antibodies must be incorporated that will react 
with the smaller, N-terminal metabolites. 
To this end, an antibody to Dyn A 1-8 was purchased and evaluated in the same ELISA 
protocol (section 6.2.2) as the above anti-Dyn A 1-17.  In this assay, immune-reactivity was not 
observed with any of the dynorphin metabolites (Figure 6.9).  One possible explanation would be 
that the quality of the antibody itself was poor.  However, another possible reason, particularly in 
the case of such a small antigen, would be that immobilization of the peptide on the microplate 
actually buried the epitope, preventing the antibody from reacting with even its intended antigen, 
as seen by the lack of reactivity with Dyn A 1-8.  In order to determine if this was the case, an 
additional assay in a solution format was performed utilizing magnetic beads.  Analysis was  
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Figure 6.8  Cross reactivity exhibited between Dyn A 1-17 and Dyn A 2-17 following a 
traditional plate ELISA with anti-Dyn A 1-17  
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Figure 6.9  Traditional plate ELISA with anti-Dyn A 1-8 exhibiting a lack of reactivity with any 
of the dynorphin peptides screened.  
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performed offline by microchip electrophoresis with laser induced fluorescence detection.  This 
protocol is detailed in section 6.2.3 of this thesis.  A schematic of the process is shown in Figure 
6.10, and the chip design is presented in Figure 6.11.  With this assay, reactivity with Dyn A 1-8 
was observed; however, cross-reactivity with other N-terminal metabolites was not (Figure 6.12 
A and B).  Therefore it would still be necessary to screen and immobilize additional antibodies 
before creating a fully functional immunoaffinity separation device for the investigation of Dyn 
A 1-17 metabolism. 
6.3.2 Determination of dynorphin peptides by microchip electrophoresis 
6.3.2.1 Amperometric detection of copper-complexed dynorphins 
The simplest microchip substrates for use with amperometric detection are 
polydimethylsiloxane (PDMS) or PDMS-glass hybrid devices.  The PDMS can be reversibly 
sealed over a glass or PDMS substrate that has a metal or carbon electrode previously 
microfabricated or micromolded onto it (Figure 6.13).  Our group has found a variety of uses for 
such devices including the detection of reactive oxygen species such as peroxynitrite [30], 
neurotransmitters [28, 29], and small peptides [31, 32]. 
Chapter 3 of this thesis described the optimization of a CE separation of dynorphin 
peptides using copper complexation and UV detection.  Copper complexation has the unique 
capability of rendering even the des-tyrosine metabolites of Dyn A 1-17 electroactive.  It has 
been shown previously in our group, with angiotensin peptides and leucine enkephalin, that 
amperometric detection of the peptide-copper complexes following CE is feasible and improves 
limits of detection in comparison to UV detection [33-35].  Gawron et al were able to detect des- 
Tyr Leu-enkephalin at a dual carbon fiber electrode in an all PDMS chip (following 
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Figure 6.10  Schematic of the offline immunoaffinity extraction with magnetic beads as 
performed for screening anti-Dyn A 1-8 reactivity.  Dyn A 1-8 (green triangles) binds to the 
antibody-coated beads.  Unbound peptides (red triangles) are removed in step 2 of this process.     
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Figure 6.11  Micralyne Standard  “borofloat” glass microchip with 8 cm separation channel and 
an offset ‘T’ for injection.  
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Figure 6.12  Reactivity of dynorphin peptides with anti-Dyn A 1-8 following off-line antibody 
screening with magnetic bead assay (A).  Microchip electropherogram of Dyn A 1-8 following 
antibody binding, elution, and labeling with Alexa Fluor  633 prior to injection and detection 
on-chip.  
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Figure 6.13   Glass-PDMS microchip for amperometric detection with a pyrolyzed photoresist 
carbon electrode.  
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precomplexation with copper) [31].  Follow up work demonstrated the use of PDMS microchips 
with a dual carbon paste electrode for the separation of the tripeptide Tyr-Gly-Gly from des-Tyr-
Leu-enkephalin [32].  Both experiments, however, were performed at extremely high 
concentrations (high hundreds of micromolar) and further characterization was not performed. 
Unfortunately, several issues arose when analyzing dynorphin-copper complexed 
peptides by microchip electrophoresis with amperometric detection.  First, even the smallest 
metabolite investigated, Dyn A 1-6, exhibited extremely broad peaks migrating over minutes as 
opposed to the seconds normally observed in ME (Figure 6.14).  This occurred even with 
inclusion of the surfactant SDS which has been shown previously to prevent such non-specific 
adsorption.  Secondly, only extremely high concentrations of dynorphin were detected under 
these conditions.  This is likely due to non-specific adsorption of dynorphin peptides to the 
PDMS surface of the microchip channels.  Peptides have been shown previously to adsorb to the 
surface of PDMS.  Lacher et al compared the behavior of substance P (SP) on PDMS and Pyrex 
microchips and observed considerable adsorption of SP to the PDMS surface [36]. 
One might assume that a simple solution would therefore be to change the microchip 
substrate material, especially since a commonly stated advantage of such devices is fabrication 
from a variety of materials.  Electrodes for detection, however, are not easily incorporated into 
other microchip materials such as glass and plastic.  The permanent thermal-bonding typically 
employed for bonding the chips made of these substrates can be disrupted by the raised electrode 
material. Also the high temperatures used for bonding can destroy the electrodes.  Therefore, 
laser induced fluorescence detection on all glass microchips was investigated in these studies. 
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Figure 6.14  Detection of copper complexed Dyn A 1-6 (250 µM) on a glass-PDMS Microchip 
for amperometric detection with a pyrolyzed photoresist carbon electrode (detection voltage = 
+900 mV versus Ag/AgCl).   Background electrolyte: 25 mM sodium borate, pH 9.0.  Sample 
buffer: 25 mM sodium borate, 3 mM tartaric acid, 2 mM CuSO4, pH 9.0.  
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6.3.2.2 Laser induced fluorescence detection of Alexa Fluor tagged dynorphins 
The detection of peptides by laser induced fluorescence detection involves tagging of the 
peptides with a fluorescent moiety prior to analysis.  An attractive family of dyes is the Alexa 
Fluor tags (Molecular Probes, Invitrogen).  These compounds are sulfonated derivatives of 
commonly used dyes (coumarins, cyanine, rhodamine, and xanthenes, i.e. fluorescein) that offer 
improved stability and brighter fluorescence.  These dyes are also less pH sensitive, making the 
use of a variety of background electrolytes feasible.  Alexa Fluor 633 has been used 
extensively by Dr. Terry Phillips in his work with both conventional and microchip separations 
[6-7, 9, 13-15, 26].  Primarily the applications in his group focus on cytokines, peptides, and 
proteins of neurochemical interest.  Work with small peptides (less than MW = 1000) has not 
been extensively explored. 
Conjugation of this dye to small peptides presents a challenge for the electrophoretic 
separation, as evidenced by the co-migration of Dyn A 1-6 and Dyn A 1-17 shown in Figure 
6.15.  This is especially true in a miniaturized device that has a separation channel that is only 8 
cm in length.  The dynorphin peptides used in these studies range in molecular weight from 
711.82 to 2147.52 g/mol.  When these small peptides are tagged with Alexa Fluor (MW = 
1200 g/mol), the mass to charge ratios are made increasingly similar.  In fact, for some of the 
peptides of interest, the dye is larger than the peptide itself.  For all intents and purposes, the 
mass to charge ratio of the dye is really what is being altered under such conditions.  Ultimately 
the resulting AF-dynorphin peptides are very similar and therefore difficult to resolve in an 8 cm 
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Figure 6.15  Detection of Alexa Fluor 633-labeled Dyn A 1-6 and Dyn A 1-17 (each 5 µg/mL) 
on a glass microchip (8 cm separation channel). Run buffer consisted of: 20 mM sodium borate, 
0.1% IgePal, pH 9.0, with a 1.0 second injection and 2.5 kV applied separation voltage.  
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channel.  A smaller Alexa Fluor dye, AF 532 (MW = 721) was therefore investigated.  Tagging 
was performed in the same manner as with the AF-633 and a Micralyne system with a 532 nm 
laser was utilized.  A significant decrease in sensitivity was observed using the AF-532 dye, and 
there were no improvements with respect to dynorphin resolution observed (Figure 6.16). 
To improve upon the resolution of AF-633-tagged dynorphin peptides, a variety of buffer 
conditions were investigated.  These are summarized in Table 6.1.  First, different background 
electrolyte systems, including sodium tetraborate, boric acid, tris borate EDTA, and sodium 
phosphate, were explored.  These investigations included a wide range of buffer concentrations 
as well as pH values in the hopes of slowing the electroosmotic flow (eof) for improved 
resolution.  Concentrations of buffers greater than 20 mM often resulted in bubble formation and 
currents that were too high for the system; therefore these were not explored. 
In addition to investigating various background electrolytes and fluorescent dyes, two 
surfactants were evaluated in the run buffers.  As discussed in Chapter 2, phytic acid was used to 
prevent adsorption of the basic peptides to the negatively charge silanol groups of the capillary 
wall.  This compound unfortunately increases the background current significantly which was 
found to be problematic in the microchip format.  Fortunately, a similar effect can be achieved 
with detergents, without the corresponding increase in current.  For these studies, two surfactants 
were investigated: Brij 35 and Igepal CA-630 (structures shown in Figure 6.17).  Brij 35 was 
found to not be very effective at preventing adsorption, and therefore its use was not explored 
extensively.  No peaks were observed upon initial peptide injections with this additive in the run 
buffer, and then after several runs, the labeled peptide would leach from the glass surface 
resulting in a large increase in background fluorescence.  IgePal, however, gave more 
promising results.  It is a non ionic, non-denaturing detergent that has been shown to prevent   
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Figure 6.16  Detection of Alexa Fluor 532-labeled dynorphin peptides, 1-6 , 1-8, 1-13, 1-17, 
and 2-17 (each 5 µg/mL) on a glass microchip (8 cm separation channel). Run buffer consisted 
of: 20 mM sodium borate, 0.1% IgePal, pH 9.0, with a 1.0 second injection and 1.0 kV applied 
separation voltage.  
 
219 
 
Background
Electrolyte
Concentration 
(µM) pH
Surfactant(s) 
(0.1% v/v)
Organic 
Modifier
Sodium 
Tetraborate 5 9.0 IgePal
Sodium 
Tetraborate 10 8.0 IgePal
Sodium 
Tetraborate 10 8.5 IgePal
Sodium 
Tetraborate 10 9.0 IgePal
Sodium 
Tetraborate 10 9.0 Brij 35
Sodium 
Tetraborate 10 9.0
Acetonitrile
(5%)
Sodium 
Tetraborate 10 9.5 IgePal
Sodium 
Tetraborate 10 10.0 IgePal
Sodium 
Tetraborate 15 9.0 IgePal
Sodium 
Tetraborate 20 9.5 IgePal
Boric Acid 10 9.0 IgePal
Boric Acid 20 9.0 IgePal
Tris Borate 
EDTA 10 8.3 IgePal
Sodium 
Phosphate 10 2.5 IgePal
Sodium 
Phosphate 10 7.0 IgePal
 
Table 6.1  Summary of buffer conditions investigated to improve resolution of dynorphin 
metabolites.   
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Figure 6.17.  Structures of two surfactants (Brij 35 and IgePal) investigated for ME separation of 
dynorphin and metabolites.   
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non-specific adsorption onto glass microchip surfaces.  Based on the sharp peak shapes observed 
with the dynorphin peptides, it did in fact prevent adsorption to the glass channels.  The most 
promising separation  was achieved with 10 mM sodium borate and 0.1% IgePal, pH 9.0 (Figure 
6.18).  However, complete resolution of the key metabolites was not achieved under any of the 
conditions investigated. 
Alterations to the chip format or derivatization chemistry could overcome some of this 
challenge.  Serpentine separation channels are a popular means for increasing N by lengthening 
the separation channel in a microchip device while maintaining the overall small footprint of the 
microchip.  Additionally, investigating peptide tagging with smaller fluorescent probes would 
potentially enable improved resolution amongst these closely related species. 
6.3.3 Future directions toward an immunoaffinity microchip device for pain neuropeptides 
Current limitations with the resolution of small peptides after tagging with a large Alexa 
Fluor dye, the adsorption of peptides to PDMS, and the difficulties associated with the 
integration of electrochemical detectors within glass matrices have stalled the progress of an 
immunoaffinity microchip electrophoresis system for the investigation of Dyn A 1-17 
metabolism; however, progress is being made by our group in each of these areas and will be 
addressed in the following chapter.  Additionally, the application of immunoaffinity techniques 
to a broader biological application is under consideration, that is, an immunoaffinity microchip 
for the investigation of neuropeptides implicated in neuropathic pain or a “pain pathway chip”.  
Preliminary work towards that end was accomplished using the conventional CE format utilizing 
a smaller fluorescent label, fluorescein isothiocyanate (FITC, MW ~ 390 g/mol).  A CE 
separation of two neuropeptides, Dyn A 1-17 and SP, was achieved and is shown in Figure 6.19.    
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Figure 6.18.  Detection of Alexa Fluor 633-labeled dynorphin peptides, 1-6, 1-8, 1-13, 1-17, 
and 2-17 (each 2.5 µg/mL) on a glass microchip (8 cm separation channel). Run buffer consisted 
of: 10 mM sodium borate, 0.1% IgePal, pH 9.0, with a 1.0 second injection and 2.0 kV applied 
separation voltage.  
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Figure 6.19  Conventional CE separation of FITC-labeled Dyn A 1-17 and  substance P (SP), 
each 500 nM on a 60 cm capillary. Run buffer consisted of: 150 mM boric acid, 7.5 mM SDS, 
pH 9.5, and a 20.0 kV applied separation voltage.  
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These results will lay the ground work for future projects investigating the relationship between 
dynorphin and substance P and their involvement in neuropathic pain. 
 
6.4 Summary 
Immunoassays were performed to screen anti-dynorphin antibodies against a panel of 
dynorphin peptides.  Anti-Dyn A 1-17 was shown to cross-react with Dyn A 2-17.  Had this 
assay been performed to quantify the amount of Dyn A 1-17 in a biological sample of interest, a 
falsely elevated level could easily have been reported for Dyn A 1-17 since any 2-17 present in 
the sample would have contributed to the overall peptide signal.  This observation highlights a 
key drawback to such techniques for investigations of neuropeptides as biomarkers for disease, 
especially when the role of a peptide’s metabolite(s) is not clearly understood.  The work 
presented here characterizes one component of the overall goal for incorporating a dynorphin 
immunoaffinity port into a microchip device. 
Additionally, a variety of microchip formats have been explored for the separation of 
Dyn A 1-17 from its metabolites.  Each of these experimental designs offers certain advantages.  
PDMS-glass hybrid chips offer the ease of integrating an electrochemical detector within a chip, 
which is essential for the future of on-animal total analysis systems.  All glass chips with LIF 
detection exhibit improved sensitivity, which will enable quantitation of endogenous levels of 
low-abundant neuropeptides.  However, each format also carries with it significant drawbacks 
such as peptide adsorption to PDMS substrates and difficulty resolving tagged-dynorphin 
peptides on short separation channels.  The following chapter will address the future work 
necessary for the development of such immunoaffinity microchip devices for further 
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characterization of dynorphin metabolism as well as the applicability of such techniques to 
neuropeptides in general. 
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7.1 Thesis summary 
 This thesis describes the development of methods for the detection  of Dyn A 1-17 and 
four of its key metabolites: Dyn A 1-6, Dyn A 1-8, Dyn A 1-13, and Dyn A 2-17 in biological 
samples.  In chapter 3, capillary electrophoresis with on-capillary copper complexation and UV 
detection is used to investigate dynorphin metabolism in human plasma as well as rat brain and 
spinal cord slices.  The method ultimately involved the incorporation of phytic acid to prevent 
peptide adsorption to the capillary wall and sulfobutyl ether-β-cyclodextrin to improve resolution 
of such closely related species.   
Chapter 4 describes the development of an LC-MS/MS assay for dynorphin peptides 
from cell culture samples, including special considerations regarding ionization in the cell media.  
A description of mass spectrometric parameter optimization is thoroughly discussed as well as 
liquid chromatographic conditions for the separation of dynorphin peptides and an appropriate 
internal standard.  This method is utilized in Chapter 5 to characterize the dynorphin metabolism 
in rat brain and spinal cord slices as well as with a cell culture model of the blood brain barrier 
(BBB).  Dyn A 1-6 is identified as the major metabolite of Dyn A 1-17.  Its transport was then 
characterized at the blood brain barrier using the bovine brain microvessels endothelial cell 
(BBMEC) BBB model.   
Chapter 6 lays the groundwork for developing an immunoaffinity microchip device for 
determining dynorphins.  Traditional ELISAs were used for antibody screening to determine 
reactivity.  Initial studies using a PDMS-glass hybrid microchip with amperometric detection 
demonstrated significant peptide adsorption.  An all glass microchip with LIF was also 
investigated, following tagging with Alexa Fluor 633.  However, incomplete resolution was 
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obtained under a variety of buffer conditions that were investigated.  Future directions of the 
project will continue optimization of the microchip separation and will further develop an 
immunoaffinity microchip for investigating neuropeptides implicated in neuropathic pain.  These 
experiments are described in more detail in the next section. 
 
7.2 Future directions 
7.2.1 Mass spectrometric detection of dynorphin peptides 
 In addition to the studies described in Chapter 5 of this thesis, additional mass 
spectrometry studies could further confirm the presence of Dyn A 1-6 as the major metabolite of 
Dyn A 1-17.  Matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) would 
also be an additional method to confirm the presence of the Dyn A 1-6 metabolite.  While not 
quantitative, the molecular weight identification would provide additional support to the data 
presented in chapters.  Identification of the 7-17 fragment would further confirm the presence of 
this metabolite as well.    
 The effect of opioid peptides on low molecular weight peptide transport could further 
be investigated using the BBMEC culture model described in Chapter 5.  Additional dynorphin 
peptides should be evaluated for their propensity to alter the integrity of the blood brain barrier.  
Studies to elucidate the mechanism by which this opening occurs would also be useful in 
examining the role this family of peptides may play in the central nervous system.  
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7.2.2 Microchip modifications for improved resolution of dynorphin metabolites 
 While the studies presented here demonstrate the difficulties in separating closely 
related species on miniaturized devices, several design modifications could potentially alleviate 
these complications.  Considerable attention in microchip research has been devoted to 
increasing separation length while maintaining the desirable small footprint of these devices 
using serpentine channels [1-4].  In this way, improved resolution can be accomplished without 
compromising the portability of the device.   
 Peptide adsorption was the most significant drawback to the use of a PDMS 
microchip.  This further hinders the use of electrochemical detection since the incorporation of 
electrodes is most easily accomplished in a PDMS device where reversible sealing over the 
electrode is rather simple.  Electrode materials typically produce defect sites during glass 
bonding and leaking around the electrode is a significant issue.  Our group is working to 
fabricate electrodes embedded into a glass substrate to alleviate this effect.  Additionally 
investigating smaller fluorescent tagging systems could help with the assay as well.  Because 
dynorphin peptides are relatively small (molecular weights of 700-2100), the large Alexa Fluor 
tags (MW = 1200) used in these studies, significantly diminish any differences in the mass to 
charge ratio of these compounds, decreasing resolution by CE.    
 
 
 
        
233 
 
7.2.3 Immunoaffinity microchip electrophoresis for neuropeptides implicated in neuropathic pain 
 Dynorphin is one of several neuropeptides involved in pain signaling pathways [5].  
Substance P (SP) is also known to play a role in pain processing.  Capsaicin-stimulated release of 
SP has been previously reported and some work suggests that dynorphin facilitates this release 
[6].  Therefore, in addition to investigating the role of dynorphin in chronic conditions such as 
neuropathic pain, the interplay between dynorphin and substance P should be considered (Figure 
7.1).  Immunoaffinity microchip electrophoresis is an attractive method for such applications.  In 
particular some of the complications with separating dynorphin metabolites can be avoided.  
Dynorphin and substance P differ structurally (Figure 7.2) making separation an easier task even 
if large fluorescent tags are utilized.   Antibody characterization is also simplified considerably 
when investigating two un-related species.  An antibody to capture each of these compounds 
should still be screened for cross-reactivity in a conventional immunoassay for comparison with 
a novel chip-based assay.   
 Prior to the fabrication of a fully integrated device, the separation of the two peptides 
on a microchip device should be optimized.  As an intermediate step, off-line extraction (most 
conveniently using antibody-functionalized magnetic beads) can be performed to assure that 
elution conditions do not alter the eletrophoretic behavior in any way.  Both SP and Dyn A 1-17 
antibodies can then be incorporated into a microchip device for a fully integrated immunoaffinity 
pain microchip.  This would make it possible to investigate the interaction between these two 
peptides at the blood brain barrier.  The effect of both peptides on BBB transport would be of 
interest to the role that each plays in neuropathic pain, as well as the in vivo role of the peptides 
on the release of excitatory amino acids and the effect on fluorescein permeability. 
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Figure 7.1. Cartoon depiction of the possible mechanism by which dynorphin potentiates 
neuropathic pain.  Normal conditions are represented on the left and the downstream effects of 
dynorphin upregulation, following nerve injury, is represented on the right.  Used with 
permission from [5].      
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Dynorphin A 1-17
Substance P
 
 
 
 
Figure 7.2  Structures of Dyn A 1-17 (NH2-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-
Leu-Lys-Trp-Asp-Asn-Gln-OH) and SP (NH2-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-
NH2) 
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 As mentioned in previous sections of this thesis, miniaturization of an electrophoresis 
system enables portability and improved temporal resolution.  Previous work in our group has 
developed a microchip device capable of on-line microdialysis sampling and on-chip 
derivatization with NDA/CN- [7-9].  Therefore, the long term goal of this project, in addition to 
other projects in our group, is the creation of a fully functional on-line microdialysis 
immunoaffinity microchip electrophoresis device for on-animal studies to correlate animal 
behavior with the physiological role of  neuropeptides (SP and Dyn A 1-17) and excitatory 
amino acids (glutamate and aspartate).          
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